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Abstracts of invited paperst
Symposium:
Reactive intermediates in drug
metabolism and carcinogenicity
The role of reactive electrophiles in biological activity
and toxicity
S.D. Nelson
Department ofMedicinal Chemistry BG-20,
University of Washington, Seattle, WA 98195 USA.
In the last two decades it has become apparent that
toxic manifestations of many chemicals arise from
covalent interactions of either the compounds
themselves or more commonly their metabolites
with tissue macromolecules. Identification of the
products of covalent interaction has demonstrated
that the reactive forms are generally electrophilic.
The nature of several classes of electrophiles will be
briefly described in regard to mechanisms of
formation and reaction with nucleophiles. Ongoing
studies in my laboratory on the pathogenesis of
toxicities caused by a halogenated alkyl phosphate
and a terpene will illustrate procedures that are
used to define mechanisms of reactive metabolite
formation. Acetaminophen metabolism will be
discussed to highlight the complex nature of
interactions of some electrophiles with tissue
nucleophiles. And, finally, our knowledge of
reactive electrophiles will be applied to describe the
preparation of suicide substrates of the enzyme,
*Enquiries to the BACR Secretariat c/o Institute of
Biology, 20 Queensberry Place, London SW7 2DZ.
tReprints of these abstracts are not available - Ed.
tThis issue pp. 239-302.
aromatase, as potential therapeutic agents in the
treatment of oestrogen-dependent tumours.
The generation and fate of free radicals in intact
cells
S. Orrenius
Department of Toxicology, Karolinska Institutet,
S-104 01 Stockholm, Sweden.
There is increasing evidence that organic radicals as
well as oxygen radicals may cause acute cell injury
and also be involved in the initiation and
promotion of tumor formation. In the cell,
peroxidase-mediated metabolism of various drugs
and carcinogens, and one-electron reduction of
many quinones, e.g. menadione, can be a source of
generation of both types of radicals. Their
subsequent interaction with reduced glutathione
(GSH) results in the formation of either glutathione
S-conjugates or glutathione disulfide (GSSG); the
latter may occur in part by dimerization of
glutathionyl (GS ) radicals generated during the
interaction of organic free radicals with GSH. Since
both glutathione S-conjugates and GSSG are
actively excreted by the cell, this may result in GSH
depletion and, if the production of free radicals
continues, their attack on other cellular nucleophilic
groups, including those in various proteins and
DNA. This may in turn result in either acute or
chronic cell damage. Thus, depletion of protein
thiols appears to be intimately associated with the
development of menadione-induced cytotoxicity in
hepatocytes, possibly via a perturbation of their
Ca2+ homeostasis.410 AGM BACR ABSTRACTS
The role of glutathione in the detoxication of
electrophilic, peroxy and free radical metabolites
B. Ketterer
Cancer Research Campaign Molecular Toxicology
Research Group, Middlesex Hospital Medical
School, London WIP 7PN, UK.
The oxidation of xenobiotics may give rise to
electrophiles, and by-products of oxygen utilization
such as phospholipid hydroperoxides both of which
are potentially cytotoxic, and may be detoxified by
glutathione (GSH) which is a nucleophile and a
reducing agent.
GSH reacts poorly with hard electrophiles, but
well with soft electrophiles, and a family of GSH
transferase enzymes has the capacity to catalyse
some if not all these reactions. Such catalysis is an
important determinant of the fate of hard
electrophiles which tend to be genotoxic. On the
other hand if good substrates are present at high
doses catalysis itself may cause toxicity due to GSH
depletion. The capacity of different tissues to
detoxify electrophiles varies: it depends on their
GSH content, the qualitative and quantitative
distribution of GSH transferase isoenzymes in each
tissue, and the nature of the electrophiles
themselves.
Reduction of phospholipid hydroperoxides by
GSH requires the concerted action of
phospholipase A2 and a range of GSH peroxidases
(the latter utilize free fatty acid hydroperoxides as
substrates).
In principle GSH might act as a trap for oxidising
free radicals and also free radicals resulting from
one electron oxidations of xenobiotics. This has yet
to be demonstrated incontrovertibly because the
resultant thiyl free radical is so difficult to detect.
Observing xenobiotic metabolism by in vivo NMR
J.K.M. Sanders
University Chemical Laboratory, Lensfield Road,
Cambridge CB2 JEW, UK.
Carbon, deuterium and proton NMR spectroscopy
have been used to monitor the metabolism of
labelled formaldehyde by a variety of bacterial and
plant cell preparations. Depending on
circumstances, the timescale per spectrum may be
as short as 2min. The rate of metabolism has been
correlated with growth and experimental
conditions, and the metabolism has been shown to
be a detoxifying process in competition with lethal
chemistry. The structures of several metabolic
products have been determined in these living
cultures, and have been shown to include
incorporation, oxidation and reduction products.
NMR observations using deuterium NMR have
enabled us to make some progress towards
determining enzyme mechanisms in vivo. These
results throw much new light on the biochemistry
of formaldehyde. More importantly they
demonstrate that these techniques are applicable to
any xenobiotic which can be labelled and handled
at the millimolar level, and to any organism which
can be put into an NMR spectrometer.
Symposium:
New Directions in the Therapy of
Cancer
Oncogenes in cancer therapy
K. Sikora
Ludwig Institutefor Cancer Research, MRC Centre,
Hills Road, Cambridge CB2 2QH, UK.
The central problem in cancer therapy is the poor
selectivity of current systemic agents against the
common solid tumours. The demonstration that
unique segments of DNA; constant in location and
conserved in evolution are involved in growth
control opens new avenues for basic and clinical
research. The functions of the products of these
genes need to be elucidated. Examples of growth
control functions include homology to growth
factors; surface receptors; protein kinases and cell
cycle control proteins. From DNA sequence data
peptides predicted to be exposed within the intact
molecule can be constructed and used to produce
monoclonal antibodies to oncogene products. Such
antibodies have now been successfully used to
demonstrate the intracellular localisation of gene
products as well as the cell cycle regulatory role of
the c-myc protein in vitro. By having a battery of
antibodies against the different gene products their
direct clinical application for diagnosis and
prognosis has become a reality. Immunohistology
and flow cytometry permit the geographical and
quantitative analysis of function in normal and
neoplastic tissues. Furthermore by purification and
biochemical analysis the molecular basis for their
action can be elucidated. It is likely that by the end
of the decade new drugs that inhibit oncoprotein
function will be available for clinical trial.
Clinical correlates of in vitro studies of small cell
lung cancer
D.N. Carney
Mater Hospital and Saint Lukes Hospital, Dublin,
Eire.
A panel of 52 cell lines (CL) derived from patients
(pts) with small cell lung cancer (SCLC) have been
analysed for morphology, cloning efficiency (CE),AGM BACR ABSTRACTS 411
radiation sensitivity, and the expression of a panel
of biomarkers including L-dopa decarboxylase
(DDC), bombesin (BN), neuron specific enolase
(NSE), and creatine kinase BB (CK-BB). Many CL
have been analysed for the c-myc and N-myc
oncogenes. Results of these studies show that SCLC
CL can be subdivided into 3 groups: (1)
Multipotent CL (N=2) which in vitro undergo
simultaneous differentiation into SCLC, adeno and
squamous cell carcinoma providing evidence for a
common stem cell for all types of lung cancer: (2)
Classic SCLC CL (N=35, 70%) grow as tight
aggregates of floating cells, have a low CE (1-5%);
a long doubling time (DT) (72h); express elevated
levels of all 4 biomarkers, and are radiosensitive.
(3) Variant SCLC CL (N= 15, 30%) grow as loose
aggregates; have a high CE (10-30%) a short DT
(26h), are radioresistant, and lack DDC and BN.
Amplified levels (20-75 fold) of the c-myc oncogene
are present in 8/9 variant CL. Studies with the N-
myc probe revealed significant amplification of the
N-myc gene in 5 CL not amplified for c-myc, and
belonging to both the classic and variant
subgroups. Tumour tissue harvested directly from 3
pts also showed tumour specific amplification of
the N-myc gene. The median survival for pts with
myc amplification was significantly shorter than
patients whose cells were not amplified. These data
suggest: (1) several distinct classes of SCLC CL can
be established from pts with SCLC; (2) Variant CL
are associated with a more malignant behaviour in
vitro and in vivo; and (3) the finding of
amplification of c-myc or N-myc in 13 SCLC CL
suggests that amplification and/or expression of a
myc-related sequence may be important for
establishing and/or maintaining SCLC.
Modelling SRC and the EGF receptors by computer
graphics
M.J.E. Stemnberg & W.R. Taylor
Laboratory ofMolecular Biology, Department Of
Crystallography, Birkbeck College, London WCJE
7HX, UK.
A three-dimensional model for the ATP-binding
site of the oncogene product v-src was proposed by
the use of interactive computer graphics. A similar
model would apply to sequence related proteins
such as other oncogene products, the epidermal
growth factor receptor, cAMP-dependent protein
kinase and the cell division control protein,
CDC28. The model was proposed on the basis of
the conservation of certain key amino acid residues
(in particular the sequence Gly-X-Gly-X-X-Gly)
between the oncogene-product family of proteins
and several nucleotide binding proteins of known
structure. The interactive computer graphics
facilities at Birkbeck were then used to construct a
stereochemically-sensible model for the ATP-
binding site of v-src. The model may prove useful
for the design of inhibitors as clinical agents.
(Stemnberg & Taylor, 1984, FEBS Lett., 175, 387).
The dependence of cancer cells on growth factors as
a target for chemotherapy
P. Alexander
CRC Medical Oncology Unit, University of
Southampton, Southampton General Hospital,
Southampton S09 4XY, UK.
Evidence is accumulating that for cancer cells as for
normal cells proliferation is dependent on a
sequence of interactions between receptors on the
outside of the cell membrane and polypeptide
growth factors. One aspect of the malignant
transformation is that cancer cells, unlike most
normal cells, constitutively synthesize both the
receptor and the growth factors and this results in
self-stimulation. This does not, however, imply that
it may not be possible to control tumour growth by
interrupting the triggering of receptors, since
coupling between the polypeptide growth factors
released by the cancer cells and their receptors on
the surface of the cell is loose. Data from the
growth of cancer cells in serum free medium in vitro
and from the study of metastases in vivo indicate
that in general an isolated cancer cell is not capable
of autonomous growth as the concentration of
growth factors in the environment is too low to be
mitogenic, presumably because much of the
released growth factor diffuses away. Such isolated
cells require factors from the surrounding host
tissue if they are to grow. Clusters of cancer cells
are capable of truly autonomous growth as the
concentrations of growth factors in the immediate
vicinity can then attain levels adequate for initiation
of mitosis. These findings suggest that it is realistic
to attempt to control tumour growth by blockading
(or antagonising) autocrine stimulation.
Symposium:
The Early Clinical Trials of Novel
Antitumour Agents
Overview of the CRC early Phase I clinical trials
project
T.A. Connors
MRC Toxicology Unit, MRC Laboratories,
Woodmansterne Road, Carshalton, Surrey SM5
4EF, UK.
Basic research in cancer chemotherapy and the
'screening' of chemicals using in vivo or in vitro
J.C.-H412 AGM BACR ABSTRACTS
systems produce quite large numbers of drugs of
interest but only a few of these are examined
further by phased clinical trials. Conventional
screening tests relying mainly on rodent
transplanted tumours have selected a variety of
novel chemical structures which have been
disappointing clinically appearing to act similarly to
known anticancer agents. The Phase I Clinical
Trials Committee of the Cancer Research
Campaign aims to increase the numbers of agents
entering Phase I clinical trials in the UK and to
select for trial chemicals which may not necessarily
be active on conventional screening tests but which
are of interest for other reasons. The Committee
has the resources to fund the synthesis,
formulation, preclinical toxicology and Phase I
clinical trials of six or more chemicals each year.
Review of the EORTC drug development program
H.H. Hansen
Oncology Department II, Finsen Institute,
Copenhagen, Denmark.
Within the last years the development of new active
anti-neoplastic agents has received increasing
attention within the EORTC and an organizational
structure has been established. Since 1981 the New
Drug Development and Coordinating Committee
(NDDCC) of the EORTC has functioned with the
purpose (1) to transmit information on the
availability of new agents in Europe to the various
EORTC groups, but especially to the Screening and
Pharmacology group, Clinical Screening group,
Early Clinical Trials group (ECTG) and the
Pharmacology and Metabolism group (PAM
group), (2) to integrate work conducted within the
latter four groups, (3) propose testing of new drugs,
(4) propose and initiate synthesis of new drugs.
Standardized guidelines for (a) preclinical
toxicology, (b) formulation of investigational
cytotoxic drugs, (c) Phase I clinical trials with
anticancer drugs have been established. Increasing
cooperation with exchange of information with
other organizations focusing on new anti-cancer
drug development is in progress, especially with
New Drug Development Program, NCI, Bethesda,
USA and the Cancer Research Campaign Phase I
Committee, UK. In 1983 the organization was
expanded with the creation of the EORTC Office
for New Drug Development (EODD) located in
Amsterdam. At present 16 new cytostatic agents are
undergoing preclinical evaluation in the EORTC
program as exemplified by the new compound a-/#-
triglycidyl-urazol (TGU), (NSC 332488).
Clinical aspects of Phase I trials
A.H. Calvert
Department ofBiochemical Pharmacology, Institute
ofCancer Research, Sutton, Surrey SM2 5PX, UK.
The conduct of a Phase I trial presents conflicting
demands on the clinician. The purely scientific
aspect demands documentation of the maximum
tolerated dose of the drug, its pharmacology and its
side effects, while ethical considerations demand
that patients should be treated in as safe a way as
possible. The usual practice has been only to admit
patients untreatable by other means to Phase I
studies, to obtain their consent having informed
them that the treatment will probably be of no
benefit and to start the trial at a dose -10 times
lower than that anticipated on the basis of
preclinical observations. These precautions have, in
general, led to the introduction of new drugs with
minimal hazard to the patients at the starting dose
level, but determination of the maximum tolerated
dose necessarily places patients at some risk at the
higher end of the dosage spectrum. Further,
patients treated at lower doses have little chance of
any therapeutic benefit. A recent survey showed
that the overall response rate in Phase I trials was
very low (-2%). We have attempted to minimise
the risk to the patient and maximise the possibility
of a therapeutic response by the following means:
(i) All the available preclinical data is assessed and
used where possible to select patients with the
maximum chance of responding; (ii) At non-toxic
levels, doses are escalated on successive courses
given to the same patient; (iii) A running analysis
of all toxicity data for a dose response effect is kept
in an attempt to anticipate side effects which may
have been trivial at a lower dose from becoming
severe on dose escalation. The advantages and
disadvantages of this approach are examined in the
context of three recently performed Phase I studies
on Carboplatin, CB3717 and Trimelamol.
The role of preclinical and clinical pharmacokinetics
in Phase I trials
P. Workman
MRC Clinical Oncology Unit, MRC Centre, Hills
Road, Cambridge CB2 2QH, UK.
The aim will be to illustrate the importance of
pharmacokinetic studies in the rational selection of
novel antitumour agents and their subsequent
evaluation in the clinic. A case will be made for
detailed pharmacokinetic studies to be carried out
in the same experimental animals used for
antitumour and toxicity testing. This allows
antitumour activity and toxicity to be related toAGM BACR ABSTRACTS 413
exposure parameters for parent drug or active
metabolites, e.g., peak concentration, area-under-
the-curve, etc. A prediction can then be made of
the minimum plasma and tumour exposures likely
to be required for antitumour activity in man.
Phase I pharmacokinetics will reveal whether these
exposures can be realized, and also identify
differences in drug handling as compared to the
screening species, e.g. extent of metabolic
activation. Similar procedures may also be used to
predict exposures likely to elicit drug toxicity.
Where a series of congeners are under development
pharmacokinetic behaviour can be a major factor in
the selection procedure. The choice of a new
analogue to replace an existing agent may be based
largely on pharmacokinetics. The following
examples are from current Phase I studies: (1)
impaired metabolic activation of a prodrug (e.g.
pentamethylmelamine) in man may lead to the use
of preactivated forms (e.g. trimelamol); (2) a drug
which gives inadequate peak levels after oral
administration (e.g. CCNU) may be replaced by an
intravenously administered agent giving a higher
peak (e.g. mitozolamide); (3) a neurotoxic
radiosensitizer (misonidazole) may give way to a
hydrophilic analogue which is excluded from
nervous tissue and cleared rapidly by the kidney
(SR 2508) or a basic analogue which exhibits both
efficient renal and metabolic clearance (Ro 03-
8799). Phase I clinical pharmacokinetics also
contribute to rational optimization of drug dose,
schedule and route of administration, as well as
identifying situations in which dosage alterations
are required because of renal or hepatic
dysfunction.
West Midlands Oncology Association Guest Lecture
Novel clinical strategies for chemotherapy
E. Frei III, Dana-Faber Cancer Institute, Boston, Mass. 02115, USA. (By title
only)
Abstracts of members' proferred papers
12-0-tetradecanoylphorbol-13-acetate (TPA)-
stimulated mono-morphonuclear leukocytes (MMNs)
cause oxidation of thiols and toxicity in A549 lung
carcinoma cells
A. Gescher', A.E. Brodie2 & D.J. Reed2
'Department ofBiochemistry and Biophysics, Oregon
State University, Corvallis, Oregon, USA; and 2CRC
Experimental Chemotherapy Group, University of
Aston, Birmingham B4 7ET, UK.
Phorbol ester tumour promoters, such as TPA, are
activators of the cytotoxic potential of human poly-
morphonuclear leukocytes (PMNs). The mechanism
by which TPA-stimulated PMNs induce toxicity in
target cells is considered to involve oxygen meta-
bolites, such as superoxide, hydrogen peroxide and
the hydroxyl radical. Effects of TPA-stimulated
MMNs on target cells are much less well
understood. An attempt was made to clarify some
of the biochemical interactions between TPA and
MMNs. TPA-stimulated MMNs were found to be
toxic towards A549 human lung carcinoma cells
which had been permanently desensitized against
the direct growth-inhibitory effect of TPA. Levels
of the intracellular protectant glutathione were
reduced by 37% in MMNs exposed to TPA for
24h; glutathione levels in the target cells were not
affected by TPA-stimulated MMNs. The
supernatant of incubations of MMNs with TPA
contained a species which oxidised 5-thio-2-nitro-
benzoic acid (TNB). The generation of this species
appeared to be dependent on the myeloperoxidase-
H202-halide system, as its formation was abolished
by catalase, azide and cyanide, but not by
superoxide dismutase (SOD). However, catalase,
azide and cyanide did not inhibit toxicity exerted
by TPA-stimulated MMNs, whereas SOD did.
Therefore the TNB oxidant does not appear to be
involved on the process which led to cytotoxicity
caused by TPA-stimulated MMNs in A549 cells.
An improved assay for 17a hydroxylase/C17-C20
lyase: A target enzyme for the treatment of hormone
dependent prostatic cancer
S.E. Barrie
Department ofBiochemistry and Pharmacology,
Institute ofCancer Research, Sutton, Surrey, UK.
Inhibition of androgen biosynthesis and thus a414 AGM BACR ABSTRACTS
reduction in the level of circulating hormone is
beneficial for the treatment of androgen dependent
prostatic cancer. To achieve this the most suitable
enzyme target is the microsomal 17a hydroxy-
lase/C17-C20 lyase which catalyses the 17a
hydroxylation of progesterone or pregnenolone,
and then the cleavage of the Cl7-C20 bond to give
androstenedione or dehydroepiandrosterone respec-
tively. Previous assays involved long extraction and
crystallisation procedures or lacked the ability to
monitor any side reactions. This assay has neither
drawback. The enzyme source (e.g. microsomal
extract from rat testis) is incubated with 3H-
progesterone (1 1M, 1 mCittmol-1), NADPH and
other cofactors in a total volume of 100jul. The
reaction is stopped by the addition of 200,ul
acetonitrile:methanol (1:2) containing 100 uM
unlabelled progesterone, 20a hydroxyprogesterone,
17a hydroxyprogesterone, androstenedione, and
testosterone. The samples are stored at -20°C until
analysed by HPLC. 200p1 is then injected onto a
30cm Apex C18 column running with acetoni-
trile:methanol:water (22:40:38) at 1.5mlmin-1 at
20°C. Under these conditions androstenedione and
testosterone run as single peak followed by 17a
hydroxyprogesterone, 20ax hydroxyprogesterone and
progesterone. The peaks corresponding to the
unlabelled steroids added to the sample are
collected into mini vials using an LKB fraction
collector fitted with a signal sensor attached to the
254nm output of the HPLC detector, and counted.
Each run takes 30min. This system allows easy
determination of the 17a hydroxylase and C17-C20
lyase activities, 20ac hydroxylation and substrate
availability.
Inhibition of CSCC and aromatase enzymes by
analogues of aminoglutethimide
M.J. Daly', P.J. Nicholls', H.J. Smith' & M.G.
Rowlands2
'Welsh School ofPharmacy, PO Box 13, Cardiff,
CFJ 3XF; and 2lnstitute ofCancer Research, Sutton,
Surrey SM2 5PX, UK.
Selective inhibition of steroidogenesis has many
applications in cancer and other research. Amino-
glutethimide, (1, 3-(4-aminophenyl)-3-ethyl-
piperidine-2,6-dione), is a treatment for mammary
carcinoma in post-menopausal and oophorectomised
women which acts by inhibiting the production of
steroids via inhibition of the cholesterol side chain
cleavage (CSCC) and aromatase enzyme complexes.
Several analogues closely resembling I have been
synthesised and tested in established in vitro assays
(Graves & Salhanik, 1979, Endocrinology, 105, 52;
Hochberg et al., 1974, Biochemistry 13, 603) for their
inhibitory activity against these enzyme systems.
3-(4-aminophenyl)-3-ethyl-pyrrolidine-2,5-dione (2),
and I were found to be potent inhibitors of
aromatase, while 5-(3-aminophenyl)-5-ethylimidazo-
lidine-2,4-dione (3) was a weak inhibitor and 5-
(3-(aminophenyl)-5-ethylpyrimidine-2,4,6-trione (4)
was totally non-inhibitory. As expected, I was a
potent inhibitor of the CSCC enzyme, while 2
possessed only weak activity, and 3 and 4 were
non-inhibitors. Using such studies, it may prove
possible to design selective inhibitors of steroido-
genesis for therapeutic use in hormone dependent
cancers.
Metabolic switching and improved antitumour
selectivity with f, i-difluorochlorambucil
F.Y.F. Lee', P. Coe2 & P. Workman'
1MRC Clinical Oncology Unit, Cambridge; and
2Department ofChemistry, University of
Birmingham, UK.
f,/3-Difluorochlorambucil (fl-F2CHL) was
synthesized in the hope of blocking the mito-
chondrial f-oxidation of chlorambucil (CHL),
which proceeds via 3,4-dehydrochlorambucil
(DeHCL) to yield phenyl acetic mustard (PAAM), a
putatively adverse metabolic pathway. In mice,
LD50 doses were 15.9, 30.0 and 60.2mgkg-1 for
PAAM, CHL and f-F2CHL respectively, while
doses to give a 15 day growth delay (ED15) in the
KHT tumour were 8.0, 14.6 and 20.0mgkg- l.
Thus, compared to CHL, PAAM was more potent
while fl-F2CHL was less potent in both cases.
However, therapeutic indices, calculated as
LD50/ED15, were 2.0, 2.1 and 3.0 for PAAM, CHL
and fl-F2CHL respectively, showing some
advantage for the new analogue. Pharmacokinetic
studies were carried out using HPLC analysis. Both
DeHCL and PAAM were detected as metabolites of
/3-F2CHL, but in much reduced quantities
compared to those produced from CHL, thereby
demonstrating that P-oxidation was not blocked
completely but was significantly impaired.
Consequently the area-under-the-curve of concen-
tration against time was 2.7 times greater for parent
fl-F2CHL compared to parent CHL, whereas the
AUC for PAAM and DeHCHL were reduced by 2-
fold and 15-fold respectively. The AUC for total
plasma bifunctional nitrogen mustards was
unchanged, but that for free mustards in plasma
water was decreased 1.6-fold. Metabolic switching
was demonstrated by the appearance of two new,
unidentified metabolites with /3-F2CHL, and
evidence suggests these may be dechloroethylation
products. The reduced potency of fl-F2CHL
compared to CHL is attributed to the lower levelsAGM BACR ABSTRACTS 415
of free plasma mustards, particularly PAAM, but
the reason for the modest improvement in thera-
peutic index is not known.
Metabolic activation of 1-naphthol, a potential
antitumour agent, in model in vitro systems
M. d'Arcy Doherty & G.M. Cohen
Toxicology Unit, The School ofPharmacy, London
University, 29/39 Brunswick Square, London WCIN
lAX, UK.
l-Naphthol is selectively toxic to short-term organ
cultures of human colonic tumour tissue compared
to normal intestinal mucosa from the same patients
(Cohen et al. (1983), Biochem. Pharmac. 32, 2363).
We have previously shown that l-naphthol is
metabolised by rat liver microsomes or a fully
reconstituted cytochrome P-450 system to 1,4-
naphthoquinone and covalent binding species
(Doherty & Cohen (1984), Biochem. Pharmac., 33,
3201; and unpublished data).
In cultured human colonic tumour cells, [1-14C]-
1-naphthol is activated to covalently bound species.
In order to investigate the possible metabolic
activation of l-naphthol by human colonic tumour
cells, we studied the metabolism of 1-naphthol in
microsomal preparations from these cells. Under
the conditions used, no significant metabolism of 1-
naphthol to soluble naphthoquinone metabolites
could be detected. Alternative pathways of
metabolic activation have been suggested by our
recent studies showing that other in vitro systems,
horseradish peroxidase and tyrosinase readily
activate l-naphthol to reactive products. The latter
observation is particularly interesting as it raises the
possibility of the selective treatment of melanotic
melanomas with 1-naphthol.
Can the anti-tumour effect of adriamycin be
mediated by a semi-quinone free radical?
N. Willmott', J. Cummings2 & A.T. Florence'
1Department ofPharmacy, University of
Strathclyde; and 2Department ofClinical Oncology,
University ofGlasgow, Glasgow, Scotland, UK.
Adriamycin (Adx)-loaded albumin microspheres
were prepared by stabilization of water in oil
emulsion droplets containing albumin and drug.
Average particle size in these studies was between
15 and 24um, and they contained on average 10
(range 6-14) ug Adx mg-1 of microspheres. To
assess the anti-tumour effect of drug-loaded
microspheres they were injected directly into s.c.
growths of a non-immunogenic rat mammary
carcinoma Sp1O7 and subsequent tumour growth
followed. It was consistently found that Adx (24-
87pg) in microspherical form exhibited a superior
anti-tumour effect to an equal or even greater
amount of drug in solution. To investigate the
levels ofunchanged drug and metabolites in tumour
tissue in this model rats were sacrificed at intervals
following intratumoral injection of either drug in
solution (80,ug) or in microspherical form (60,ug)
and tumours analysed using an HPLC method that
can discriminate between Adx and fluorescent meta-
bolites (Cummings et al. (1984), J. Chromatography,
311, 125). Two rats were used per time point and
results were analysed using a two-way analysis of
variance with replication. It was observed that Adx
in microspherical form promoted a significantly
higher level of the metabolite adriamycinol 7-
deoxyaglycone in tumour tissue compared to drug
in solution (peak level 3.9pg at 48h after injection
compared to 0.6jg at 16h). Since it has been
shown in vitro that 7-deoxyaglycone metabolites
of Adx are a by-product ofsemiquinone free radical
formation (Gutierrez et al. (1983), Arch Biochem.
Biophys. 223, 68), these results are consistent with
the enhanced anti-tumour effect of Adx in micro-
spherical form being due to generation of a semi-
quinone free radical intermediate.
Enzymic pathways in the in vitro metabolism of
mitozantrone
C.R. Wolf, J.S. Macpherson & J.F. Smyth
Imperial Cancer Research Fund Medical Oncology
Unit, Western General Hospital, Crewe Road,
Edinburgh, EH4 2XU, UK.
Mitozantrone is an anthraquinone derivative with
potential use in the treatment of breast cancer. In
conjunction with our pharmacokinetic studies we
have investigated the in vitro metabolism of this
compound in rat liver microsomal preparations to
determine the probable pathways of metabolism in
man. On incubation of liver microsomal samples
with mitozantrone and UDPGA a metabolite was
detected by HPLC which was sensitive to treatment
with fl-glucuronidase. The formation of this
product was also inhibited by inhibitors of
UDPGA-glucuronyl transferase. In a second
incubation system containing microsomes, NADPH
and glutathione, two metabolites were formed. The
production of these metabolites were dependent on
the presence of both glutathione and NADPH. This
suggests that initial oxidation by cytochrome P-450
is followed by a conjugation reaction with
glutathione. The formation of these products was
sensitive to inhibitors of both cytochrome P-450
and the glutathione transferases (GST), the
inhibitors being chtorodinitrobenzene and hexa-416 AGM BACR ABSTRACTS
chlorobutadiene. Hexachlorobutadiene is a
particularly good substrate for the microsomal
GST. This fact together with the finding that the
addition of cytosol to the incubation systems did
not increase metabolite formation suggests that the
as yet poorly characterised microsomal GST play
an important role in the disposition of
mitozantrone. The above data provide evidence that
mitozantrone is metabolized to both glucuronide
and glutathione conjugates. Whether there is any
further processing of these metabolites in vivo
remains to be established.
Lack of mitoxantrone free radicals and redox cycling
in rabbit heart sarcoplasmic reticulum; comparison
with doxorubicin
L.H. Patterson & J. Basra
School ofPharmacy, Leicester Polytechnic, Leicester
LE] 9BH, UK.
Mitoxantrone is a bisalkylaminoanthraquinone
antitumour agent broadly based on the anthra-
cyclines such as doxorubicin. In this study we have
investigated free radical formation and redox
cycling by mitoxantrone in heart tissue since these
events are associated with doxorubicin cardio-
toxicity. Electron spin resonance (esr) spectrometry
was used to directly monitor free radical formation
in NADPH fortified rabbit heart sarcoplasmic
reticulum (SR) incubated under anaerobic
conditions with drugs essentially as previously
described (Oldcorne et al. (1984), Biochem. Soc.
Trans. 12, 681). NADPH oxidation and superoxide
formation measured as described by Kharasch &
Novak (1983) (Arch. Biochem. Biophys., 224, 682)
were used as indicators of SR mediated drug redox
cycling. Mitoxantrone free radicals were not
observed in mitoxantrone (400pum)-SR incubations
up to 1 h although under identical conditions
doxorubicin free radicals were readily obtained.
Furthermore, mitoxantrone diminished doxorubicin
free radical esr signal intensity when the two drugs
were coincubated in heart tissue. Doxorubicin free
radical esr signal intensity was dependent on SR
protein concentration and could be partially
inhibited by ascorbic acid (500uM). Mitoxantrone
(50uM) inhibited SR basal rate NADPH oxidation
(2.9+0.3) and superoxide formation (2.0+0.3), both
measured as nmol.mg protein 1 min-1, by 32% and
39% respectively. Doxorubicin (50,M) however
stimulated these events by 27% and 53%
respectively. These results show that mitoxantrone
does not redox cycle in heart SR to produce
reactive oxygen species. It is unlikely, therefore, that
the cardiotoxic potential of mitoxantrone is
mediated by the same mechanism suggested for
doxorubicin.
Iminium ion formation vs carbinolamine-
aminoaldehyde tautomerism in the solvolysis of
triazine and triazene carbinolamines: A model system
for the metabolism ofN-alkyl xenobiotics
K. Vaughan, R.J. LaFrance, H.W. Manning &
C.M. Hemens
Department ofChemistry, Saint Mary's University,
Halifax, Nova Scotia B3H 3C3, Canada.
The oxidative metabolism of N-alkylamines to N-
(I-hydroxyalkyl)amines, 'carbinolamines' is a
ubiquitous pathway for many classes of xenobiotic
molecules bearing an N-alkyl group. It has been
suggested that ionization of the intermediary
carbinolamine gives rise to electrophilic iminium
ions, which might form covalent bonds with
nucleophilic functionalities present in biomacro-
molecules (Murphy (1973), J. Biol. Chem., 248,
2796). To test this hypothesis, we have studied the
behaviour of a number of stable carbinolamines of
the triazine and triazene series under chemical
conditions where iminium ion formation should be
favoured. There is no evidence for iminium ion
formation from the acyclic carbinolamines, whereas
when the hydroxyl group is derivatised as an
acetate functionality, iminium ion formation can be
clearly demonstrated by classical chemical kinetics.
In contrast, cyclic carbinolamines undergo facile
attack by a nucleophilic solvent without the
requirement for derivatisation; the reactivity of the
cyclic carbinolamine can be explained by the
phenomenon of carbinolamine=aminoaldehyde
ring-chain tautomerism, which is an unavailable
option for the acyclic carbinolamine. The
conclusion of this study is that the formation of
iminium ions during metabolism of some N-alkyl
xenobiotics must involve biological conjugation of
the a-hydroxyalkyl function, whereas, in those cases
where a cyclic carbinolamine is the intermediary
metabolite, the suggested reactivity with bio-
nucleophiles may involve pathways other than the
formation ofiminium ions.
The metabolism of N,N-dimethylformamide (DMF)
and N-methylformamide (NMF) in mice
P. Kestell & A. Gescher
CRC Experimental Chemotherapy Research Group,
University ofAston, Birmingham, UK.
The formamides NMF and DMF possess anti-
tumour activity in mice (Gescher et al., (1982), Br.
J. Cancer, 45, 843; Dexter et al. (1982), Cancer Res.
42, 5018) and induce terminal differentiation in
HL-60 human promyelocytic leukaemia cells.
(Collins et al., (1978), Proc. Natl Acad. Sci (USA)
75, 2458). Whether their antitumour activity in vivoAGM BACR ABSTRACTS 417
and ability to induce differentiation in vitro are
related is not known. In order to elucidate the
mechanism of antitumour activity of NMF and
DMF we studied their metabolism in male
CBA/CA mice. [14C]Methyl labelled drugs were
injected intraperitoneally (6.8mmolkg-1). The
drugs were partially metabolized to [14C]CO2.
Within 72h after administration of [14C]NMF
14.1% of the dose was exhaled as [14C]CO2, and
after [14C]DMF 23.1%. Of the radioactivity
injected with [14C]NMF 73.3% was excreted in the
urine. In case of [14C]DMF 62.4% of the dose was
recovered in the urine. Examination of urine
samples collected after injection of [14C]NMF by
TLC-autoradiography revealed the presence of
metabolites, one of which was identified as methy-
lamine after reaction with 2,4-dinitrobenzene-
sulphonate. The product, N-methyl-2,4-dinitroani-
line, was isolated and characterized by mass
spectrometry. DMF does not appear to undergo an
analogous metabolic route, as similar treatment of
urine samples collected from mice dosed with
[14C]DMF did not detect the presence of
dimethylamine.
Differential susceptibility to N-methylformamide
induced hepatotoxicity in rats and mice
K. Tulip, J.K. Nicholson & J.A. Timbrell
Toxicology Unit, The School ofPharmacy,
University ofLondon, 29/39 Brunswick Square,
London WCJN lAX, UK.
N-methylformamide (NMF) is a potential
antitumour drug which has been associated with
liver damage in mice, rats and humans. The
mechanism of this hepatoxicity is unknown. We
have investigated the hepatotoxicity of NMF in
male Sprague Dawley rats. In this strain NMF in
single doses of 200-800mgkg-1 was not hepato-
toxic and was only mildly hepatotoxic at
1000mgkg-1, as judged both histopathologically
and by measurement of aspartate and alanine
transaminase levels in plasma. In Balb/c mice,
however, a dose of 200mgkg-1 caused a significant
degree of hepatic damage, principally centrilobular
necrosis. At doses of 400 and 800mgkg-1 massive
haemorrhagic necrosis was observed. The level of
non-protein sulphydryls in mouse liver was reduced
by 75%, two hours after a hepatotoxic dose
(400mgkg-1) of NMF. Pretreatment of rats and
mice with phenobarbitone did not increase the
hepatotoxicity.
The metabolism and distribution of 14C methyl
labelled NMF was studied in rats. After 72h, 62%
of the dose was excreted in urine, 2% in faeces and
6.3% as expired CO2. High field proton NMR
spectroscopy was used to identify NMF and its
metabolites in urine samples. The metabolites
identified include formate, formamide and methyl-
amine. Two resonances characteristic of acetyl
groups and a group of resonances characteristic
of the cysteine conjugate were also detected in the
urine. Quantitative analysis of 0-24h urine by
GC, TLC and high field proton NMR revealed
mainly unchanged NMF (16% of the dose), also
formamide (2% of the dose), formate (4% of the
dose) and methylamine (2% ofthe dose). The results
suggest a species difference in NMF induced hepato-
toxicity between Sprague Dawley rats and Balb/c
mice. In the Sprague Dawley rats we found very
little metabolism of NMF and only mild hepato-
toxicity.
DNA and protein adducts as indicators of in vivo
methylation by nitrosatable drugs
P.B. Farmer & D.E.G. Shuker
MRC Toxicology Unit, Woodmansterne Road,
Carshalton, Surrey, UK.
The analgesic drug aminopyrine is known to be
carcinogenic in animals, when administered in the
presence of nitrite. This is believed to be due to the
intragastric production of the methylating agent
dimethylnitrosamine. Many other drugs (e.g.
cimetidine, oxytetracycline) have been suggested as
potential hazards if ingested in the presence of
nitrite. We have been exploring the extent of these
possible hazards by measurements of the methy-
lation of guanine in nucleic acids and of cysteine in
haemoglobin following administration to rats of
nitrosatable drugs. 7-Methylguanine, which is
rapidly excised from DNA after its formation, was
determined in urine samples by capillary GC-MS
following its partial purification and derivatisation.
Similarly, S-methylcysteine was isolated from acidic
hydrolysates of globin samples. derivatised and
determined by GC-MS. Stable isotope labelled
drugs have been used, in order to distinguish
methylation products from naturally occurring
methylated materials.
For example we have observed 7-CD3 guanine
(47.3 nmol24h-1 post dosing) in urine, following
intragastric administration of a mixture of nitrite
and aminopyrene labelled with 6 deuterium atoms
in its dimethylamino group (100mgkg-1). Urinary
excretion of 7-CD3 guanine was undetectable after
5 days. In contrast S-CD3 cysteine could be
determined in globin samples at 7 days
(22.7nmolg 1) and 15 days (10nmolg-1) following
treatment. Its rate of loss from globin was faster
than the normal turnover rate of haemoglobin in418 AGM BACR ABSTRACTS
rats (lifetime 60 days). Similar studies with
cimetidine and pyrilamine have shown no evidence
of methylation of guanine or ofcysteine.
We hope to use this methodology to examine the
potential of nitrosatable drugs to give rise to
methylating agents in humans undergoing therapy.
Immunohistochemical analysis of lymphoid and
epithelial tumours using 'lineage specific' including
MHC class II monoclonal antibodies (MO-ABS)
F.G. Hay', C.M. Steel2, P. Elder2, B. Cohen1 &
R.C.F. Leonard1
'Department of Clinical Oncology and 2MRC
Clinical and Population Cytogenetics Unit, Western
General Hospital, Edinburgh, Scotland, UK.
Most human tumour preparations contain a
mixture of lymphoid and other 'reactive' cells. The
value of immunocytochemistry in assigning lineage
in these situations depends upon morphology and
the use of truly lineage-specific MO-ABS or
technically complex cell sorting and double
labelling. A library of MO-ABS, including 'lineage
specific' markers, has been applied to human
epithelial lymphoid tumours freshly obtained
and/or 'purified' in cell culture. Immunoperoxidase
techniques were applied to imprints and cytospin
preparations. See Table below.
(1) MHC class II antigens, of which DR is a
subset, are expressed in NHL but are restricted in
the epithelial tumours and their cell lines. (2) The
anti SCLC (299) is expressed in other epithelial but
not lymphoid cells. (3) HMFG2 does show some
restriction in expression in epithelial tumours. (4)
The MHC pattern in ovarian cancer indicates that
positivity may be due to admixed lymphoid cells.
The possibility of true cross-reactivity due to
expression of common antigens will be explored by
biochemical techniques.
Lymphomas positive for the Ki-1 antigen do not
express macrophage markers
D.B. Jones1, H. Stein2, N. Hogg3, H. Radzun4 &
J. Gerdes2
1University Department ofPathology, Southampton,
Institutes ofPathology, 2Berlin, and 4Kiel and
3ICRF, London, UK.
The Ki-l antigen has been previously described as
identifying Reed-Stemnberg and mononuclear
Hodgkins Cells in frozen section and also staining a
population of dividing cells in reactive lymph node
and tonsil. Further studies have demonstrated that
this marker also stains lymphomas positive for al
anti-trypsin and considered as being of histiocytic
origin. In this study we have examined a series of
ten Ki-I lymphomas with antibodies known to
identify macrophages and monocytes in reactive
and neoplastic tissue. Five of these tumours were
positive for al anti-trypsin. All cases were negative
with the markers UCH-Ml, MOl, M02, SHCL-3,
3.9, 44, Ki-MI, KiM6 and KiM8. Node based
lymphoma in a patient previously shown to have
monocytic leukaemia is positive with these reagents,
but negative with Ki-I. These data indicate that
whilst al anti-trypsin may be present in
macrophages, its association with the Ki-l antigen
does not indicate a macrophage origin and are in
keeping withm metabolic studies which show that
whilst the production of al anti-trypsin is a feature
of macrophage rich cell preparations, low levels of
synthesis can also be seen in heavily macrophage-
depleted cell cultures.
Autoproliferative and cytotoxic responses to human
tumours
T.E. Roberts and M. Moore
Department ofImmunology, Paterson Laboratories,
Christie Hospital and Holt Radium Institute,
Manchester, M20 9BX, UK.
Peripheral blood T cells activated in vitro by
rable
aJB aB2 '(MHC)PAN 'DR TF b229 CHMFG2
'Lymphoma F 0/4 1/4 4/4 4/4 4/4 0/3 0/3
lymphoblastoid C 6/6 3/6 6/6 6/6 6/6 NT NT
bSmall cell F 0/3 1/1 1/7 0/8 1/5 8/8 0/5
lung cancer C 0/1 0/1 0/1 0/1 0/1 1/1 1/1
COvarian cancer F 2/2 2/2 2/2 1/1 1/2 2/2 2/2
C 2/2 2/2 0/2 0/2 0/2 2/2 2/2
F=Fresh specimens. C=Cell lines. B1, B2 from L. Nadler; HMFG2, J. Taylor-
Papadimitriou; TF, G. Brown.AGM BACR ABSTRACTS 419
cocultivation for 6 days with autologous tumour
cells originating from pleural effusions or lymph
node metastases, were cultured in IL-2 and cloned
by limiting dilution. Helper function was assayed in
the primed lymphocyte test (PLT) and cytotoxic
activity (CTX) by 51Cr release against autologous
and allogeneic tumour targets and NK-sensitive
K562 cells. Of 9 clones assayed against tumour BA
(ovarian ca.), 7 exhibited autologous but not
allogeneic or NK-like CTX, one expressed NK-like
activity, while another possessed no CTX. None of
the clones (3 of which were of T4, and 6 of T8
phenotype) lysed allogeneic peripheral blood
mononuclear cells (PBMC). By contrast, clones
(two T4+, three T8+) generated against a breast
carcinoma (BR) expressed only NK-like activity,
autologous and allogeneic targets proving
uniformly resistant. A renal carcinoma (CW)
generated clones with similar activity, but with
lesser frequency. Unlike BR, however, CW clones
(mostly T4+) were reactive in the PLT to
autologous but not allogeneic tumour cells. T4+
clones developed against HK tumour (ovarian ca.)
also exhibited helper activity, which was not
noticeably enhanced by tumour cell pretreatment
with IFN-y. Concomitant NK-like and autologous
CTX was a feature of these clones, though the
majority were cytolytically inactive. The data
indicate that (i) cultured T cells (CTC) generated in
mixed tumour: lymphocyte cultures may possess
tumour-associated cytotoxic and/or helper activity;
(ii) CTC of classical T cell phenotype may also
show NK-like activity and (iii) phenotyping
provides only a limited indication of functional
status.
Lymphokine-activated killing of fresh human
leukaemias and solid neoplasms
M.M. Dawson', T.E. Roberts', M. Moore' &
G.M. Taylor2
'Department ofImmunology, Paterson Laboratories,
Christie Hospital and Holt Radium Institute; and
2Department Medical Genetics, St Mary's Hospital,
Manchester, UK.
Culture of normal non-immune peripheral blood
lymphocytes (PBL) for a minimum of 2 days in
Interleukin-2 (IL-2) results in the generation of
lymphokine-activated killer (LAK) cells, as defined
by amplified killing of cell-line targets. These
effectors purportedly differ from NK cells, among
other factors by their capacity to lyse tumours
which have not been adapted to tissue culture and
from cytotoxic T lymphocytes (CTL) because
killing is non MHC-restricted. The susceptibility of
fresh tumours to lysis by LAK was investigated
using a panel of autologous and allogeneic PBL
activated in vitro by MLA-144 containing IL-2
supernatants or recombinant IL-2 (Biogen). Cyto-
toxicity was donor-dependent, the susceptibility of
8/12 myelomonocytic leukaemias being comparable
only with that ofrelatively LAK-resistant B lympho-
blastoid cell lines. However, 4 leukaemias showed
slightly greater susceptibility, one of them (E84)
from a patient surviving 5 years. Autologous LAK
was demonstrable in the remission lymphocytes of
this patient. E84 cells failed to cold inhibit lysis of
erythroleukaemic K562 cells suggesting recognition
by LAK of different target structures. Using solid
tumours as targets, LAK by normal allogeneic PBL
has been observed, to date, in 2/11 combinations
and by autologous PBL in 1/3 combinations and
cytotoxicity (at E:T ratio, 20:1) has not exceeded
25% (against a carcinoid tumour). The factors
which determine sensitivity of fresh tumour agents,
of whatever provenance, to LAK, are unknown.
Comparison of an immunoperoxidase and a
biochemical technique in assessing oestrogen receptor
content of human breast tumours
R.A. McClelland', E. Jensen2, L. Miller3,
U. Berger' & R.C. Coombes'
'Ludwig Institutefor Cancer Research (LICR)
(London Branch), Royal Marsden Hospital, Sutton,
Surrey, SM2 SPX, UK; 2LICR, Zurich, Switzerland;
and 3Abbott Laboratories, Diagnostics Division,
North Chicago, USA.
An immunocytochemical procedure for determining
the presence of oestrogen receptor (ER) in human
breast tissue is currently being evaluated in our
laboratory with respect to its comparability with
the widely used dextran coated charcoal method
(DCC) (McGuire & De La Garza (1973), J. Clin.
Endocrinol. Metab. 37, 986). Using an indirect
immunoperoxidase technique and a rat anti-human
ER monoclonal antibody (H222 Spy) we have been
able to show specific staining of nuclear oestrogen
receptor in many frozen, formol-saline fixed
sections of breast tumour (68%).
Parallel DCC and immunocytochemical
(ER/ICA) assays on stored breast tumour biopsies
have to date given good qualitative correlation of
results (Table). A quantitative comparison of results
has also been attempted by utilising a mean
staining intensity index for ER/ICA and the
concurrence of results is again good.420 AGM BACR ABSTRACTS
Table
Total
ER/ICA +ve -ve (% correlation)
+ve> 15 fmolmg-1 cyt. protein 24 1 25 (96)
DCC -ve<10 fmolmg- I cyt. protein 1 9 10 (90)
borderline 10-15 fmolmg-1 cyt. protein 1 2 3
Totals 26 (68%) 12 (32%) 38
Results obtained so far suggest that ERICA, with
its inherent advantages in terms of the speed of
assessment and its requirement for only small
quantities of tissue, may in the future, represent a
valuable means of selecting oestrogen dependent
tumours for endocrine therapy (McGuire & De La
Garza (1973), J. Clin. Endocrinol. Metab. 37, 986).
Relationship of sialyltransferase activity in the serum
of breast cancer patients to tumour burden
J. Nelson', B.J. McDermott2, L. Jeffrey3 &
R.F. Murphy1
'Department ofBiochemistry, Queen's University of
Belfast; 2Clinical Oncology Unit, University of
Bradford; and 3Belvoir Park Hospital, Belfast, UK.
Increases in sialyltransferase (ST) activity in serum
have been commonly reported to correlate with
progression of neoplastic disease, but in a
preliminary study in post-mastectomy patients,
enzyme levels were not associated uniformly with
tumour burden (McDermott et al. (1982), Br. J.
Cancer, 46, 511). ST activities have now been
measured in the sera of 135 patients of which 64
were monitored for periods up to 32 months. In a
vertical study, patients were divided into 3 groups: I
clinically tumour-free; II, minimal disease (lymph-
node involvement and recurrence); III, metastatic
disease. SR activities (mean + s.e.) were 5.77+0.34
8.31+0.41 and 7.12+0.53pmol sialic acid
transferredmg - protein h- and the % of values
above the upper limit of normal (8.2 units) were
12.2, 53.2 and 25.6 for Groups I, II and III
respectively. A prognostic significance was observed
for Group I patients who did not receive treatment,
in which the mean initial value of ST in cases where
disease progressed (5.93 units) was greater
(P<0.05) than in cases of stable disease (4.26
units). Also, in Group II patients, the mean pre-
treatment value of ST in the sub-group who
progressed (8.65 units) was greater (P<0.01) than
in that which regressed (5.70 units). When lymph-
node or systemic metastases developed in 22
patients in Groups I or II, ST levels elevated
synchronously in 5 cases but more often were
raised before the overt development of metastatic
disease: ST activity in serum reached a peak and
then declined up to 13 months before the clinical
detection of progressive disease in 10 of these
patients. The sensitivity of ST for detecting early
metastatic disease is consistent with the
consideration that the enzyme maybe a measure of
the metastatic potential of the tumour.
Aggressive short duration chemotherapy and
radiotherapy in locally advanced nonmetastatic breast
cancer - report of a pilot study
A. Rodger', J.F. Smyth1, R.F. Leonard',
0. Eremin2 & U. Chetty2
Departments of1Clinical Oncology and 2Clinical
Surgery, Edinburgh University, UK.
Twenty-five patients with locally advanced
nonmetastatic breast cancer underwent
chemotherapy (CHOP) with cyclophosphamide
(1000mgm-2), adriamycin (50mgm-2) vincristine
(1.4mgm-2 to a maximum of 2mg) and
prednisolone (40mgday-1 orally for 5 days) given
on a 3 weekly cycle for a total of 4 courses. One
month later they commenced a course of
megavoltage X-ray therapy to the breast and
peripheral lymphatics given in 20 fractions over 4
weeks to a maximum tissue absorbed dose in the
breast, central axilla and supraclavicular fossa of
45-50Gy. If appropriate one month later a boost
to the axilla and/or breast mass was given using
10MeV electrons (15Gy in 5 fractions) or iridium
implant (reference dose 2-30Gy). Toxicity was
acceptable and patient compliance was 100%. Only
5 patients experienced any delay in planned courses
of chemotherapy. Acute radiation skin reactions
were not enhanced by the preradiation
chemotherapy and were radiation dose related.
After chemotherapy there was a complete remission
(CR) of 20% and partial remission (PR) of 48%
with only 8 patients (32%) showing static or
progressive disease. Following the radiotherapy the
overall CR was 64% and PR 32% with only 1
patient (4%) who failed to show any response to
combined treatment. Persistent local control at timeAGM BACR ABSTRACTS 421
of evaluation (4-30 months) was achieved in 14/25
(56%). Local control was not related to menstrual
status, oestrogen receptor (E2R) level, primary
tumour size, extent of nodal metastases, or
radiation boost. E2R level predicted response to
neither chemotherapy nor to radiotherapy. The
crude 1 and 2 year survivals are 83.3% and 71.4%
respectively. This regime has the advantage of
excellent compliance and acceptable morbidity.
Preliminary characterisation of a tamoxifen resistant
variant of the oestrogen responsive human breast
cancer cell line ZR-75-1
H.W. Vandenberg' & R. Clarke2
Departments of 1Therapeutics and 2Biochemistry,
The Queen's University ofBelfast, Northern Ireland,
UK.
The oestrogen receptor (ER) positive human breast
cancer cell line ZR-75-1 is sensitive to growth
inhibition by the antioestrogen tamoxifen. In an
attempt to generate a tamoxifen-resistant variant
line, parent cells were grown in the presence of
10-6 M tamoxifen for a period of two weeks
followed by a further two weeks in the presence of
2 x 10-6 tamoxifen. Surviving cells were then grown
in the absence of antioestrogen for 2 further weeks
prior to assessment of the effect of tamoxifen on
DNA synthesis and cell proliferation. Whilst DNA
synthesis, as measured by [3H] thymidine
incorporation, and cell proliferation were inhibited
in a dose-dependent manner by tamoxifen,
(10-8 M 10-6 M) in parent cells, the antioestrogen
failed to significantly affect these parameters in the
variant line, (designated ZR-75-1R), at
concentrations up to 10-6M. Determination of ER
levels in the two lines using a whole cell binding
assay revealed that the ZR-75-1R line contained
- 20% of the oestrogen binding capacity of the
parent line. Resistance to tamoxifen in this variant
line therefore correlates with a reduction in ER
levels, in contrast to an earlier report of a resistant
sub-line of MCF-7 cells which retained an ER
content equivalent to wild type cells, (Nawata et al.,
(1981) J. Biol. Chem. 256, 5016).
The treatment of premenopausal patients with breast
cancer with buserelin nasal spray
S.J. Harland', J.H. Waxman2, L. Rees2, H.T.
Ford', J.C. Gazet', A. Nash', T.J. Powles' &
R.C. Coombes'
'Royal Marsden and 2St Bartholomew's Hospitals,
London, UK.
Luteinising hormone-releasing hormone (LHRH)
analogues suppress pituitary gonadotrophin release,
and have been used as an alternative to artificial
menopause in breast cancer patients (Klijn & de
Jong (1982), Lancet i, 1213). We have treated 13
premenopausal patients with the LHRH analogue,
buserelin, given by nasal spray.
Gonadotrophin response to LHRH injection,
assessed before treatment and after 4 weeks,
showed satisfactory pituitary inhibition. Significant
changes in sex hormone levels were not seen
however: mean plasma oestradiol levels were 453
(range: <50-1400)pmoll-' before treatment and
284 (range: 130-870)pmol 1 ' 4 weeks after
starting. Only one patient experienced hot flushes,
but all 5 patients who remained on buserelin for 3
months stopped having normal periods.
Two partial responses, one minimal response and
two disease stabilisations were seen. Five patients
had an artificial menopause at disease progression.
Two patients responded at this stage. Although
buserelin nasal spray produces tumour responses in
premenopausal patients with breast cancer it is not
effective as artificial menopause.
4-hydroxyandrostenedione - A new treatment for
postmenopausal patients with metastatic breast
cancer
P. Goss', R.C. Coombes2'3, T.J. Powles3,
M. Dowsett4 & A. Brodie'
'Cancer Research Campaign; 2Ludwig Institutefor
Cancer Research; 3Royal Marsden Hospital, Sutton,
Surrey SM2 5PX; 4Department ofEndocrinology,
Chelsea Hospitalfor Women, London, SW3, UK;
and IUniversity ofMaryland, Baltimore, Maryland,
USA.
4-Hydroxyandrost-4-ene-3, 17-dione (4-OHA) is a
potent, selective inhibitor of the aromatase enzyme
complex responsible for the conversion of
androgenic precursors to oestrogens. Thirty-nine
postmenopausal patients with metastatic breast
cancer have been treated with once weekly i.m.
injections of 500mg 4-OHA. Of 19 assessable
patients to date 9 have responded for treatment for
periods up to 9 months. Healing of bone metastases
and palliation of pain as well as reduction and
resolution of soft tissue metastases have occurred.
Troublesome pain and induration at the injection
sites has been decreased by deep i.m. injection and
formulation of the compound in a micronised form.
Occasional vaginal bleeding and hot flushes have
been reported. After a single 500mg i.m. injection,
a sustained reduction in plasma oestradiol levels
was observed for at least one week in 5 patients.
Both the oral and vaginal route of administration
are currently being investigated.
4-OHA is a promising new agent in the
management of breast cancer.422 AGM BACR ABSTRACTS
Prednisolone, adriamycin, bleomycin, vincristine and
etoposide (pabloe) alternating with ChlVPP in the
treatment of advanced Hodgkin's disease
N.S.A. Stuart', M.H. Cullen', C.M. Woodroffel,
G.R.P. Blackledgel, E.L. Jones2, J. Fletcher3, J.A.
Child4, A.D. Chetiyawardanal, D. Spooner' &
J.J. Mould'
'Queen Elizabeth Hospital, Birmingham; 2University
ofBirmingham; 3City Hospital, Nottingham; and
4General Infirmary, Leeds, UK.
There are theoretical attractions and some clinical
data to support the use of alternating, non-cross
resistant combinations of active drugs in advanced
Hodgkin's Disease. The best studied approach is
with MOPP/ABVD and we have modified this
regime in the hope of identifying an equally
effective regime with less short-term toxicity and
hence greater patient acceptability.
Ch1VPP has been substituted for MOPP;
etoposide and vincristine substituted for
dacarbazine and vinblastine in ABVD. ChlVPP
comprises vinblastine 6mgm-2 i.v. on days 1 and
8, and chlorambucil 6 mg m 2, procarbazine
100 mgm-2 and prednisolone 30 mgm-2 orally on
days 1-15. PABLOE comprises prednisolone
40mgm-2 dl-15. Adriamycin 40mgm-2 (i.v. dl)
bleomycin 10 mg m -2 and vincristine 1 mgm-2 (i.V.
dl, d8) and etoposide 200mgm-2 orally daily d2-
4. PABLOE commences on day 29 following
ChlVPP and the whole cycle repeats on day 50.
Patients resistant to conventional chemotherapy
receive PABLOE alone every 21 days.
Seventy patients are currently on study with 40
evaluable for treatment response. Of 25 patients
who had received no prior chemotherapy 18 (72%)
achieved CR and 5 (20%) PR. Of 15 patients who
had relapsed or failed after previous chemotherapy
7 (47%) achieved CR and 4 (27%) PR. The regime
has been well accepted producing little nausea and
vomiting. All patients experience alopecia. Infection
has been the commonest complication affecting
25% of patients at some stage during treatment.
There have been 4 deaths to which treatment
induced neutropenia may have contributed.
Evaluation of vincristine as an adjunct to intermittent
melphalan and prednisone therapy in myelomatosis
I.C.M. MacLennan
Department ofImmunology, University of
Birmingham B15 2TJ (for the Medical Research
Council's Working Party on Leukaemia in Adults).
Vincristine has been widely used in combination
with other cytotoxic agents in the treatment of
myelomatosis. Evaluation of the results of this use
of vincristine have resulted in claims that vincristine
is an important agent in the first line treatment of
this disease. However, there has been lack of
objective evidence to support this conclusion.
Between 1 March 1980 and 28 February 1982 the
MRC Working Party on Leukaemia in Adults
admitted 530 patients with previously untreated
myelomatosis to its lVth trial in this disease. In this
trial vincristine was added as a single randomised
variable to intermittent melphalan and prednisone.
Vincristine was given as 1 mg i.v. on the first day of
7 day courses of melphalan 10mg daily orally and
prednisone 40mg daily orally. The interval between
the first day of courses was 4 weeks. Patients were
treated to plateau plus 6 months at which stage
they were re-randomised either to continue first line
therapy for a further year or discontinue treatment.
Analysis of the trial to 1 February 1984 shows no
survival advantage in patients allocated vincristine.
Analysis by prognostic groups failed to identify any
group which benefitted from the addition of
vincristine. Patients randomised to stop at plateau
fared slightly better than those continuing first line
therapy but this difference is not significant
(P=0.2).
Antitumour effect of new anthracyclines in mice
H.R. Hartmann', M.J. Broadhurst2, G.J. Thomas2
& J.A. Martin2
'Hoffman-La Roche and Co. Ltd., Basel,
Switzerland; and 2Roche Products Ltd., Welwyn
Garden City, Herts, UK.
New anthracyclines prepared by total synthesis in
the Roche laboratories in England were evaluated
for cytostatic effects against a range of murine
tumours in the Swiss laboratories.
The antitumour activity was calculated from the
mean survival time of treated and control groups of
mice bearing L1210 (T/C) and the mean 13C
mammary tumour weight of controls relative to
treated mice (C/T). In the L1210 model drugs were
administered daily, 5 times per week, either i.p. or
p.o. for 4 weeks or until death, whereas the solid
tumour bearing mice were dosed i.p. for 2 weeks,
the tumours were excised and weighed on day 15.
Toxicity was evaluated on day 15 following
multiple i.p. dosing. Body weight change and white
blood cell count were measured.
Many compounds showed superior efficacy
and/or potency in comparison with doxorubicin.
For example, the alcohol Ro 31-1741 had the same
cytostatic activity as doxorubicin at a 15 times
reduced dose. Two other compounds Ro 31-1215 (a
9-methyl derivative) and Ro 31-2035 (a 9-
substituted urethane) showed superior inhibition ofAGM BACR ABSTRACTS 423
L1210 and 13C relative to doxorubicin at similar
doses, the latter compound displayed oral activity
against L1210. Another urethane Ro 31-2383 was
more potent and more efficacious than doxorubicin,
and also had oral activity against L1210.
New anthracycines. In vitro effects and cross-
resistance patterns in control and adriamycin-
resistant cell lines
P.R. Twentyman', N.E. Fox', K.A. Wright', P.
Workman', M.J. Broadhurst2 & J.A. Martin2
'MRC Clinical Oncology and Radiotherapeutics
Unit, Hills Road, Cambridge; and 2Roche Products
Ltd., Welwyn Garden City, UK.
A range of new anthracyclines, structurally related
to adriamycin, has been synthesised by Roche
Products Ltd. and studied in vitro. Three
compounds being evaluated extensively in
preclinical studies are shown below. In the
EMT6/VJ/AC mouse tumour cell line, the
continuous drug concentration to inhibit colony
formation by 90% was similar for ADM, 1741 and
1215, The value for 2035 was higher by a factor of
10. For 1 h drug incubation followed by colony
growth in drug-free medium, 1741 and 1215 were
3 x more potent than ADM whilst 2035 was 3 x
less potent. In the human small cell lung cancer line
NCI-H69 results for continuous drug exposure were
similar to those for the mouse cells. In mouse
models, 2035 showed greater potency and efficacy
than would have been predicted from these in vitro
results (Hartmann et al., this meeting). ADM-
resistant sublines of the two cell lines have also
been studied. For compounds 2035 and 1741 there
was complete cross-resistance (CR) for both lines.
For 1215, however, there was only partial CR in
the mouse cells and a total absence of CR in the
human line. A subline of the mouse cells selected
for continuous growth in 1215 was resistant to both
1215 and ADM. The cellular pharmacology of
0 OH
a3




Drug RI R2 R3 R4
Adriamycin OH H COCH2OH OCH3
Ro 31-2035 H OH CH2OCONHPh H
Ro 31-1741 H OH CH2OH H
Ro 31-1215 OH H CH3 H
ADM and 1215 in control and resistant cell lines is
being studied.
9-Alkyl anthracyclines. Absence of cross resistance in
a human cell line
C.A. Scott, D. Westmacott, M.J. Broadhurst, G.J.
Thomas & M.J. Hall
Roche Products Limited, Welwyn Garden City,
Herts AL7 3AY, UK.
Twentyman et al. have observed (this meeting) that
a novel 9-methyl anthracycline Ro 31-1215
indicated absence of cross resistance in an
adriamycin (ADM) resistant human cell culture.
We have investigated the resistance pattern in a
series of related 9-alkyl anthracyclines using a
human T-lymphoblastoid line.
The compounds examined were the 9-methyl and
9-ethyl substituted 4-demethoxy anthracyclines
containing the daunosamine or 4'-epi-daunosamine
sugar moiety (Ro 31-1215, Ro 31-1740, Ro 31-1749
and Ro 31-1966).
The parental cell line (CCRF CEM) was
rendered resistant by several serial passages in
medium RPMI 1640 containing ADM at
0.01 igml-'. This produced a 2.3 to 5-fold increase
in resistance factor to ADM and related
compounds. Resistance to the 9-alkyl analogues
was then determined by continuous exposure of the
cell cultures over a period of 4 days followed by
assessment of cell growth.
Without exception all standard compounds
evaluated, including 4'-epi-adriamycin, daunomycin,
mitoxanthrone and also novel compounds not
possessing 9-alkyl substituents were cross resistant
with ADM.
By contrast, the cell line rendered resistant to
ADM retained full sensitivity to all four 9-alkyl
analogues irrespective of the configuration of the
sugar residue.
Human liver microsomal generation of doxorubicin
and mitoxantrone free radicals
J. Basra', C.R. Wolf2 & L.H. Patterson'
'School ofPharmacy, Leicester Polytechnic,
Leicester LEJ 9BH; and 2Imperial Cancer Research
Fund, Medical Oncology Unit, Western General
Hospital, Edinburgh, EH4 2XU, UK.
Liver microsomes from animals are well established
as a source of enzymes mediating doxorubicin and
related anthraquinone free radical formation and
redox cycling. Such studies are often used to
rationalise the activities of these antitumour agents
in humans (Olsen et al., (1981), Life Sci., 29, 1393).424 AGM BACR ABSTRACTS
In this study we have investigated the occurrence of
doxorubicin and mitoxantrone free radical
formation in human liver microsomes (HLM)
prepared from five organ transplant donors.
Cytochrome P450 content (0.22+0.017nmolmg-1
protein) and cyt.c reductase activity
(166.4+44.Onmolmg-1 proteinmin-1) were similar
to that described for various animals (Pelkonen et
al. (1974) Chem. Biol. Interact, 9, 205). NADPH
fortified HLM under anaerobic conditions
generated doxorubicin free radicals (g=2.0038) and
mitoxantrone free radicals (g=2.0036) when
incubated with respective parent compound as
monitored by electron spin resonance spectrometry
(as described by Oldcorne et al. (1984) Biochem.
Soc. Trans., 12, 681). Basal rates of NADPH
oxidation (8.5-18.4nmolmg-1 proteinmin-1) and
superoxide formation (32.3-114.2nmolmg-1
protein min-1) measured in individual liver
samples, (Kharasch and Novak (1983) Arch.
Biochem. Biophys., 224, 682), were significantly
stimulated by doxorubicin. However, mitoxantrone
only slightly increased NADPH oxidation and had
little effect on the basal rate of superoxide
formation. The results show that doxorubicin and
mitoxantrone free radicals are generated in HLM
but that only doxorubicin participates in a redox
cycle that leads to a significant increase in
superoxide formation. Also the results support the
use of animal models to investigate drug activation
in humans.
Intracellular uptake of 4'-deoxydoxorubicin and
adriamycin by human lung tumour cells in culture
and its relationship to cell survival
D.J. Kerr, A.M. Kerr, R.I. Freshney & S.B. Kaye
Department ofClinical Oncology, University of
Glasgow, Glasgow G12, 9LX, UK.
4'-Deoxydoxorubicin (4') is an anthracycline
antitumour agent with a similar spectrum of
activity to adriamycin (A). Although differing only
in substitution of a hydroxyl grouping on the
daunosamine sugar the 4' derivative is considerably
more lipophilic than A, and might have an
enhanced rate of cell uptake. Non-small cell lung
tumour cells (L-DAN) were maintained as a
monolayer in exponential growth in Hams F-10
medium supplemented with foetal calf serum. The
cells were exposed to varying drug concentrations
for different times and were then harvested with
0.25% trypsin. The cells were then centrifuged,
washed twice and resuspended in distilled water.
Drug and metabolites were extracted using a
standard procedure and were measured by reverse
phase HPLC utilising a fluorescence detector. Cell
survival was determined by clonogenic assay. The
time course of drug uptake showed that
intracellular drug concentration depended on drug
concentration in the medium and the duration of
drug cell contact. The rate of uptake of 4'
(Vmax=30ng 10- 5 cellsmin-1) was far greater
than A (Vmax=0.15ng 10-5cellsmin-1) and
consequently higher intracellular drug levels were
achieved for 4'. It was possible to detect
intracellular metabolism of 4' to its alcohol but this
may have been due to the high intracellular levels
of parent drug allowing metabolite detection. There
was a strong correlation between intracellular drug
concentration and survival of exponentially growing
cells, however, there was only a minor difference in
the cell survival curves at low drug concentrations
comparing 4' and A. We would conclude that
substitution at the 4' position of adriamycin
enhances cell uptake but does not improve
cytotoxicity.
Marked inter-patient variations in the metabolism of
adriamycin to 7-deoxyaglycone metabolites
J. Cummings', R. Milsted', G.J. Forrest2,
D. Cunningham2 & S.B. Kaye'
'Department of Clinical Oncology. University of
Glasgow, Glasgow G12 9LX; and 2Royal Infirmary,
Glasgow, G4 OSF, UK.
Although several studies have observed large inter-
patient variations in the pharmacokinetics of
Adriamycin (ADR) few have detected metabolites
present in serum or considered metabolism as a
serious factor contributing to these variations. In 25
patients with normal liver and kidney function, in
most cases receiving ADR (30 or 40mgm 2 i.v.)
for the first time, three major metabolites were
identified which accounted for between 97-100% of
the total serum concentration of fluorescent
metabolites. The total serum concentration of ADR
and metabolites was determined by integrating the
area under the concentration/time profiles over 24h
(AUC). Adriamycinol (AOL), the most abundant
species in 21/25 patients, accounted for between 5
and 26% of the total serum concentration of ADR
and its metabolites (TSC). Adriamycin 7-
deoxyaglycone (ADR-DONE) was not detected in
10/25 patients and in the others it accounted for
only a small proportion of the TSC (1-5%).
Adriamycinol 7-deoxyaglycone was nor detected in
12/25 patients, but when present accounted for a
more substantial amount of the TSC (10-20%) and
in 4/25 patients was the predominant metabolite
species. Its AUC exhibited a large inter-patient
variation (from 3ngml -1x h to 240ngml -1 x h).
There was a correlation between degree ofAGM BACR ABSTRACTS 425
metabolism and the AUC of ADR in serum
(r=0.73). The greater the TSC of the metabolites
the less the AUC of ADR. Metabolism may partly,
if not wholly, explain certain aspects of inter-
patient variations in the pharmacokinetics of ADR.
In turn, variations in metabolism are dictated, to a
large degree, by whether or not ADR and AOL are
converted to 7-deoxyaglycones, a process which
may have a bearing on patient toxicity and
response.
Mechanisms of resistance and its reversal in a
daunorubicin insensitive P388 cell line
A.T. McGown, T.H. Ward & B.W. Fox
Paterson Laboratories, Christie Hospital and Holt
Radium Institute, Manchester M20 9BX, UK.
A P388 cell resistant to the anthracycline antibiotic
daunorubicin (ID50 =650nm) has been developed
from the parental line (ID50= =19nm) in vitro.
Resistance to this agent has been demonstrated to
be associated with a 4-fold decreased cellular
accumulation of the drug: both by direct
quantitation of intracellular anthracycline levels, by
flow cytometry, and by extraction of drug from cell
homogenates. The cell cycle position of the cells is
shown to affect the overall level of drug
accumulation, and subsequent cell survival. An
increase in DNA content is associated with
increased drug incorporation and decreased cell
survival.
The patterns of cross-sensitivity of the
daunorubicin resistant cell line towards other
anthracyclines, anthracycline analogues, and mitotic
inhibitors correlates with the ability of the cells to
exclude drug.
Daunorubicin levels can be increased in the
resistant cell line by metabolic inhibition or by
simultaneous incubation with the vinca alkaloids.
A group of novel compounds are also shown to
inhibit the efflux of daunorubicin from the resistant
cell line, resulting in cellular accumulation equal to
that observed in the parental line.
Phase I and II study of oral verapamil (VRP) and
intravenous vindesine (VDN)
B. Cantwell, P. Buamah & A.L. Harris
University Department ofClinical Oncology,
Newcastle General Hospital, Newcastle upon Tyne,
UK.
The calcium antagonist VRP enhances the
cytotoxicity of vinca alkaloids in tumour cell lines
(Tsuruo (1983), Cancer Treat. Rep. 67, 889). We
treated 23 patients in Phase I with advanced cancer
with escalating doses of oral VRP either
continuously (c) or intermittently (i) and i.v. VDN
every 2 weeks until progression or 6 courses of
VDN. VRP (i) was given the day before, the day
and 2 days after i.v. VDN. Fifteen patients had
previous chemotherapy. In the Phase I study, VRP
was given 80mg 3 x day (c); at each VDN dose
level 3 patients were treated (2mg, 3mg, 4mg, 5mg
i.v. q 2 weeks). Four patients received 5mg VDN
with VRP 160mg 3 x day (c). VRP (i) was then
given to reduce toxicity. Final dose escalation was
7mg VDN q 2 weeks, VRP 160mg 3 xday (i).
Eighteen patients have been treated in Phase II. In
12 so far assessable, 3 responses have occurred (1
hypernephtoma, 1 squamous, 1 adenocarcinoma
lung). Phase I and II toxicity was alopecia (37%),
myelosuppression (9%), neurotoxicity (20%),
constipation (14%), symptomatic postural hypo-
tension (17%), ECG abnormalities (9%). a, acid
glycoprotein, the major plasma binding protein for
VRP was raised in patients and VRP plasma levels
were >350ngml-1 in 6 of 7 patients who received
VRP 480mg daily. Levels >350ngml-1 have been
associated with in vitro cytotoxic potentiation, and
in animals improvement of tumour blood flow
occurred at plasma VRP levels > 100ngml-1
(Kaelin et al. (1982), Cancer Res. 42, 3944). VRP is
being assessed in a randomised trial.
Investigations ofmechanisms of resistance to
etoposide in a human tumour continuous cell line
R.B. Lock & B.T. Hill
Laboratory ofCellular Chemotherapy, Imperial
Cancer Research Fund, Lincoln's Inn Fields, London
WC2A 3PX, UK.
A human tumour cell line derived from an
epithelioid carcinoma of the tongue has been made
resistant to etoposide (VP-16-213) following
fractionated X-irradiation exposure (total 22.5 Gy)
or continuous drug exposure (100ngml-1). The
order of resistance is 5- and 7-fold for the X-
irradiation treated and drug treated sub-lines
respectively, as established by assessing cell
survival, following drug treatment (0.85MM for
24h), by clonogenic assay (Courtenay et al. (1978),
Br. J. Cancer, 38, 77). The mechanisms of resis-
tance of these sub-lines investigated include (i)
levels of non-protein sulphydryl compounds, (ii)
drug transport, and (iii) analysis of DNA damage
after drug treatment.
No significant differences in glutathione content
have been found between parent and resistant sub-
lines, with values of 45-60nmolmg-1 total cellular
protein in logarithmically growing cultures,
suggesting that glutathione is not involved in the
mechanisms of resistance to etoposide. Etoposide426 AGM BACR ABSTRACTS
resistant sub-lines exhibit cross-resistance with
vincristine, and the drug treated sub-line has been
found to accumulate after 30min only 33%
(30.4pmolmg-1 total cellular protein) of radio-
actively labelled vincristine compared to the X-
irradiation treated sub-line (92.9pmolmg- 1 total
cellular protein), indicating that different
mechanisms of resistance may be involved. Earlier
studies (Hill & Bellamy (1984), Int. J. Cancer, 33,
599) showed no difference in alkaline sucrose
gradient sedimentation profiles between parent and
an X-irradiation treated sub-line after a 24h
exposure to etoposide. However, after a shorter
exposure time (1 h) the profiles suggest that both
this X-irradiation treated and the drug treated sub-
lines may sustain less DNA damage than the
parental line.
Flow cytometric studies of the vinca alkaloids on
populations of parental L1210 and gene-amplified
methotrexate resistant cells
D.G. Poppitt, A.T. McGowan & B.W. Fox
Paterson Laboratories, Christie Hospital and Holt
Radium Institute, Manchester M20 9BX, UK.
Comparative studies of the effects of three vinca
alkaloids on two cell lines, differentially sensitive to
methotrexate have been undertaken. Using
propidium iodide staining of the DNA following
vinca alkaloid treatment at doses up to 10-7 M,
a build up of fluorescence was observed at the
4n position. On an equimolar basis, the intensity
of this effect decreased in the order
vinblastine >vindesine >vincristine. Following con-
tinuous exposures to a concentration of 10-8 M
vincristine, and above, an accumulation of material
at the 8n position was observed from the DNA
fluorescent histograms. This was shown by
chromosome analysis to be due to polyploidy. The
median chromosome count in the L1210 was
38.2+1.4 for the untreated sample and 71.2+12.5
for a 48h 10-7M vincristine treated sample. The
corresponding values for the L1210/R7A line were
37.2+1.5 and 80.4+19.7 respectively. By careful
adjustment of the level of vinblastine to a mixed
population of sensitive and resistant cells, the
selective removal of the latter population has been
demonstrated at a concentration of 5 x 10-8 M.
A 'spectrum of sensitivity' model which might explain
the development of resistance to cytotoxic drugs in
some tumours
T.C. Stephens, L. Fiszer-Maliszewska, J.H. Peacock
& T.J. McMillan
Radiotherapy Research Unit, Institute ofCancer
Research, Sutton, Surrey, UK.
One model of induced drug resistance envisages
that tumour cells may be heterogeneous with
respect to their sensitivity to certain cytotoxic drugs
and that tumour resistance may emerge due to the
gradual selection of the more resistant variants
during repeated treatment regimes.
In experimental studies we have begun to
examine this model by measuring the sensitivity of
clones of cells selected from tumours. Using MT
carcinoma, we have already shown that cell
populations derived from individual lung colonies
exhibit a spectrum of sensitivities to melphalan in
vitro (D1o range 0.35-0.98yugml-') but there seems
to be less variation in the sensitivity of Lewis lung
tumour cells to MeCCNU (D1o range 1.5-
2.39jugml ').
At a theoretical level, we have explored the shape
of the distribution of cellular sensitivities (in terms
of survival curve slope) that is needed to give
substantial levels of drug resistance following
repeated drug treatments. The sensitivity
distribution must have a long tail reflecting the
presence of some highly resistant cells. One of the
consequences of assuming that the individual cells
in a tumour vary in drug sensitivity is that the
acute survival curve will tend to bend upward with
increasing dose, but this may not be distinguishable
in cell survival studies due to scatter in the data.
The model predicts that resistance may not develop
if very high drug doses are used, due to the
'extinction' of small populations of resistant cells.
Characterisation of two L1210 leukaemias
P.M. Goddard, R.M. Orr, M.R. Trafford, A.W.R.
Payne & K.R. Harrap
Department ofBiochem. Pharmacol., Institute of
Cancer Research, Sutton, Surrey, UK.
The quinazoline antifolate, CB3717, a potent
thymidylate synthetase inhibitor, now undergoing
clinical evaluation, failed to show significant
antitumour activity when screened against a panel
of rodent tumours which included the TLX/5
lymphoma, ADJ/PC6 plasmacytoma and Walker
carcinosarcoma 256. However, CB 3717 treatment
of two L1210 murine leukaemia ascitic tumours,
designate L1210/ICR and L1210/NCI led to long-
term survivors in mice bearing the L1210/ICR line
whereas only a moderate antitumour response was
noted for the L1210/NCI tumour. DNA cytofluori-
metric studies identified a ploidy difference between
these two wild type L1210 lines. The L1210/ICR
being tetraploid and the L1210/NCI, diploid. Their
ploidy characteristics were retained when they were
established in long-term suspension culture and in
vitro ID50 values for CB 3717 were similar. When
the L1210/ICR tumour was innoculated
intraperitoneally into BDF1 mice a spread in theAGM BACR ABSTRACTS 427
day of death was observed. However, this spread
was also noted in the syngeneic DBA2 host and the
athymic nude mouse indicating that antigenicity
was not a major contributing factor to the
behaviour of this cell line. Preliminary studies on
tumour migration after initial i.p. innoculation of
DBA2 mice showed tumour cells in the liver, spleen
and kidney from both cell lines by day 3 and in the
bone marrow of mice bearing the L1210/ICR
tumour. When other cytotoxic agents were screened
against the two L1210 lines in vivo there were no
differential antitumour responses. The marked
sensitivity of the tetraploid L1210/ICR tumour to
CB 3717 in vivo may be due to a higher thymidine
requirement for DNA synthesis or other cellular
factors as yet unidentified.
Suitability ofNMU rat model for testing endocrine
agents for breast cancer
J.R. Wilkinson & R.C. Coombes
Ludwig Institutefor Cancer Research (London
Branch), Royal Marsden Hospital, Sutton, Surrey
SM2 5PX, UK
Currently, the DMBA and NMU induced rat
mammary tumour is the standard screen for
possible endocrine agents for use in patients with
breast cancer. Using the NMU rat model, we
compared response in rats and patients to a variety
of treatments, e.g. tamoxifen, danazol, aminoglute-
thimide singly and in combination, ovariectomy,
triolastane and 4-hydroxyandrostenedione(4-OHA)
and from this determined whether it is possible to
rank various therapies for clinical evaluation. The
correlation is moderately good for premenopausal
women, the exception being 4-OHA. For post
menopausal women Aminoglutethimide is inactive
in the rat model, but extremely active in patients.
This study supports the use of such a model for
selecting endocrine agents but does not predict
whether the drug will be effective in pre- or post-
menopausal women. For adequate evaluation, the
mode of action of the drug and its metabolism
should be similar in both species, and these criteria
should be compared before committing large
numbers ofpatients to clinical trials.
The effects of a and y interferons on human lung
cancer cells grown in vitro or as xenografts in nude
mice
P.R. Twentyman, P. Workman, K.A. Wright &
N.M. Bleehen
MRC Clinical Oncology and Radiotherapeutics Unit,
Hills Road, Cambridge, UK.
We have compared the effects of a and
recombinant y interferons (IFNs) on the growth of
human lung cancer cell lines in vitro. There was a
diversity of response amongst the lines studied,
several being unresponsive and the most sensitive
being COR-L23 (a large cell anaplastic carcinoma
line) and POC (a small cell line). In general, IFN-y
was found to be more potent that IFN-a. For the
lines COR-L23 and POC the response to
recombinant IFN-y was dose-related in the region
0104IUml-1 with the major part of the effect
occurring below IO' IUml- . During cell growth of
line POC in the presence of IFN-y no significant
shift in cell cycle distribution occurred. When lines
COR-L23 and POC were grown as xenograft
tumours in nude mice, daily injection of
4 x 1O0 IUmouse- day- of IFN-y produced no
discernible retardation of tumour growth.
Potentiation of cis-platinum activity by interferon in
non-small cell lung cancer xenografts
J. Carmichael, C.R. Wolf, F.R. Balkwill, R.C.F.
Leonard & J.F. Smyth
Imperial Cancer Research Fund Medical Oncology
Unit, Edinburgh University andLondon, UK.
In recently confirming the activity of cis-platinum
(CP) for the treatment of non-small cell lung cancer
(NSCLC) we found the toxicity unacceptable for
the modest response rate achieved. To explore ways
of enhancing the therapeutic ratio of CP for
NSCLC, squamous, adenocarcinoma and
adenosquamous lung tumour xenografts established
in CBA mice immunosuppressed by neonatal
thymectomy, cytosine arabinoside and TBI have
been treated with CP, analogues of CP or cyclo-
phosphamide (CTX) ± human a lymphoblastoid
interferon (IFN). IFN was administered s.c. at a
site distant to the tumour at 1.8 x l05 IUday-1 x 35
days. Drugs were given i.p. weekly x 5 at 20%
MTD (CP 1.4mgkg-1). Using median tumour
doubling times, the activity of each agent and
combination was expressed in terms of growth
delay extrapolated from control. In addition all
groups were analysed in terms of % increase in
tumour volume over 35 days. The adenocarcinoma
had a control doubling time of 11 days and gave
growth delays of 0.36 with CP, 0.64 with CTX and
0.91 with IFN alone. In combination CP+IFN and
CTX+IFN gave growth delays of 3.18 and 1.27
doubling times respectively. This difference was
highly significant (P<0.01) with a similar result
when the results were based on % increase in
tumour volume over 35 days. For squamous and
adenosquamous tumours, responses were less
dramatic 'but IFN+CP was the most active, giving
growth delays of 1.74 (squamous) and 1.56428 AGM BACR ABSTRACTS
(adenocarcinoma) 0.84 and 0.44 CP alone, and
<0.2 and 0.44 IFN alone in squamous and
adenosquamous tumours respectively. In view of
this highly significant potentiation of CP by IFN
against adenocarcinoma we are now evaluating
other IFNs to optimise the selection of conditions
for a clinical trial.
Does human recombinant interferon alpha potentiate
the anti-proliferative effect of tamoxifen towards
oestrogen receptor positive human breast cancer
cells?
H.W. van den Berg1 & R. Clarke2
Departments of 1Therapeutics and 2Biochemistry,
The Queen's University ofBelfast, UK.
It has been reported that patients receiving
interferon (IFN) for the treatment of breast cancer
showed increased levels of oestrogen receptor (ER)
in skin metastases after therapy (Pouillart et al.
(1982), Eur. J. Cancer Clin. Oncol. 18, 929). Since
response to tamoxifen is largely dependent on the
presence of ER we reasoned that IFN might
potentiate the activity of the antioestrogen. The ER
positive human breast cancer cell line ZR-75-1 has
been used as a model to test this hypothesis. We
have found that the sensitivity of cell monolayers to
human recombinant IFN-cx is markedly dependent
on initial cell seeding density. At low density IFN-oa
(500 and 103IUml-1) caused a 30-50% reduction
in proliferative capacity after 6 days continuous
treatment, whilst no effect was observed if cells were
initially plated at higher density. Pre-treatment of
cells at low density for 3 days with IFN-a (500 or
103 IUml-') followed by a continuous 6 day
treatment with IFN and tamoxifen, (10-8_10-6M),
resulted in effects on cell proliferation which were
additive rather than synergistic although some
potentiation of the antiproliferative effect of tamo-
xifen, (10-8 and 10-6M), by 5OOIUmml- IFN was
observed 3 days after cotreatment.
In contrast to the antiproliferative effect of IFN
alone, 3H thymidine incorporation into DNA was
markedly inhibited at IFN concentrations as low as
10IUml-. We are currently investigating the
possibility that the effect of IFN on ER levels may
be similarly dissociated from effects on cell
proliferation.
A model system for investigating the factors involved
in tumour cell sensitivity to chemotherapeutic drugs
M.C. Walker, J.R.M. Masters & C.N. Parris
Department ofHistopathology, Institute of Urology,
St Paul's Hospital, 24 Endell Street, London WC2,
UK.
Chemotherapy has improved the prognosis of
patients with certain tumours (e.g. testicular germ
cell tumours), but has made little impact on the
survival of most patients with 'solid' tumours. It is
not known why certain histological types of tumour
are particularly sensitive to chemotherapeutic drugs.
In order to study this question, the in vitro drug
sensitivities of continuous cell lines derived from
five human testicular germ cell tumours (833K,
Tera II, SuSa, NEC-8, T3B,) and five transitional
cell carcinomas of the bladder (RT4, RT112, T24,
HT1197, HT1376) were compared. Inhibition of
colony formation by continuous exposure to a
range of concentrations of cisplatin and adriamycin
was determined for each cell line. The testicular cell
lines were on average five times more sensitive to
these drugs than the bladder cell lines, using the
ID70s (dose required to inhibit colony formation by
70%) as a basis for comparison.
While host and pharmacological factors are
known to influence the anti-tumour activity of
chemotherapeutic drugs, these data indicate that
inherent differences in sensitivity between tumours
of different histological types of primary
importance. Furthermore, these differences in
chemosensitivity are retained in long-term culture.
These cell lines provide a model system with which
the biochemical basis for drug sensitivity may be
investigated, an approach which could lead to more
effective treatment for all tumours.
The response to ionizing radiation and cytotoxic
drugs of human small cell lung cancer spheroids -
growth delay and cell survival endpoints
T.T. Kwok & P.R. Twentyman
MRC Clinical Oncology and Radiotherapeutics Unit,
Hills Road, Cambridge, UK.
The response of 250gim diameter multicellular
spheroids of a human small cell lung carcinoma cell
line (POC) to a variety of cytotoxic drugs and X-
rays was measured in terms of growth delay (GD)
and cell surviving fraction (SF). SF was measured
immediately (Oh) and 24h after acute X-irradiation
or a 1 h exposure to adriamycin (ADM), nitrogen
mustard (HN2), vincristine (VCR) and CCNU. GD
was measured as the difference in time for treated
and control spheroids to double their initial
diameter. SF (24h) was the same as SF (Oh) for X-
rays, VCR and CCNU indicating an absence of
recovery from potentially lethal damage (PLD). In
HN2 treated spheroids a small amount of PLD
recovery was seen, whereas, for ADM, increased cell
killing was observed between Oh and 24h. Using
the formula:
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(Twentyman (1980), Br. J. Cancer, 41, 297), the
doubling times (Tds) for surviving clonogenic cells
in CCNU, VCR and X-rays treated POC spheroids
lie in the range 50-55 h. For HN2, calculated Tds
are 52h for SF (Oh) and 69h for SF (24h) while
for ADM, Tds are 49h for SF (Oh) and 91 h for SF
(24h). The doubling time of untreated POC cells
during exponential growth is 42h. The relationships
between response endpoints clearly differ between
agents and also differ in a number of aspects from
those which we have previously reported for EMT6
mouse tumour spheroids (Twentyman, 1980).
Recovery from potentially lethal damage in other
human small cell lung cancer lines is currently
under investigation.
The incorporation of 75Se and [3H]TdR by renal
carcinoma cells exposed to cytotoxic agents -
possible test for drug sensitivity
D. Heinemann, A.V. Kaisary, P.J.B. Smith &
M.O. Symes
Departments ofSurgery and Urology, University of
Bristol and Bristol and Weston District Health
Authority, UK.
Tumour tissue from 12 patients with renal cell
carcinoma was disaggregated using collagenase and
DNase and a pure tumour cell suspension was
separated on a Nycodenz column (Umpleby et al.
(1984), Br. J. Surg. 71, 659). The tumour cells were
cultured in TCM 199+10% FCS to which were
added depoprovera, mitomycin C, methotrexate,
vinblastine or vincristine. After 24-72h the cultures
were washed free of drug and pulsed with either
1 juCiml 1 of 75Se in methionine free MEM or (in 4
cases) 2.5,Ciml-1 of [3H]TdR in TCM 199.
Isotope incorporation by the tumour cells was
measured after a further 24-72h culture and the
results compared with those for cells not previously
exposed to a drug. The drug to which the tumour
cells were most sensitive was that producing the
greatest reduction in 75Se incorporation. On this
basis 3 tumours were most sensitive to depo-
provera, 3 to mitomycin C, 2 to methotrexate, 1 to
vinblastine and 1 to vincristine. In 4 cases
sensitivity as indicated by [3H]TdR incorporation
concurred with that predicted by 7'Se. One tumour
was well differentiated and a second had been
embolised via the renal artery prior to
nephrectomy. The cells of these 2 tumours did not
incorporate 75Se. One tumour, sensitive to
vinblastine, was established in tissue culture, and its
cells showed that 75Se incorporation was dependent
on the dose of drug to which they had been
exposed.
Improvement in plating efficiency of lung tumours by
clonogenic assay - Implications for drug sensitivity
testing
A.P. Simmonds', H. Kerr', K.G. Davidson2 & A.
Faichney2
1Cell Laboratory, Department ofBiochemistry; and
2Cardiothoracic Surgical Unit, Royal Infirmary,
Glasgow, UK.
Following an earlier study (Simmonds et al. (1983),
Br. J. Cancer, 48, 119) in which significant drug
results were obtained in only 10/26 successful
cultures due to low PE, we attempted growth
enhancement with the use of REL medium
(Sheridan and Simmons (1981), J. Cell Physiol. 107,
85) HITES and HITES+FBS (Carney et al., (1981),
PNAS 78, 3185). Fifteen samples of NSCCL were
set up at 2 x 105 viable cells/plate in 0.3% agar in
these 3 media; a further 9 were set up in REL and
HITES+FBS. Underlayers of medium in 0.5% agar
were used for the HITES system. Colony scoring of
triplicate plates was at 12 days following incubation
at 37°C in 5% C02/air. In REL medium, growth
was 100% with PE 0.026-1.9% (23/24>0.05%); in
HITES+FBS growth was 100% with PE 0.019-
0.2% (18/24>0.05%); and in HITES alone growth
was 100% with PE 0.008-0.15% (3/15>0.05%). REL
medium was therefore used in subsequent drug
sensitivity tests where 2 x 105 cells/plate were
exposed for 1 h to 10% peak plasma concentrations
of vindesine and cis-platinum. Colony counts in
drug treated plates were expressed as percentage
survival of control and recorded as sensitive if this
was <50%. 40/45 specimens tested yielded
significant (PE>0.015%) results for the 2 drugs.
20/40 (50%) were S to cis-platinum and 22/24 (55%)
S to vindesine. 17/40 (43%) were S to both drugs
and 13/40 (33%) were R to both drugs. This high
yield of drug results (c. 89%) ensures the usefulness
of this assay as a laboratory test and medium using
rat erythrocyte lysate (REL) is now used routinely
for lung tumour culture in this laboratory.
A comparison of a soft agar clonogenic assay and an
isotope uptake assay to assess cell kill after both
drug and radiation treatments using both a high
cloning line (CHO) and a low cloning human tumour
xenograft line (V7)
J.A. Hanson, A.E. Bean & J.L. Moore
Radiation Sciences Laboratories, Velindre Hospital,
Cardiff
Along with other centres using the in vitro soft agar
assay of Courtenay & Mills, (1978), (Br. J. Cancer,
37, 261) for in vitro drug testing of patient tumour
cells, we have encountered problems that include430 AGM BACR ABSTRACTS
the length of time required for cloning, often up to
6 weeks, and the difficulties of preparing a good
single cell suspension (Agrez et al. (1982), Br. J.
Cancer, 46, 880). The tritiated thymidine uptake
assay developed by Friedman & Glaubiger (1982)
(Cancer Res. 42, 4683) can be completed within a
week and is not dependent on single cells.
Essentially the technique involves culturing non
adherent cells for 4 days before giving a 24h pulse
of tritiated thymidine.
We have directly compared these 2 assays both
on the high cloning CHO-KI line (CE 0.6 and
- 12h doubling time) and a low cloning human
ovarian tumour xenograft line V7 (CE -0.04 and
-60h doubling time). Time course studies to
determine the pattern of isotope uptake over the
first week in culture showed an increasing rate of
uptake in 2 of 4 xenografts tested. Linearity
between incorporated label (c.p.m.) and cell number
was also obtained. Cis-platin, melphalan and
vinblastine were tested with the V7 line using 1 h in
vitro exposures and survival in both assays was in
good agreement over the first two decades of cell
kill. Similar agreement was found after radiation
exposures except that the survival, as measured by
the isotope uptake assay, showed increasing
resistance once the 0.01 level was reached. Survival
data obtained at daily intervals during the first 6
days in culture show that survival falls to the
clonogenic survival after 4 days with little change
from day 4 to 6.
Culture and drug sensitivity of human breast
carcinoma: Effect of hormone and RBC supplements
A.P. Simmonds', J. McKinlay1 & C.S. McArdle2
'Cell Laboratory, Biochemistry Department and
2Department ofSurgery, Royal Infirmary,
Glasgow, UK.
We have cultured breast cancer cells by clonogenic
assay in agarose using hormone supplemented
DHEM (HD) (Calvo et al. (1983), Br. J. Cancer,
48, 683) both alone and with rat rbc added at 1%
of final volume (HDR). Thirteen tumour samples
were disaggregated with collagenase/DNase and
suspended at 105 viable cells in 1 ml HD/0.3%
agarose over 0.5% agarose underlayers containing
either HD or HDR. Incubation was at 37°C for 12
days in 5% CO2/air and plates were stained with
INT violet prior to microscopic counting of
colonies. All samples but one, a well-differentiated
adenocarcinoma, grew with plating efficiencies (PE)
ranging from 0.2-0.63% (majority in range 0.1-
0.3%). With rbc (HDR) enhancement of PE
occurred up to 12 fold with the majority of samples
enhanced 1.6-6.9. However, one ductal carcinoma
had decreased PE but the adenocarcinoma which
failed to grow in HD grew well in HDR. HDR was
used for drug studies, with a 1 h incubation at 10%
peak plasma concentration of MTX, 5FU,
adriamycin and mitomycin C prior to plating.
Sensitivity was deemed to be <50% survival as a
function of control. Of samples available for test,
4/11 (36%) were sensitive to 5FU and 2/12 (17%)
sensitive to MTX. Seven out of twelve patients were
resistant to all drugs tested, 1 being additionally
resistant to adriamycin and mitomycin C and only
1 was sensitive. Clinical correlations will be made
for 3 patients. Further samples will be evaluated for
drug sensitivity using both media, as it has not been
established wherher the change in PE affects such
measurements.
Azido analogues of lipophilic antitumour 2,4-
diaminopyrimidine DHFR inhibitors
R.J. Griffin, M.F.G. Stevens & E. Bliss
Cancer Research Campaign Experimental
Chemotherapy Group, Department ofPharmaceutical
Sciences, University ofAston, Birmingham B4 7ET,
UK.
The aromatic azido group is the forgotten
substituent in antitumour drug design although it
has three noteworthy features: (i) it can replace key
halogen substituents (e.g. chloro) because its
lipophilic and electronic characteristics are
comparable; (ii) it can act as a pro-drug
modification of the corresponding aryl amine; (iii)
it can degrade photolytically, thermally and
(possibly) biologically to reactive nitrene species
with covalent bonding potential. A series of azido
analogues of the lipophilic drug pyrimethamine (1)
has been prepared (see Table). The m-azido
NH2 1
H2N N R
Table Activity of azidophenylpyrimidines against rat
liver DHFR
R R1 R2 ID50(M) Ki(M)
1 Cl H Et 1.8x10-6 2.6x10-9
2 Cl N3 Et 1.3 x 10-6 1.6x 10-9a
3 Cl N3 Me 3.2x 10'6 2.6x 109
4 OMe N3 Et 6.6 x 10-7 1.7 x 10-9
5 OEt N3 Et 1.6 x 10-6 1.7 x 10-9
6 N3 Cl Et 3.4 x 10-7 3.8 x 10- 10
7 N3 Cl Me 1.0x10-6 8.2x 10-10
aAlso Ki 2.4 x 1o-' against L1210 DHFR.AGM BACR ABSTRACTS 431
compounds (2-5) are equi-inhibitory against rat
liver DHFR but less active than the p-azido
analogues (6 and 7).
The ethanesulphonic acid salt (MZPES) of
m-azidopyrimethamine (2) has been selected for
clinical tests.
Dipyridamole induced inhibition of thymidine
incorporation in vivo and potentiation of CB3717
cytotoxicity in vitro
D.R. Newell, P.M. O'Connor, J. Bishop, A.H.
Calvert & K.R. Harrap
Department ofBiochemistry and Pharmacology,
Institute ofCancer Research, Sutton, Surrey, UK.
Dipyridamole (DP) is a non-specific inhibitor of
thymidine (TdR) transport into cultured cells.
Extracellular TdR is an important determinant of
cytotoxicity for N1 -propargyl-5,8-dideazafolic acid
(CB3737), an inhibitor of de novo thymidylate
synthesis (Jackman et al. (1984), Biochem.
Pharmacol. 33, 3269). We have (a) determined the
ability of DP to inhibit TdR salvage in bone
marrow, gastrointestinal tract epithilium (GIT) and
Walker 256 tumour cells in vivo and (b) investigated
the cytotoxicity of CB3717/DP combinations in
vitro. DP was given by i.v. infusion to rats, and
tissues removed 2h after an i.v. bolus of [3H]-TdR.
As shown in the Table, TdR incorporation into
normal tissue DNA was DP sensitive, whilst




DP dose DPplasma level (% control x + s.d. n=4-5)
(mgkg-1) (pM) Tumour Bone marrow GIT
40 13+2 88+31 32+3 35+ 14
100 52+ 13 118+37 20+3 24+6
200 125+32 43+23 19+5 28+6
In vitro DP (10 M) largely prevented the TdR
(10uM) reversal of CB3717 cytotoxicity in L1210
cells (83% inhibition of cell growth) but not in
Walker cells (14% inhibition of cell growth). The
results with Walker cells in vitro and in vivo are
consistent with the observation that, unlike the
L1210, Walker cells have a transport-inhibitor
resistant TdR uptake mechanism (Belt (1983), Mol.
Pharmacol. 24, 479). Incorporation of TdR into
bone marrow and GIT is
- 80% transport-inhibitor
sensitive, a value similar to that reported for the
L1210. Thus as salvage of TdR may limit the
effectiveness of CB3717 in vivo, combination with
DP should enhance the activity of CB3717 against
transport-inhibitor sensitive tumours.
Transport studies with [3H]-CB3717
A.L. Jackman, B. Grezelakowska-Sztabert,
D.R. Newell, A.H. Calvert & K.R. Harrap
Department ofBiochemical Pharmacology, Institute
of Cancer Research, Sutton, Surrey, UK.
N10-propargyl-5,8-dideazafolic acid (CB3717) is a
tight-binding inhibitor of thymidylate synthetase
(TS) (Ki-4nM). Inhibition of this enzyme is
reponsible for the anti-tumour properties of this
drug both in vitro and in vivo. However, CB3717
has a high dose requirement for tumour cell growth
inhibition even in the absence of salvageable TdR.
The ID50 for CB3717 in culture (continuous
exposure for 48h) is 5yM. We therefore studied the
transport characteristics of 3H CB3717 into L1210
cells. Uptake of a toxic dose of 3H CB3717 (50yM)
was linear ( 0.09pmolmin-1 10-6 cells) and by
24h the intracellular level exceeded that of the
medium but because of avid intracellular protein-
binding this may not represent concentration of free
drug. In the presence of thymidine, however, the
intracellular level had plateaued at equilibrium
levels by 24h but dilution by cell division was a
complicating factor. When these cells were
resuspended in drug-free medium (+TdR) 35% of
the drug was effluxed within 4h after which the
drug concentration reduced proportionately to the
number of cell divisions implying that efflux did not
occur. The incorporation of [3H]UdR into acid-
precipitable material remained completely inhibited
in the absence of extracellular drug (>24h). It
seems probable that a non-effluxable pool of
CB3717 is formed within the cell (possibly as poly-
glutamates) that is able to maintain the inhibition
of TS for long periods. As the kinetics for CB3717
were not saturable (linear up to 100l M) a Kt value
could not be obtained, even in 160mM HEPES
buffer. However, the addition of a 14-fold excess of
either folic or folinic acid did not affect [3H]-
CB3717 uptake suggesting that CB3717 is not
transported via the mechanisms operative for these
compounds.
Effects of CB3717 onradiolabelied nucleoside
incorporation by human epithelial A549 cells
A.C. Simpson & A.L. Harris
Cancer Research Unit, Royal Victoria Infirmary,
Newcastle upon Tyne NE] 4LP, UK.
The antimetabolite CB3717, a quinazoline432 AGM BACR ABSTRACTS
antifolate, is a competitive inhibitor of the binding
of 5-10 methylene tetrahydrofolate to thymidylate
synthetase (TS), the rate limiting enzyme in the de
novo synthesis of thymidylate (Jones et al. (1981),
Eur. J. Cancer, 17, 11). This drug is active against
methotrexate resistant L1210 leukaemia cells and is
presently undergoing Phase II trials. The effect of
CB3717 on epithelial and lymphoid tumour cell
lines in vitro was studied, both alone and in
combination with other drugs. The in vitro
measurement of [methyl-3H] thymidine (*TdR) and
6-[3H] deoxyuridine (*dUR) by human epithelial
and lymphoid cell lines was used to indirectly
measure the effect of CB3717 on nucleic acid
synthesis and repair. Epithelial cells were harvested
at 50% confluence and incubated for 72h in
concentrations of CB3717 from lOOnM to 200,uM.
The ID 50 was 2.3pM. *TdR uptake was
stimulated after 3h exposure. A decrease in *dUR
uptake was observed at concentrations above
10gm, at lower concentration *dU uptake was
stimulated. 5FU and MTX, which also indirectly
affect TS, inhibited *dU uptake and stimulated
*TdR but did not stimulate *dU uptake. The time
course of the effect with CB3717 was much slower
than that of 5FU or MTX. In a human lymphoid
cell line CB3717 inhibited *dU uptake but did not
stimulate *TdR uptake. Epithelial cell confluence
markedly affected response to CB3717 and uptake
of *TdR and *dU was only slightly altered in cells
near confluence. Incorporation of *5FU was also
stimulated by CB3717. These results show a marked
difference in response of epithelial compared with
lymphoid cell lines and suggest that whilst CB3717
is an inhibitor of TS, it may have other effects on
nucleoside transport.
In vitro comparisons between monoclonal antibody-
targeted drug and toxin conjugates
M.J. Embleton', V.S. Byers2, M.C. Garnettl &
R.W. Baldwin'
1Cancer Research Campaign Laboratory, University
ofNottingham, Nottingham NG7 2RD, UK; and
2The XOMA Corporation, Berkeley, California
94710, USA.
Monoclonal antibody 791T/36, raised against
human osteogenic sarcoma cell line 791T, has been
conjugated to several cytotoxic drugs and toxins in
order to derive selectively active reagents. The
conjugates which proved to be most active were
prepared using methotrexate (MTX) attached by
means of an albumin carrier (Garnett et al. (1983),
Int. J. Cancer, 31, 661), and ricin A-chain (RTA),
respectively. The cytotoxic action of these
conjugates was compared on cell lines bearing
different concentrations of 791T/36-defined antigen,
the most antigenic (791T) bearing 106 antibody-
binding sites per cell.
In clonogenic assays the best MTX conjugate
achieved an IC50 against 791T of 10-9M in terms
of MTX content. For RTA conjugates the IC50
was as low as 5 x 10-IIM. However, when tested
against poorly antigenic cells the MTX conjugate
showed greater selectivity. For example, T24
bladder carcinoma cells which have only 104
791T/36-binding sites per cell, were -100 times less
sensitive to the MTX conjugate than 791T but the
difference in sensitivity of the two lines to RTA
conjugate was 10-15 fold.
It appears that toxin conjugates have an
advantage over drug conjugates in terms of
cytotoxic activity, but this may be offset by poorer
discrimination in situations where antigenic
differences are quantitative rather than qualitative.
Endocytosis of monoclonal antibody 791T/36 and
methotrexate-HSA-791T/36 conjugate by an
osteogenic sarcoma cell line
M.C. Garnett & R.W. Baldwin
Cancer Research Campaign Laboratories, University
ofNottingham, University Park, Nottingham NG7
2RD, UK.
The preparation and properties of a methotrexate-
human serum albumin-antibody conjugate which
retains both antibody binding activity and complete
drug cytotoxicity has been previously reported
(Garnett et al. (1983), Int. J. Cancer, 31, 661). It
has been proposed that drug conjugates would be
taken up into cells and the drug released by
lyosomal enzymes (De Duve et al. (1974), Biochem.
Pharmacol. 23, 2495). We have already demon-
strated a reduction in cytotoxicity of conjugate by
inhibitors of lysosomal enzymes and wished to find
direct evidence for the endocytosis of antibody and
conjugate in our osteogenic sarcoma cell line model
system.
This problem has been tackled using 3 different
fluorescent probes. First, methotrexate-HSA-
791T/36 conjugate. Cells were saturated with
conjugate at 0°C, washed and incubated at 37°C for
varying time periods. Conjugate remaining on the
cell surface was then quantitated using a
fluorescence activated cell sorter to measure bound
fluoresceinated rabbit anti HSA. Second,
fluoresceinated 791T/36. Upon endocytosis
fluorescein is quenched due to a reduction in pH.
This fluorescence can be unmasked by agents which
perturb lyosomal pH, e.g. monensin. Both of these
methods show endocytosis of up to 65% over a 3 h
period.AGM BACR ABSTRACTS 433
Finally the distribution of fluorescence was
investigated microscopically using fluoresceinated
HSA conjugated to 791T/36. This probe shows a
change from an even distribution at 0°C to a
perinuclear distribution after 3h incubation at
37°C, confirming the quantitative results obtained
with the other two probes.
Effect of linkage variation on pharmacokinetics of
ricin A chain antibody conjugates
A.J. Cumber, N.R. Worrell, G.D. Parnell, J.A.
Forrester & W.C.J. Ross
Chester Beatty Laboratories, Institute ofCancer
Research, Fulham Road, London SW3 6JB, UK.
Conjugates of ricin A chain with tumour specific
antibodies have been proposed as cancer chemo-
therapeutic agents. Linkage of ricin A chain to
antibody by a bridge containing a disulphide bond
generally results in a conjugate with specific cyto-
toxicity to antigen bearing cells in vitro but only
limited in vivo efficacy. It has been suggested that
this may be due to lability in vivo of the disulphide
bond. We have investigated the pharmacokinetics
of three antibody-ricin A chain conjugates with
linkages containing a disulphide bond, a sterically
hindered disulphide bond and a non-reducible
sulphide bond. An ELISA assay was used to
measure blood levels of each conjugate at time
points up to 48h following i.v. administration. All
3 conjugates appeared to obey two-compartment
kinetics and a and ,B phase half-lives were
calculated using a curve fitting routine. The results
are shown in the Table.
The results suggest that lability of the linkage
affects the / phase half-life while the half-life for
the a phase, when rapid disappearance of the intact
conjugate from the blood occurs, is the same for
the 3 conjugates studied.
Table
WaI+s.d. f1ti±s.d.
Ricin A disulphide conjugate 0.76+0.14 9.72+0.58
Ricin A hindered disulphide conjugate 0.76+0.09 14.40+ 1.42a
Ricin A sulphide conjugate 1.12+0.73 21.50+ 5.04a
ap<0.05 with respect to the disulphide conjugate by Student's t-test.
Heat potentiation of melphalan: Are drug transport
mechanisms involved?
D.J. Honess & N.M. Bleehen
MRC Unit and University Department ofClinical
Oncology and Radiotherapeutics, Hills Road,
Cambridge, CB2 2QH, UK.
We have previously shown that the potentiation of
melphalan (Mel) toxicity in C3H mice by systemic
hyperthermia (Hx) at 41°C is greater in RIF-I and
KHT tumours than in marrow stem cells (CFUs)
resulting in therapeutic gain; also that this is not
accounted for by the higher Mel concentrations in
Hx tumours. Mel is known to be transported into
tumour cells in vitro by 2 separate amino acid
carriers, one of which (system L) is reportedly
absent in CFUs in vitro. In vitro, leucine (leu)
competitively inhibits both carriers and BCH (a leu
analogue) specifically inhibits system L. We have
used these inhibitors in mice to confirm the in vitro
findings at 370C and to investigate their effect on
heat potentiation of Mel, using doses non-toxic to
tumour or marrow: 1 mmolkg 1 (a) and
4mmolkg-1 (b) leu and I mmolkg- BCH. Mel
toxicity to CFUs was unaffected by BCH at 37 or
41°C, confirming the absence of system L in CFUs
in vivo, but was reduced by leu at 37°C. Results for
RIF-I tumour treated with 15mgkg-1 Mel,
without (Cont) and with inhibitors are shown on
the left for 37°C (unshaded) and 41°C (shaded) (see
Figure). Mel toxicity (assayed by clonogenic cell
survival 24h after treatment) was reduced by leu
and BCH very similarly at 37 and 41°C, suggesting
that carrier activities are largely unchanged at 41°C.
Data for KHT tumour assayed by growth delay
support these data. We conclude that effects on
intracellular transport are probably not involved in
Hx potentiation of Mel, and do not account for the
greater potentiation in tumour than marrow. See
Figure.
Cont BCH lou leu BCH+
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Misonidazole protects against oral CCNU
F.Y.F. Lee & P. Workman
MRC Clinical Oncology and Radiotherapeutics Unit,
Hills Road, Cambridge, UK.
Nitroimidazoles such as misonidazole (MISO) are
able to enhance the response of experimental
tumours to certain cytotoxic agents. This 'chemo-
sensitization' is normally greater than in normal
tissues, resulting in an improved therapeutic index.
In previous studies where both agents were injected
i.p. in the mouse we have shown that 500mgkg-1
MISO reduces the plasma clearance of CCNU,
leading to a preferential increase in nitrosourea
concentration in the KHT tumour; these pharmaco-
kinetic changes thus explained the improved thera-
peutic index obtained for the combination (Lee &
Workman (1983), Br. J. Cancer, 47, 659). We have
now carried out similar experiments but giving the
CCNU orally, with quite different results. MISO
reduced the antitumour activity (growth delay
endpoint) of oral CCNU by a dose-modifying
factor (DMF) of 0.59-0.71, and likewise increased
the acute LD50 by a DMF of 0.74. Thus MISO
protected both tumour and normal tissues from the
toxicity of oral CCNU, the net effect being no
change (or possibly a slight decrease) in therapeutic
index. Nitrosourea pharmacokinetics were studied
by HPLC. Concentration of parent drug were
considerably increased by MISO, thus demon-
strating inhibition of CCNU metabolism by the
nitroimidazole. For example, peak plasma
concentrations were increased 6.7-fold from 0.46 to
3.1 jgml-. In contrast, due to decreased hydroxy-
lated metabolite levels, peak total nitrosoureas were
diminished by 1.5- and 1.7-fold in plasma and
tumour respectively. Values ofAUCO - 0 for plasma
and tumour were unchanged by MISO, but AUC
values for concentrations > 1-2jigml- were
markedly reduced. In conclusion, inhibition of
CCNU hydroxylation, leading to reduced nitro-
sourea exposure, is responsible for the protective
effect of MISO against the toxicity of oral CCNU
in mouse tumour and normal tissue.
Mechanistic studies on the cytotoxic and
radiosensitizing properties of RSU 1069
I.J. Stratford, A.R.J. Silver, J.M. Walling & G.E.
Adams
MRC Radiobiology Unit, Harwell, Oxfordshire OXJJ
ORD, UK.
RSU 1069 has a similar one-electron reduction
potential to that of misonidazole but is 10 x more
efficient as a radiosensitizer in vitro and in vivo.
RSU 1069 differs from misonidazole in that it
contains a monofunctional alkylating group
(aziridine) in the side chain. We have indirect
evidence that RSU 1069 interacts with intracellular
DNA, e.g. 3 hours exposure of V79 cells to 50jm
RSU 1069 in N2 reduces survival to 10-2 for
unlabelled cells and 10-3 for cells labelled with 5-
BUdR. In contrast, control and labelled cells show
the same sensitivity to misonidazole. Further, the
enzyme poly(ADP-ribose) synthetase, which can be
involved in excision repair of DNA/mono-adducts
can be inhibited with 3-aminobenzamide (3-AB).
Treatment of cells with 3-AB substantially increases
the toxicity of RSU 1069 in air, with a dose
modification factor of 2. 3-AB has no affect on
the cytotoxicity of misonidazole. However, the
drug-DNA interaction that would be inferred from
the above contributes only slightly to the enhanced
radiosensitizing efficiency of RSU 1069. We have
shown this by treating cells with minimally-toxic
concentrations of RSU 1069. These concentrations
would normally radiosensitize hypoxic cells but if,
instead, cells are washed free of unbound drug
immediately before irradiation in N2 then very little
sensitization is observed. Thus it is likely that the
molecular properties of RSU 1069 that confer high
sensitizing efficiency may not be those that are
related to its toxicity.
The effects of combinations of benznidazole and
methyl CCNU on transplantable adenocarcinomas of
the mouse colon
J.A. Double & M.C. Bibby
Clinical Oncology Unit, University ofBradford,
Bradford BD7 JDP, West Yorkshire, UK.
There is considerable interest in the combined use
of nitroimidazoles and cytotoxic therapy.
Twentyman & Workman (1983) (Br. J. Cancer, 48,
17) suggested that a combination of CCNU with
benznidazole (BENZO) may have significant
clinical potential. The present study investigates the
effect of BENZO together with methyl CCNU on
three transplantable adenocarcinomata of the
mouse colon (MAC). The MAC series is generally
poorly responsive to cytotoxic therapy with
responses seen only close to maximum tolerated
dose. Methyl CCNU is the most active agent tested
to date. MAC 13 is poorly differentiated, MAC 26,
well differentiated and MAC 15A, an ascitic variant
of the solid MAC 15. BENZO alone produced no
significant anti-tumour effects on any of the
tumour lines. Treatment of MAC 13 and MAC
15A with BENZO (78mgkg-1) 30min prior to
maximum tolerated dose cytotoxic therapy resulted
in increased toxicity with no enhancement of anti-
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Pretreatment with BENZO failed to improve the
anti-tumour response of MAC 26 to methyl CCNU
at a range of dose levels even though there was a
considerable increase in toxicity. These results differ
from those ofearlier workers using CCNU and it is
possible that the differences may be explained by
the pharmacokinetic properties of the two agents
and by the different chemosensitivities of the
tumour systems employed.
The results to date seem to indicate no potential
clinical gain from the present combination.
Growth-inhibitory effects of a 5-aza-2'-deoxycytidine
(5AZAdCYD) in human leukaemic cells and solid-
tumour-derived cells
A. Leyva, L.C.M. Boeije, E.I.M. Meijne & H.M.
Pinedo
Department ofOncology, Free University Hospital,
De Boelelaan 1117, 1081 HV Amsterdam, The
Netherlands.
5AzadCyd is a potent antileukaemic agent with a
mechanism of action which may involve induction
of differentiation due to suppression of DNA
methylation. The aim of the present study was to
determine whether 5azadCyd was active against
solid tumours. Seven human cell lines representing
4 solid-tumor types (3 squamous cell carcinoma, 2
melanoma, 1 breast cancer and 1 colon cancer)
were examined for sensitivity to 5azadCyd in vitro.
Comparison was made with the human leukaemic
cell lines HL60 and CEM. Cells were maintained in
exponential growth as suspension (leukaemic cells)
or as monolayer (solid-tumor-derived cells) cultures.
Cells were exposed for 3 or 24h to drug
concentrations of 0.01 to lOO1 M and cell growth
was determined daily for up to 4 days. Growth-
inhibition kinetics varied for the 9 cell lines but
consistently showed a delayed drug effect of 24-
48h, even at high drug concentrations. With 24h
drug exposure, inhibition of growth was eventually
>80% in the 2 leukaemic cell lines and 5 solid-
tumour-derived cell lines at 1IM SazadCyd.
Comparing 3h and 24h drug exposures, leukaemic
cells were similarly sensitive. Solid-tumour-derived
cells were several fold less sensitive using 3 h
exposure, with the exception of MCF-7 breast
cancer cells which were inhibited by >50% at
10jM SazadCyd. Using either drug exposure
period, resistance was observed in 1 squamous cell
carcinoma and 1 melanoma. The data suggest that
SazadCyd has a spectrum of activity which is not
restricted to leukaemias. Prolonged drug exposure
may be required to best exploit the cytotoxic effects
of SazadCyd, particularly in solid tumours. In
addition, preliminary studies show that the amount
of SazadCyd triphosphate formed correlates with
drug sensitivity.
Differential DNA damage induced by 5-aza-2'-
deoxyazacytidine (Aza-dC) and 5,6-
dihydroazacytidine (DHAC) in mouse L1210 and in
two human lymphoblastoid cell lines
M. D'Incalcil, J.M. Covey2, D.S. Zaharko2, E.
Erbal & K.W. Kohn2
'Mario Negri Institute, 20157 Milan, Italy; and
2DTP Division of Cancer Treatment, NCI, NIH,
Bethesda, MD 20205, USA.
Aza-dC is a compound with activity against mouse
and human leukaemias. Its mode of action is
unknown, but cytotoxicity has been related to its
ability to inhibit DNA-cytosine methyltransferase
when the analogue is incorporated into DNA.
DHAC is a more stable analogue which is much
less potent as an inhibitor of DNA methylation and
as a cytotoxic agent. Using the alkaline elution
technique, we have comparatively evaluated the
DNA damage produced by the 2 drugs in mouse
L1210 cells, in a lymphoblastoid cell line derived
from a patient with xeroderma pigmentosum (XP)
(GM2345A), and in a lymphoblastoid cell line
derived from a clinically normal subject (GM3714).
When cells were treated with Aza-dC (0.1-
lOj1gml-P) or DHAC (1-lOOgml-1) and
simultaneously labelled with '4C-thymidine for 24h,
a dose-dependent increase in the elution rate of
"4C-DNA was observed, whereas no significant
effect was observed when same treatment was
performed on '4C prelabelled cells. This suggests
each drug must be incorporated in DNA to
produce DNA damage. The elution rate of DNA
after Aza-dC treatment was much greater at pH
12.6 than at pH 12.1 and the elution curves were
convex, suggesting the presence of DNA-alkali-
labile sites (ALS), possibly due to base-free sites in
DNA. In contrast DHAC produced DNA single-
strand breaks (SSB) with a linear elution rate, not
pH-dependent. Aza-dC induced ALS persisted for
48 h after drug treatment, and were only moderately
repaired at 72h. SSB induced by DHAC were
almost completely repaired 24h after drug washout.
Neither Aza-dC nor DHAC caused greater damage
in XP cells compared to the normal human line.
Flow cytometry studies showed that Aza-dC
increased the % of cells in G2 whereas DHAC did
not. The differing biological activities of Aza-dC
and DHAC may be related to the contrasting
nature and persistence of DNA damage caused by
these agents.
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Potentiation of cis-platin and melphalan by methyl
methane-sulphonate
J.M. Walling & I.J. Stratford
MRC Radiobiology Unit, Harwell, Didcot, Oxford,
UK.
The monofunctional alkylating agent MNNG
potentiates cell killing by bifunctional alkylators
operating at the same position in DNA (06
guanine). It is proposed that this occurs via
saturation of the suicide enzyme 06 methyl-
transferase. We report here the ability of methyl-
methanesulphonate (MMS), which alkylates
extensively at the N7 position of guanine but not
detectably at the 06 position, to potentiate cis-
platin and melphalan. These are bifunctional agents
which initially alkylate at N7.
When V79 cells are given 1 mM MMS for 1 h in
air at 37°C prior to a range of doses of cis-platin,
their sensitivity to this drug is greatly increased. At
a surviving fraction (SF) of 0.5 the dose
modification factor (DMF) is 6.00. At lower SFs
the DMF increases; SF 0.1 DMF=2.93, SF 0.01
DMF=2.41. This effect on the shoulder of the dose
response curve may indicate an inhibition of DNA
repair. A similar treatment with MMS also
increases the cytotoxicity of melphalan SF=0.1
DMF= 1.73; SF=0.01 DMF= 1.73. The poten-
tiation is dependent on drug scheduling. If MMS is
given before cis-platin, potentiation is only
obtained at doses below 15pm cis-platin, above this
protection results. Isobologram analysis shows that
MMS is synergistic with cis-platin at doses of
MMS approaching 1 mM lower doses produce
antagonism.
In contrast a dose of MNNG (06 alkylator)
equitoxic with 1 mM MMS, i.e. 0.01 mM MNNG
(SF=0.35) does not potentiate either cis-platin or-
melphalan.
We are currently investigating the rate and extent
of DNA platination and crosslinking following
MMS pretreatments in order to determine the
mechanism of potentiation.
DNA damage and cytotoxicity produced by 1,5,2,4-
dioxadithiepene-2,2,4,4-tetraoxide (cyclic SOSO)
N.W. Gibson, K.W. Kohn & J.A. Hartley
Laboratory ofMolecular Pharmacology, National
Cancer Institute, Bethesda, Maryland 20205, USA.
1,5,2,4-dioxadithiepene-2,2,4,4-tetraoxide (Cyclic
SoSo) was found to be active against the L1210 and
P388 leukaemias, M5076 sarcoma, and the human
MX-1 mammary tumour xenograft in the NCI
screening programme. As a result this compound is
due to enter Phase I clinical trials in USA. Cyclic
SoSo structurally resembles two other classes of
antitumour agents; the haloethylsulfonates and the
dimethgnesulphonic acid esters. Both of these
classes of compounds are thought to exert their
antitumour activity through crosslinking of DNA.
We have studied the effects of Cyclic SoSo on
DNA in IMR-90 and VA-13 human embryo cells
by means of DNA alkaline elution analysis. In
contrast to a number of alkylating agents Cyclic
SoSo produced no DNA-DNA interstrand
crosslinks in either cell line, even at concentrations
which produced a greater than a 3 log cell kill. At
equimolar concentrations Cyclic SoSo induced
DNA-protein crosslinks in both cell lines to a
similar extent. Frank DNA breaks and alkali-labile
DNA strand breaks were detected in both cell lines.
These breaks did not appear to be related to a
DNA topoisomerase II activity. A greater quantity
of strand breaks appeared in the IMR-90 than the
VA-13 cell line after exposure to Cyclic SoSo. The
IMR-90 cell line, however, was less sensitive to the
cytotoxic effects of Cyclic SoSo than was the VA-
13 cell line.
A comparison of the DNA base adducts formed after
alkylation with two novel chloroethylating agents
J.A. Hartley, J. Strong, K.W. Kohn & N.W.
Gibson
Laboratory ofMolecular Pharmacology, National
Cancer Institute, Bethesda, Maryland 20205, USA.
A major cytotoxic reaction of chloroethylating
agents with DNA appears to involve alkylation of
the guanine-06 position. We have studied 2 novel
chloroethylating agents: 8-carbamoyl-3-(2-chloro-
ethyl)imidazo 15, 1-dj-1, 2, 3, 5-tetrazin-4(3H)-one
(mitozolomide) and 2-chloroethyl (methylsulfonyl)-
methanesulfonate (ClEtSoSo) and found that they
cause effects attributable to chloroethylation of the
06-position of guanine in DNA. We have now
analysed the DNA adducts produced by ClEtSoSo
and mitozolomide. The two compounds, "4C-ethyl
labelled, were reacted with calf thymus DNA for 4h
at 370C pH7. After precipitation with ethanol, the
reacted DNA was depurinated by 0.15N HCl for
60min at 100°C followed by neutralisation with
0.3 N NaOH. The resulting hydrolysate was
analysed by reverse phase high pressure liquid
chromatography (HPLC). Five major radioactive
peaks were found on analysis of the mitozolomide
treated DNA eluting at 4, 9, 16, 23 and 27min
respectively. Only 3 major peaks were found on
analysis of the ClEtSoSo treated DNA, eluting at 4,
9 and 27min respectively. The 27min peak has been
identified as 7-chloroethylguanine by HPLC
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confirmed by mass spectral analysis. Preliminary
analysis of the synthesised 7-hydroxyethylguanine
and 06-hydroxyethylguanine standards indicates
that they correspond to the 16 and 23min peaks
respectively. Thus unlike mitozolomide, ClEtSoSo
does not appear to hydroxyethylate guanine in calf
thymus DNA. The biological implications of these
results are currently being investigated.
Structure-activity relationships in antitumour
3-alkylimidazo-tetrazinones
S.P. Langdon', D. Chubb', L. Vickers', R. Stone',
M.F.G. Stevens', G.U. Baig1, N.W. Gibson', J.A.
Hickman', E. Lunt2, C.G. Newton2, P.J. Warren2
& C. Smith2
1CRC Experimental Chemotherapy group, University
ofAston, Birmingham B4 7ET; and 2May & Baker
Ltd., Dagenham, Essex RMJO 7XS, UK.
Mitozolomide (1) has potent broad spectrum anti-
tumour activity against murine screens and is
currently undergoing Phase II trials in man. In
other series of N-alkyl antitumour agents -
triazenes, nitrosoureas, hydrazines, melamines and
formamides - the nature of the N-alkyl substituent
has a critical bearing on activity. Several N-alkyl
congeners of mitozolomide were screened for anti-
tumour activity against the TLX5 lymphoma
(2 x 105 cells injected s.c. into groups of 5 female
CBA/ca mice). Results are shown in the Table. In
Table
Optimum dosea
R (mgkg) T/C x100%
1 (CH2)2C1 40 5/5 curesb
2 Me 160 157
3 Et 640 123c
4 n-Pr 320 103
5 (CH2)2OMe 80 103
6 CH2CH=CH2 80 103
7 (CH2)2Br 160 137
8 (CH2)3C1 320 108
9 CH2CH(Cl)CH2CI 160 105
10 Benzyl 20 107
aDrugs administered day 3 post implantation. bDay 60.
CT/C< 125% is considered inactive.
the present series the 3-methyl analogue of
mitozolomide has anti tumour activity, the 3-(2-
bromethyl)-derivative has marginal activity and
other 3-alkyl analogues are all inactive against this
tumour on a single dose schedule.
Activity ofmitozolomide (NSC 353451) against
human tumour xenografts
S. Aamdal, 0. Fodstad & A. Pihl
Norsk Hydro's Institutefor Cancer Research,
Montebello, Oslo 3, Norway.
The effect of mitozolomide, a new imidazotetrazine
(Horgan et al. (1983), Br. J. Cancer 48, 132;
Stevens et al. (1984), J. Med. Chem. 27, 196), on
xenografted human tumours was studied in 3
different assay systems. In concentrations of 1-
500pgml-', mitozolomide inhibited the colony
forming ability in soft agar of cell suspensions from
5 sarcomas, 5 melanomas, 5 lung and 2 colon
cancers, and a mammary carcinoma. Four sensitive
tumours of different histological types were also
tested in the 6-day subrenal capsule assay in
conventional mice and as s.c. growing tumours in
nude mice. In the melanoma, the effect of
mitozolomide was similar to that of CCNU.
Mitozolomide was far more effective than ADM
and VP16 in a small cell lung cancer and clearly
superior to ADM and abrin in an osteogenic
sarcoma. In fact, the tumour size measurements
and histological examinations indicated that nude
mice carrying these tumours were cured by the
mitozolomide treatment. In the colon cancer,
mitozolomide showed a significant, but less
pronounced effect than that of 5-FU. The same
ranking order was obtained when the effects of the
different drugs in the 2 in vivo assays were
compared, supporting the validity of the subrenal
capsule assay. Phase II trials of mitozolomide in
malignant melanoma, soft tissue sarcoma and small
cell lung cancer have recently been initiated.
Tissue disposition of radiolabelied mitozolomide in
mice
P. Kestell', C. Brindley2, P. Antoniw2, J.A. Slack'
& E. Newlands2
'CRC Experimental Chemotherapy Research Group,
University ofAston, Birmingham; and 2Department
ofMedical Oncology, Charing Cross Hospital,
London, UK.
Mitozolomide [8-carbamoyl-3-(2-chloroethyl)imi-
dazo-[5,1-d]-1,2,3,5-tetrazin-4(H)-one], a new anti-
tumour agent, has recently undergone Phase I
clinical evaluation. As part of pre-clinical studies438 AGM BACR ABSTRACTS
the disposition of this compound in BALB/c mice
following a single i.p. dose at 20mgkg- was
determined in plasma, heart, lung, spleen, kidneys,
stomach, small intestine, large intestine, liver, eyes,
fat, muscle, brain and residual carcass, using [14C]-
mitozolomide labelled either in the imidazole ring
or in the chloroethyl side chain. The concentration
of non-radiolabelled mitozolomide after its i.p.
administration at 20mgkg-1 was also determined
in plasma, liver, brain, kidney, muscle, lung and
spleen of BALB/c mice. After 1 h following
administration, radioactivity was detected in all the
tissues and plasma and the concentrations of radio-
activity in plasma, liver, brain, kidney, muscle, lung
and spleen (4.3-13.0jug equivalents g-') were
virtually identical to unchanged drug (5.5-13.1,g
equivalents g-1). However much higher concen-
trations of radioactivity were found in the livers
(36.44g equivalents g-') and kidneys (22.3jg
equivalents g-') of those mice which had received
[14C-chloroethyl]-mitozolomide. The elimination of
non-radiolabelled mitozolomide from tissues
exhibited first order kinetics with an apparent half-
life of <1 h. Over an 8h period following
administration, the concentration of radioactivity
associated with either of the radiolabelled
compounds decreased in most tissues but the
decline did not mirror that of plasma. However, in
liver, kidney, lung, spleen and heart of mice treated
with [14C-imidazole]-mitozolomide, the radio-
activity concentration increased or remained
constant during the same period. After 48h, the
concentrations of radioactivity had significantly
decreased but were still measurable. %
Plasma and tissue disposition of mitozolomide (NSC
353451) in tumour-bearing mice
C.J. Brindley, P. Antoniw & E.S. Newlands
Department ofMedical Oncology, Charing Cross
Hospital, London W6 8RF, UK.
Mitozolomide (M) is a novel and potent anti-
tumour agent with significant activity against a
wide range of murine tumours. We investigated the
distribution of (M) in the plasma and tissues of
mice bearing the ROS osteosarcoma by HPLC.
Peak plasma and tissue concentrations were reached
within 30min and drug disposition appeared to fit
a first-order, one-compartment kinetic model with
an elimination half life of <1 h . The disposition of
(M) in tumour-bearing mice also followed a first-
order process but in this case elimination of drug
was significantly faster from plasma, liver, lung and
kidney tissue compared to the elimination half life
of drug in the same tissues of mice without tumour
(P<0.05). (M) was well distributed to all tissues
including brain and tumour.
Workman and Lee (1984) (Br. J. Cancer, 50, 251)
have shown that phenobarbitone pre-treatment
reduces the antitumour activity of (M) against the
KHT mouse sarcoma. We found that AUC values
calculated from (M) concentration versus time
profiles in plasma and tissues were significantly
lower in mice pretreated with phenobarbitone
compared to those values obtained for mice
receiving saline alone (P<0.005).
It has been proposed that (M) chemically
degrades to the chloroethyl triazine, MCTIC
(Horgan & Tisdale (1984), Biochem. Pharmac. 33,
2185). However, the above observations suggest
that metabolism may be involved in the
decomposition of (M).
Pharmacokinetic factors affecting comparative
tumour response to CCNU and mitozolamide
P. Workman, F.Y.F. Lee & J. Donaldson
MRC Clinical Oncology and Radiotherapeutics Unit,
Hills Road, Cambridge, UK.
The novel antitumour agent mitozolamide exhibits
a similar spectrum of experimental antitumour
activity to that of the nitrosourea CCNU,
suggesting, as do biochemical studies, a common
mechanism of action. The two agents also have
identical potencies and therapeutic indices in mice.
However, since we have shown that the clinical
efficacy of CCNU is limited by ineffective plasma
and tumour concentrations, mitozolamide might
possess an advantage in terms of improved
pharmacokinetics. For this reason we have used
HPLC to compare the mouse plasma, tumour and
brain pharmacokinetics of mitozolamide and
CCNU, both given i.p. at a dose of 20mgkg-1.
With mitozolamide this produced a peak plasma
concentration of 19,ugml'- at 10min, compared to
the much lower peak total nitrosourea concen-
tration of 5.5pgml-1 at 10-45min after CCNU.
The plasma elimination t2 was also shorter for
mitozolamide (58min) compared to that for total
nitrosoureas (94min), but the plasma AUC was
greater for mitozolamide at 1349 compared to
502 gml-1 min. In the KHT tumour the peak
mitozolamide concentration of 16yjgg-1 was seen
at 15-30min and the levels remained closely similar
to those in plasma from then on. For total nitro-
soureas after CCNU, the peak tumour concen-
tration was much lower (4jgml-1), with
concentrations at later times again being similar to
plasma. In brain the peak mitozolamide
concentration of 8jigg-1 occurred at 15-30min,AGM BACR ABSTRACTS 439
and brain/plasma ratios were constant at 70% from
then on. With CCNU brain concentrations were
similar to or higher than those in plasma. The
clinical efficacy of mitozolamide is likely to require
the achievement in man of plasma and tumour
concentrations of a similar order to those described
above.
CCRG 81045 - An antitumour imidazotetrazinone
with potential as a clinical alternative to DTIC
S.P. Langdon', M.F.G. Stevens', R. Stone', N.W.
Gibson', G.U. Baig', J.A. Hickman', C.G.
Newton2 & E. Lunt2
'CRC Experimental Chemotherapy Group,
University ofAston, Birmingham B4 7ET; and 2May
and Baker Ltd., Dagenham, Essex, UK.
CCRG 81045 (M&B 39831; NSC 362856)
(1:R=Me) is the 3-methyl analogue of the
antitumour drug mitozolomide (1: R=CH2CH2C1)
and decomposes in aqueous media to afford MTIC








It has been suggested that DTIC may be poorly
metabolized to MTIC by patients. Unlike DTIC,
CCRG 81045 does not require metabolic activation
and is being developed for clinical trial as a
chemically activated prodrug of MTIC. The activity
of CCRG 81045 against a panel of murine tumours
in vivo (see Table) is superior to that of DTIC.
(Goldin et al. (1981), Eur. J. Cancer, 17, 129).
Potentiation of the action of DTIC by inhibitors of
poly (ADP-ribose) polymerase
J.M. Lunn', C. Pierpoint2, B.T. Golding2 & A.L.
Harris'
'Cancer Research Unit and 2Department ofOrganic
Chemistry, University ofNewcastle-upon-Tyne,
Newcastle-upon-Tyne NE] 4LP, UK.
The drug 5-(3,3-dimethyl-1-triazeno)imi-
dazole-4-carboxamide (DTIC) is metabolised by
humans to the related monomethyl compound
(MTIC), whose subsequent breakdown gives rise to
short-lived reactive species which methylate cellular
DNA.
To obviate the need for this activation step,
MTIC has been synthesized and its effects on cul-
tured A549 (lung carcinoma derived) cells examined.
Exposure to MTIC was found to cause a dose-
dependent inhibition of cell growth. The effects
observed were similar to those found with equimolar
concentrations of the methylating agent methyl
nitrosourea (MNU). Substitution of 5-amino-
1 - (f - D - ribofuranosyl) -imidazole -4 -carboxamide
(AICAR), the riboside of a degradation product of
MTIC, for MTIC produced no effect on cellular
proliferation, indicating that cytotoxicity was not
due to perturbation of purine biosynthesis. Further
MTIC which had been allowed to stand in aqueous
solution for 1 h before application had no effect on
cellular proliferation. DNA strand breaks were
detected by an alkaline unwinding technique, and
were found to increase linearly with increasing
concentrations of MTIC. Formation of poly (ADP-
ribose) seems to be involved in the repair of DNA
damage produced by MTIC because inclusion of 3-
acetamidobenzamide (3AAB), an inhibitor of poly
(ADP-ribose) synthetase, in the growth medium
enhanced the cytotoxicity of MTIC (LD50 in the
absence or presence of 3AAB was 200pm or 50pm
respectively). Cellular NAD levels dropped after
exposure to MTIC concentrations in excess of 1 mM.
Our findings suggest that it may be possible to
extend the limited clinical usefulness of DTIC by
Table Antitumour activity of CCRG 81045
Site of Schedule Optimum dose
Tumour implantation (days) (mgkg'- i.p.) TIC ( x 100o%)
P388 i.p. 1-5 200 254a
L1210 i.p. 1-9 100 193a
TLX5 s.c. 3-7 40 18lb
M5076 i.m. 1-17 20 0c
ADJ/PC6A i.m. 14 40 0c
aMedian survival time.bMean survival time.CMean tumour volume index.440 AGM BACR ABSTRACTS
concurrently suppressing the synthesis of poly
(ADP-ribose).
Induction of haemoglobin synthesis in K562 cells by
N-methyl but not N-ethyl compounds
M.J. Tisdale
CRC Experimental Chemotherapy Group,
Department ofPharmaceutical Sciences, University
ofAston, Birmingham B4 7ET, UK.
We have been investigating the structure-activity
relationships of a group of imidazotetrazinones, the
2-chloroethyl analogue of which (mitozolomide) is
currently undergoing a clinical trial. Among the
other members of the series the methyl analogue (8-
carbamoyl-3-methyl-imidazo- [5,1-d]-1,2,3,5-tetrazin-
4-(3H)-one, CCRG 81045) showed potent anti-
tumour activity, while the ethyl analogue was
inactive, in analogy with the dialkyltriazenes. When
tested against the K562 human erythroleukaemia
cell line both a monomethyltriazene and CCRG
81045 were effective in the induction of
haemoglobin production, a marker of red cell
differentiation, while the corresponding ethyl
homologues were inactive in the modification of
gene expression in this cell line, even at concen-
trations which have an equivalent effect on cell
growth. Growth inhibition alone seems to be
insufficient for the induction of haemoglobin
synthesis since other members of the series inhibited
growth without substantially increasing the number
of haemoglobin producing cells. Differentiation
appeared not to arise by selective toxicity to the
original non-differentiated cellcompartment followed
by clonal expansion of the differentiated cells.
Treatment with CCRG 81045 caused a lower level
of enzymatic methylation of newly synthesized
DNA which coincided with the increased gene
transcription.
Receptors for epidermal growth factor are present on
human bladder tumours
D.E. Neal1"3, C. Marsh2, M.K. Bennett2, P.D.
Abel1, R.J. Sainsbury3, R.R. Hall1 & A.L. Harris4
Departments of 1 Urology and 2Pathology, Freeman
Hospital, Freeman Rd, High Heaton,
Newcastle-upon-Tyne NE7 7DN; Departments
of3Surgery and 4Clinical Oncology University of
Newcastle-upon-Tyne, UK.
Epidermal growth factor (EGF) is a small
polypeptide that stimulates cell growth and
division. It is found in high concentration in urine.
Close similarities have been found between EGF
receptors (EGF-r) and contain oncogene proteins.
Sixty patients have been studies to determine
whether EGF-r can be detected on transitional cell
carcinoma (TCC). Twenty-four patients with
superficial TCC (pTA 15, pT1 9) and 24 with
invasive TCC (pT3) have been compared with 12
controls. Frozen sections were studied histologically
by an indirect immunoperoxidase technique with a
monoclonal antibody to EGF-r.
Twenty-one of the 24 invasive TCC and 7 of the
24 superficial TCC were positive for EGF-r
(x2 =14.9; P<0.001). Significantly more of the
poorly differentiated tumours were positive for
EGF-r (18 of 21) compared with moderately
differentiated tumours (10 of 27; x2=9.6; P<0.01).
Normal urothelium was not positive for EGF-r.
EGF receptors have been identified on human
bladder tumours. They were observed more
frequently on invasive tumours than on superficial
tumours, suggesting that expression of the EGF-r is
associated with a capacity for invasion.
Fibroblast cell lines derived from human breast
cancers have epidermal growth factor receptors and
produce an epidermal growth factor like molecule
J.R.C. Sainsbury, E.A. Hirst, G.K. Needham, J.R.
Farndon & A.L. Harris
Departments ofSurgery and Oncology, University of
Newcastle-upon-Tyne, UK.
We have demonstrated the presence of high affinity
EGF receptors on human beast cancers by
radioligand and monoclonal techniques. It is known
that the stroma in which epithelial cells grow is
important and differences in the type of fibroblasts
are found in breast cancer specimens and normal
patients.
We derived fibroblast lines from 19 breast
cancers and examined them for EGFr by
radioligand binding. Sixteen (82%) bound from 0.15
to 2.2fmol 125-I-EGFmg-1 protein. The binding
was of a lower affinity than that found on the
breast cancers (1.2 x 10-8 vs 1.9 x 10-9).
Fibroblast cultures binding no EGF arose from
EGFr positive tumours whilst the high binding
cultures (>1.5fmolmg-1) came from EGFr -ve
tumours. The conditioned media from the
fibroblast cultures was examined for the presence of
epidermal growth factor like molecules by either
interference with a radioligand assay after concen-
tration on a Sep-pak or by immunoprecipitation by
a urogastrone-EGF antibody of 35-S-methionine
labelled cells and resolution on a SDS/PAGE
system. No interference of binding could be found
on cells grown in EMEM media but after oestrogen
stimulation with 10-7 DES identifiable bands of
6000 daltons were seen. These results indicateAGM BACR ABSTRACTS 441
that the EGFr on human breast cancer cells may be
being stimulated by EGF like factors derived from
the surrounding fibroblasts.
Epidermal growth factor and oestrogen receptors in
human breast cancers - Is there a link?
E.A. Hirst, J.R.C. Sainsbury & A.L. Harris
Departments ofSurgery and Cancer Research,
University ofNewcastle-upon-Tyne, UK.
Epidermal growth factor (EGF) and oestrogen
receptor (ER) status of both breast tumour biopsies
and established human breast cancer cell lines
(MCF 7, 4 sources, MDA-MB-231) have previously
been shown to be inversely correlated (Sainsbury et
al. (1983), Br. J. Cancer, 53, 235).
The exception to this finding was for the T 47D
cell line which showed both types of receptor to be
present at lower numbers. During recent
experiments investigating EGF binding to T47D
cells it was noted that the amount of 125-I-EGF
bound Mg- 1 protein increased with passage number.
T47D cells (a gift from Dr O'Hare, Ludwig Inst.)
were routinely maintained in DMEM +10% FBS
and subcultured weekly. EGF binding was carried
out according to the method of Osborne et al.
(1982) (J. Clin. Endocrinol. Metab. 55, 86) on ice for
2h. ER was measured by a dextran coated charcoal
method. Cells were examined between passage
numbers 25 and 45. A 3 to 4 fold increase in EGF
binding was seen over this time.
A fall in ER number was found as EGFr binding
increased. This observation provides further
evidence that EGFr and ER are linked. Further
work is needed to study the implication of this
finding and to see if the action of anti-oestrogen
drugs causes further changes.
EGF receptors in non small cell lung cancer
D. Vealel, C. Marsh2, T. Ashcroft2 & A.L. Harris'
'Clinical Oncology, Newcastle General Hospital,
Newcastle-upon-Tyne NE4 6BE; and 2Thoracic
Medicine and Pathology, Freeman Hospital,
Newcastle-upon-Tyne NE7 7DN, UK.
The presence of epidermal growth factor receptors
on tumour cells has been found to be related to the
degree of invasion of bladder tumours and breast
cancer.
Fourteen non small cell lung cancers (NSCLC)
have been studied for the presence of epidermal
growth factor (EGF) and its receptor (EGFr). A
monoclonal antibody to the receptor and a
polyclonal antibody to EGF were used in an
immunoperoxidase technique. EGFr has been
assayed on membrane preparations by radioligand
binding with I125 EGF and Scatchard analysis. The
slides were graded by 2 independent observers, 0,
+, + +, + + +, for positive staining. Squamous
carcinoma stained for EGF showed 2/8 + ++,
5/8+ +, 1/8+, 2 adenocarcinomas stained + +,
and +, and 2 large cell carcinomas stained + + for
EGF.
Staining for EGFr was graded + + + 5 of 8
squamous carcinomas; and 2/8 were + +, 1/8 +.
The adenocarcinomas were + + for receptor and
one large cell stained + + + for receptor and one
was +.
Multipoint radioligand assay for EGF receptor
showed high affinity binding sites with Kd of
1-2 x 10-9 M. There were also low affinity sites.
Thus we have demonstrated the presence of
EGFr on each type of NSCLC and we plan to
study the association of the presence of these
receptors with subsequent outcome and response to
therapy.
A sensitive enzymic assay for 06-methylguanine in
DNA
T.A. Meyer', D.P. Cooper', J. Brennand2 & G.P.
Margison'
Departments oflCarcinogenesis and 2Biochemical
Genetics, Paterson Laboratories, Christie Hospital,
Manchester M20 9BX, UK.
A plasmid has been isolated from an E. coli
genomic DNA expression library which increases
the amount of 06-methylguanine (06-meG) methyl-
transferase (MT) in the host bacteria. Extracts of
such bacteria have been used to determine the
amounts of O6-meG in DNA methylated in vitro or
in vivo in a simple competition assay which
measures the inhibition of transfer of label from
[3H]-methylated DNA to protein. The lower limit
of detection of O6-meG by this method is less than
10fmol and using in vitro methylated DNA there
was a good correlation (coefficient 0.999) between
this and conventional liquid chromatographic
methods. Addition of different amounts of non-
methylated DNA to the assay had no detectable
effect. Rat liver DNA methylated to different
extents in vivo by administration of dimethylnitro-
samine was found to contain levels of O6-meG
generally closely similar (±7%) to those found by
conventional methods. The technique used to
measure the levels of 06-meG in rat liver DNA
following administration of different doses of
dimethylnitrosamine: after lower doses,
disproportionally lower levels of 06-meG were
detected indicating a more efficient repair of this
product.442 AGM BACR ABSTRACTS
Effect of X-rays on rat hepatic 06-methylguanine
methyltransferase activity
B. Hoeyt, J. Butler1 & G.P. Margison2
Departments of'Radiation Chemistry and
2Carcinogenesis, Paterson Laboratories, Christie
Hospital, Manchester, M20 9BX, UK.
Studies on the relationships between alkylation
damage in DNA and carcinogenesis have shown
that the promutagenic lesion 06-methylguanine
(06-meG) can be subject to a repair process which
results in the transfer of the methyl group from the
06-position to a cysteine residue which is probably
within the methyltransferase (MT) protein itself. In
rat liver, the activity of the enzyme can be increased
by pretreatment of the animals with a variety of
hepatotoxic agents or by partial hepatectomy. In
order to explore further the response, we have
examined the effects of whole body X-irradiation
on 06-meG MT activity using a rapid in vitro
assay. Forty-eight hours after 1 Krad of electrons
from the linear accelerator, there was a 3-fold
increase in MT levels in liver extracts. Similar
effects have been produced in various strains of
mice, a species in which enhanced 06-meG MT
activity has not previously been reported. Initial
examinations of the possible mechanism of the
response has shown that 06-meG MT can be
inhibited in vitro by X-irradiated DNA. However,
this appears to be due to denaturation rather than
to the presence of modified bases.
Isolation of an E. coli gene coding for a repair
protein containing both 06-methylguanine and
methylphosphotriester methyltransferases
G.P. Margison1, D.P. Cooper1 & J. Brennand2
Departments of1Carcinogenesis and 2Biochemical
Genetics, Paterson Laboratories, Christie Hospital,
Manchester M20 9BX, UK.
The repair of methylphosphotriesters (MP) and 06_
methylguanine (06-meG) produced in DNA by
reaction with methylating agents has been shown to
occur in E. coli by transfer of the methyl groups to
protein. Using a rapid and sensitive assay which
can measure total MT activity we have identified
and isolated from an E. coli genomic DNA library
a plasmid which codes for both 06-meG and MP
MT activity. These have been shown by in vitro
assays and by fluorography of proteins labelled by
incubation of bacterial extracts with [3H]-
methylated DNA and subjected to polyacrylamide
gel electrophoresis (PAGE) to be part of a single
protein molecule of mol. wt. -37Kd. In various
other strains of E. coli, the plasmid causes
production of varying amount of 37, 18 and
13Kmd MT proteins. A partial restriction
endonuclease map of the DNA has been produced
and subclone plasmids have been characterised.
Different plasmids increased the production of
either 06-meG MT or MP MT which had mol. wts.
of - 18 and 13 Kd respectively, although additional
bands were seen on fluorograph in the former case. In
vitro DNA-directed protein synthesis using [35S]_
methionine or cysteine followed by PAGE-
fluorography showed that these plasmids contained
the structural genes for the MT.
Examination of mammalian DNA and mRNA
for sequences homologous to the E. coli
06-methylguanine-methylphosphotriester
methyl-transferase gene
P.M. Potter1, D.P. Cooper', J. Brennand2 &
G.P. Margison1
Departments of 1Carcinogenesis and 2Biochemical
Genetics, Paterson Laboratories, Christie Hospital,
Manchester M20 9BX, UK.
Using a functional assay to screen an E. coli DNA
library carried in an expression vector we have
identified a plasmid carrying a section of DNA
which codes for 06-methylguanine and methyl-
phosphotriester methyltransferases. A subfragment
of this, which codes for both activities has been
isolated by agarose gel electrophoresis and labelled
by nick translation using [32P]dCTP. Poly A'
messenger RNA was isolated by oligo dT-cellulose
chromatography from total RNA extracted from
the liver of rats in which 06-methylguanine methyl-
transferase activity had been increased by pre-
treatment with 2-acetylaminofluorene. This, and
Hind-III digested human spleen DNA was
subjected to agarose gel electrophoresis and
transferred to nitrocellulose before hybridisation
with the labelled probe. Under the conditions used
no indications of any sequence homology have so
far been found indicating that the sequences are not
highly conserved.
Analysis of c-Ha-ras-l proto-oncogene activation
induced by carcinogen-modification and by
depurination
D.H. Phillips1, K.H. Vousden1, H. Bos2 &
C.J. Marshall1
1Chester Beatty Laboratories, Institute ofCancer
Research, London SW3 6JB; and 2Department of
Medical Biochemistry, University ofLeiden, The
Netherlands.
The mechanism by which ras proto-oncogenes
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tumours has been shown to be through a single
point mutation resulting in the alteration of an
amino acid in the p21 protein product. We have
shown that in vitro modification of pEC, a plasmid
containing the normal cellular c-Has-ras-1 proto-
oncogene, by covalent reaction with (±)anti-
benzo[a]pyrene-7,8-diol-9,10-oxide (anti-BPDE),
causes mutations that activate the gene when the
plasmid is transfected into NIH 3T3 mouse cells
(Nature 310, 586, 1984). DNA from each of 5
transformed foci were found by restriction
endonuclease analysis to contain a point mutation
in the 12th codon (GGC). DNA from a further 10
foci have now been found by hybridization with
20mer oligonucleotide probes to contain a point
mutation in the 61st codon (CAG). Of these, 4 of
the alterations are in the 1st nucleotide, 3 are in the
2nd and 3 are in the 3rd. Experiments to determine
the exact nature of these point mutations are in
progress. Modification of pEC *ith N-acetoxy-2-
acetylaminofluorene, resulting in I adduct per 140
nucleotides, produced transformed foci, as did
modification with 1'-acetoxysafrole, at a level of 1
adduct per 30 nucleotides. Heating pEC at low pH
also produced transformed foci, providing evidence
that depurination can be mutagenic in mammalian
cells.
Isolation of DNA repair mutants of CHO cells
C.N. Robson, A.L. Harris & I.D. Hickson
Cancer Research Unit, University of
Newcastle-upon-Tyne, Royal Victoria Infirmary,
Newcastle-upon-Tyne NE] 4LP, UK.
A number of DNA repair mutants of CHO-KI
cells have been isolated by the 'toothpicking'
method of replica-plating. These cells were isolated
on the basis of their sensitivity to the anticancer
drugs mitomycin-C or bleomycin, and were
subsequently found to differ in their cross-
sensitivity to other DNA damaging agents, such as
EMS, cis-Pt and u.v. light. One mutant, designated
MMC-2, exhibits a 6-fold hypersensitivity to
mitomycin-C as well as 10-fold hypersensitivity to
u.v. light. Five other mutants also show approxi-
mately this level of sensitivity to mitomycin-C but
are resistant to u.v. light. One of these mutants
(BLM-2) is also hypersensitive to bleomycin. One
further mutant (BLM-1) exhibits sensitivity to
bleomycin only. Since their cross-sensitivity to
DNA damaging agents differs so markedly, it
would appear that they represent several different
complementation groups.
A human gene bank of -300,000 recombinants
has been constructed in the cosmid vector pNNL.
This DNA is currently being introduced into the
repair mutants by polycation transfection selecting
for resistant to mitomycin-C, u.v. or bleomycin.
Interaction ofN-nitrosoglycocholic acid with DNA
in vitro
D.E.G. Shukerl & S.R. Tannenbaum2
'MRC Toxicology Unit, MRC Laboratories,
Woodmansterne Road, Carshalton, Surrey, SM5
4EF, UK and 2Department ofNutrition and Food
Science, MIT, Cambridge, MA 02139, USA.
The N-nitrosation of endogenous amides in gastric
contents has been postulated as a source of
carcinogenic N-nitrosamides which may have a role
in the induction ofgastric cancer.
N-nitrosoglycocholic acid (NOGC), (Shuker et al.
(1981), J. Org. Chem. 46, 2092) is a mutagenic and
carcinogenic derivative of the naturally occurring
bile acid conjugate, glycocholic acid (GC). By
analogy with structuirally simpler N-nitrosamides
NOGC would be expected to act as an alkylating
agent giving rise to carboxymethylated
(-CH2CO2H) adducts.
[14C}-NOGC (with label in the glycine carboxyl
group) was synthesised by nitrosation of the
commercially available [14C]-_GC. Overnight
incubation of [14C]-NOGC with calf thymus DNA
at pH 7.2 and 37°C resulted in radioactively
labelled DNA. Most of the activity (>75%) was
removed on heating the DNA at 100GC at pH 7.4
for 30mm ('neutral thermal hydrolysis') which is
known to remove labile alkylated purines. After
precipitation of the depurinated DNA, HPLC of
the supernatant on reversed phase and aminopropyl
columns showed that some some of the
radioactivity co-chromatographed with authentic
carboxymethyl purines (N-7-carboxymethyl guanine
and N-3-carboxymethyl adenine).
RSU 1069 binding to DNA in vitro - evidence for
binding to both the bases and the phosphate of DNA
A.R.J. Silver, P. O'Neill & T.C. Jenkins
MRC Radiobiology Unit, Harwell, Didcot, Oxford,
OXJJ ORD, UK.
12-14c4-RSU 1069 (1(2-nitro-1-imidazolyl)-3-aziri-
dino-2-propanol), either as parent (unreduced) or
following radiation reduction, binds to calf thymus
DNA in vitro. Radiation reduced RSU 1069 binds
to a greater extent and more rapidly than the
parent compound. RSU 1137, a non-aziridino
analogue of RSU 1069, only binds following
radiation reduction. Radiation reduced
misonidazole (1-(2-nitro-1-imidazolyl)-3-methyoxy-
2-propanol) exhibits binding ratios a thousand-fold444 AGM BACR ABSTRACTS
less than reduced RSU 1069. There is no evidence
for binding of parent misonidazole.
Parent and reduced 1069 causes single strand
breaks (ssbs) in pSV2 gpt plasmid DNA with the
reduced compound causing a greater number of
breaks at a given concentration. Parent and
reduced RSU 1137 and misonidazole do not cause
ssbs. It is inferred that the aziridine of parent and
reduced RSU 1069 is required for ssb production.
The aziridine of RSU 1069 reacts with inorganic
phosphate via nucleophilic ring-opening of the
aziridine fragment. Incubation of plasmid DNA
with reduced RSU 1069 in the presence of
phosphate or deoxyribose-5-phosphate at
concentrations greater than 0.5moldm 3 prevents
strand breakage, whereas the presence of
2moldm 3 deoxyribose does not protect against
strand breakage formation.
From these findings it is proposed that the
observed binding to DNA occurs via the reduced
nitro group and the aziridine of RSU 1069 and that
these two have different target sites. Binding to
DNA via the reduced nitro group may serve to
increase aziridine attack due to localisation near its
target. RSU 1069 binding to DNA is discussed in
terms of both base and phosphate sites of attack.
Tiazofurin and poly(ADP-ribose)synthetase in A549
cells
M.R. Purnell, J.M. Lunn & A.L. Harris
Cancer Research Unit, Royal Victoria Infirmary,
Newcastle-upon-Tyne NE] 4LP, UK.
Tiazofurin (TR) and selenotiazofurin are cytostatic
nucleosides which act by inhibition of IMP
dehydrogenase following their conversion to NAD
analogues. Inhibition of growth of A549 human
lung carcinoma cells (IC50 after 4 days 20pM and
2 MM respectively) can be largely prevented by the
provision of exogenous guanosine. Nicotinamide
(up to 1OmM) is largely ineffective. We investigated
whether TR or its NAD analogue affected
poly(ADP-ribose)synthetase, a nuclear - enzyme
utilizing NAD and inhibited by analogues of NAD
nicotinamide. When data were corrected for
intrinsic growth inhibition, TR increased the IC50
of 3-acetamidobenzamide (AAB), an inhibitor of
poly(ADP-ribose)synthetase: 10MM TR increased
the IC50 from 2.85mM to 3.2mM and 50MM TR
increased it to 3.7mM. Non-cytostatic concen-
trations of AAB (1 or 2mM) enhance the toxicity
of bleomycin (IC50= 118ngml-') by 50%. In
contrast, 30MM TR had no synergistic effect on
growth inhibition. Monofunctional alkylating agents
such as NMU decrease cellular NAD by activating
poly(ADP-ribose)synthetase. AAB at concentrations
as low as 300pM can decrease the extent of the
NAD drop mediated by 10mM NMU. TR (up to
300pM) had no significant effect on NAD levels
alone or following NMU treatment.
We therefore conclude that neither tiazofurin nor
its NAD analogue have any significant effect on
poly(ADP-ribose)synthetase in these cells.
The cytogenetic effects of razoxane (ICRF 159) and
its structural analogues in cultured human
lymphocytes
R. Albanese
ICI Pharmaceuticals Division, Alderley Park,
Macclesfield, Cheshire SKJO 4TG, UK.
The antitumour agent razoxane and its structural
analogues ICRF 202, 187 and 154 have been found
to possess widely differing degrees of activity
against experimental tumours. Their mode of action
is unknown but in 1970 razoxane was shown to
affect chromosome condensation in cultured human
lymphocytes (CHL). The effect of these compounds
on CHL chromosomes has been compared in the
present study.
Lymphocytes were stimulated to divide in culture
using phytohaemagglutinin. The compounds (each
at two doses) or vehicle were added to the cultures
43h later. This corresponds to the G2/M stage of
the first cell cycle. Chromosome preparations were
made at 48, 72 and 96h after stimulation.
At 48h, each compound (but not the vehicle
control) induced abnormal chromosome conden-
sation; the chromosomes were elongated and had
the appearance of very early prophase-type
chromosomes. At 72 and 96h chromosome con-
densation appeared normal but there was a dose-
dependent increase in both structural chromosome
damage (breaks, fragments and chromosome
exchanges) and polyploid cells; at 72h a 25 fold
increase with ICRF 202 (0.5 ugml-') a 5-fold
increase with both 187 and 159 (50Mmml-1) and a
4-fold increase with 154 (50ugml-') compared to
the vehicle control.
These results show razoxane and its structural
analogues to be clastogenic in vitro.
Faecal steroids and colo-rectal cancer: New markers
for detecting high risk populations
R.W. Owen', P.J. Henly', D. Day2, M.H.
Thompson1 & M.J. Hill'
PHLS, CAMR, BMRL, Salisbury, Wiltshire; and
2Department ofPathology, University ofLiverpool,
Liverpool, UK.
This study was designed to compare the faecal bileAGM BACR ABSTRACTS 445
Table
Group LCAa DCAa CDCAa CAa
Asian (70) 1.11+0.11 1.99+0.22 0.41 +0.09 0.55+0.17
British (36) 2.78+0.36 3.93+0.54
Small adenoma (23)b 2.76+0.54 5.49+ 1.32
Large adenoma (34)C 3.51 +0.64 3.70+0.68
CRC (34) 4.01+0.63 3.39+0.59
FBAa LCA/DCA LCA/DCA x FBA





aResults expressed in mgg-' dry faeces+s.e.; LCA, lithocholic acid; DCA,
deoxycholic acid; CDCA, chenodeoxycholic acid; CA, cholic acid.
bAdenoma diameter 0-0.4cm. CAdenoma diameter 0.4-1.5cm.
acid profiles of healthy British subjects and colo-
rectal cancer (CRC) patients incorporating
immigrant Asians (a very low CRC risk group) and
an adenoma group (sub-divided into low and high
risk groups). Faecal bile acids were analysed and
data- for the major free bile acids are shown in the
Tahlc.
In summary, the ratio of LCA to DCA and the
LCA/DCA x FBA index are powerful indicators of
CRC risk, and show a remarkable positive gradient
from the very low risk group (Asians) through the
intermediate risk groups to colo-rectal cancer.
Faecal steroids and colorectal cancer: Alto bile acids
R. Wait, M.H. Thompson & M.J. Hill
Bacterial Metabolism Research Laboratory, PHLS-
CAMR, Porton Down, Salisbury, Wiltshire SP4
OJG, UK.
Several bile acids have been shown to be tumour
promoters in animal systems, while epidemiological
studies have demonstrated an association between
large bowel cancer (LBC) risk, elevated faecal bile
acid concentration and carriage of clostridia able to
dehydrogenate the steroid nucleus (NDH
Clostridia). These observations have been explained
by the bacterial production of unsaturated steroidal
ketones (especially 4-ene-3-one compounds). (Hill,
M.J. (1977). In Origins of Human Cancer (Hiatt,
ed.) p. 1927. Cold Spring Harbour). This reaction
readily occurs in vitro, but only trace amounts of
4-ene-3-one steroids have been found in human
faeces. We have analysed the faeces of healthy
NDH clostridia carriers by gel chromatography,
capillary chromatography and glc/mass spectro-
metry. We did not detect any unsaturated steroid
ketones, but have tentatively identified a number
of bile acids having the 5a (allo) ring junction.
These include 3a,12a-dihroxy-5a-cholan-24-oate,
3,B,12a-dihydroxy-5a-chlolan-24-oate, and 3,B-
hydroxy-5a-cholan-24-oate. Since these compounds
are produced via a 4-ene-3-one intermediate, they
provide indirect evidence for the occurrence of the
NDH reaction in vivo. Furthermore, they could
themselves modify LBC risk. Allo deoxycholic acid
has been shown to be a more powerful co-mutagen
than deoxycholic acid in bacterial assay systems
(Wilpart et al. (1983), Carcinogenesis 4, 1239).
Data are unavailable on allo bile acids as promoters,
but the potency of promoters such as phorbol
esters is extremely sensitive to subtle variations in
structure, including changes in ring geometry. We
hypothesise that the promoting potency of bile
acids is similarly structure dependent. LBC risk
could thus be modulated by the metabolic activity
of the intestinal flora by producing more or less
potent promoters from bile acids.
Faecal steroids and colorectal cancer: Faecal bile
acids in a low risk population
M. Thompson', P. McKeigue2, R. Owen1, P.
Henly', M. Hill', M. Marmot2 & A. Adelstein2
1BMRL, PHLS-CAMR, Salisbury, Wiltshire; and
2Department ofEpidemiology, London School of
Hygiene and Tropical Medicine, London WCJ, UK.
It has been demonstrated that faecal bile acids
(FBA) may influence the development of colorectal446 AGM BACR ABSTRACTS
Table
Population LCA DCA CDCA CA Total FBA
Asians (70) 1.1+0.9a 2.0+ 1.9 0.4+0.8 0.6+1.4 4.1+2.9
Vegetarian (40) 0.9+0.7 1.6+1.4 0.4+0.6 0.5+0.9 3.5+2.0
Meat eating (21) 1.4+1.0 2.6+2.6 0.2+0.3 0.2+0.3 4.3+3.6
Welsh (36) 2.8+2.2 3.9+2.3 6.7+5.2
LCA=Lithocholicacid,DCA=Deoxycholicacid,CDCA=Chenodeoxycholicacid,CA
=Cholic acid.
amgg ' dry faeces+s.d.
cancer (CRC) either as initiators or promoters. In
this study the FBA profiles of subjects from a low
risk predominantly vegetarian Asian community in
NW London, consuming a high fat-high fibre diet
were compared to those of a Welsh population.
Total free FBA concentrations were lower in the
Asian subjects than the comparison group, with a
high proportion (61%) excreting primary FBAs
(CDCA and CA). In the low risk group, whilst the
vegetarians excrete higher concentrations of total
FBAs, a greater proportion of these acids are in the
undegraded form when compared to meat eaters.
Thus in this study low risk subjects excrete lower
concentrations of FBAs with a known tumour
promoting activity (LCA and DCA) than the high
risk comparison group, with vegetarians excreting
the lowest concentrations of all. Therefore the
reduced risk of developing CRC in this population
may be associated with the suppression of bile acid
degradation in the colon.
Gastric juice analyses in patients at high risk of
gastric cancer
A. Cook', M. Hill1, N. Hall2, T. Northfield2, J.
Kirkham2, N. Viney3 & D. Darkin3
1PHLS-CAMR, Salisbury, Wilts SP4 OJG; 2St
James' Hospital, Balham, London; and 3SK & F
Research Ltd., Welwyn, Hertfordshire, UK.
An excess risk of gastric cancer has been observed
in patients treated for peptic ulcer by Polya partial
gastrectomy (PG) and in pernicious anaemia
patients (PA). We have therefore assayed over 24h
periods the gastric juice of these high cancer risk
groups of patients for bacteria, nitrate and nitrite.
In 8 PA patients there was throughout the 24h
period a resident bacterial flora (> 106
organismsml-1 including faecal species of for
example streptococci and bacteroides), a high
proportion of which was able to reduce nitrate. The
pH of the gastric juice in almost all samples was
greater than 5 - a pH favourable to bacterial
growth and nitrate reductase activity. The most
commonly isolated organisms were all oral species
of streptococci, lactobacilli, bacteroides, veillonellae
although faecal species were present. The 9 PG
patients could be divided into two groups. In one
(n=5) the gastric juice analyses were similar to
those of PA patients. In the other group (n=4)
g,astric acid secretion was sufficient to produce a
bactericidal pH (1.5-3.0) at night and at times
between meals; at these times the gastric juice was
essentially sterile (<103 organisms ml-1) and
contained no nitrate reducing bacteria and low
nitrite concentrations. Meals produced a high pH
(>5), high counts of total bacteria (> 106
organisms ml-1) and nitrate reducing bacteria
(> 106 organisms ml-1) and increased but very
variable nitrite concentration. All samples from all
patients contained nitrate but at concentrations
which ranged between 4-4701M. Statistical analysis
showed that the nitrite concentration was
significantly higher in PA and group 1 of PG
patients than in group 2 PG patients (P<0.05). The
results are compatible with the hypothesis that the
gastric cancer in these patients is caused by a
metabolite (possibly nitrite) produced by the
resident bacterial flora.
Gastric bacterial overgrowth as a risk factor in
human carcinogenesis
C.P.J. Caygill1, M.J. Hill1, J. Kirkham2, & T.
Northfield2
1BMRL, PHLS-CAMR, Porton Down, Salisbury,
Wiltshire SP4 OJG; and 2Gastroenterology Unit, St
James Hospital, Sarsfleld Road, London SW12
8HW, UK.
It has been reported that in persons with bacterial
overgrowth of the stomach there is a high
concentration of nitrite in the gastric juice and in
some reports also of N-nitroso compounds, and
that these may be the cause of the increased gastric
carcinogenesis associated with this condition. If
N-nitroso compounds are important human
carcinogens then cancers at distant sites would
also be expected. Pilot studies of Polya partial
gastrectomy and of pernicious anemia patients
suggested an increased incidence of colorectal andAGM BACR ABSTRACTS 447
biliary tract cancers as well as of gastric cancers. In
this study a group of 4,235 patients treated
surgically for peptic ulcer at St James Hospital,
Balham, between 1940 and 1960 have been
identified, their death certificates obtained and their
mortality from cancers of various organs
determined using a 'years at risk' calculation in 5
year bands. The excess mortality from gastric
cancer (4-fold) with a latency of 20 years, reported
by others, was observed and in addition there was
an excess mortality from colorectal (2.5-fold) and
from biliary tract cancers (8.6-fold) also with a
latency of 20 years. There was no increased risk of
mortality from these cancers in the first 20 years
after operation. The mortality from cancers of the
pancreas, lung and all sites was as expected during
the first 20 post-operative years, but was increased
thereafter by 3.2, 5.0 and 2.9 fold respectively. The
results are compatible with the hypothesis that N-
nitroso compounds formed in the stomach may be
human carcinogens but the association of gastric,
biliary tract and colorectal cancers in these patients
also suggests a role for modified bile. The excess of
cancers of all sites and particularly the lung and
pancreas may be due to the high prevalence of
smoking in this group ofpatients.
Development of anti-mouse IgG and anti-idiotypic
antibodies by patients receiving radiolabelled
monoclonal antibody (791T/36) for diagnostic
immunoscintigraphy
M.V. Pimm', R. Rowel, A.C. Perkins2 & R.W.
Baldwin'
'Cancer Research Campaign Laboratories,
University ofNottingham; and 2Department of
Medical Physics, University Hospital, Nottingham,
UK.
Imaging of tumours following administration of
radiolabelled antibodies has been reported from a
number of trials. Because antibodies used for
immunoscintigraphy are of mouse origin it is likely
that these will evoke antibody responses in patients
and this needs to be appreciated in the design of
repeated imaging protocols. However, production
of anti-idiotype antibodies has been reported to
beneficially modulate the patients' immune response
to tumour (Koprowski et al. (1984), Proc. Natl
Acad. Sci. 81, 216). In the present study the
production of anti-mouse IgG and anti-idiotype
antibodies by patients receiving radio-labelled
791T/36 antibody has been assessed.
All 40 patients produced antibody reactive with
791T/36 antibody (mouse IgG2b) detected by
binding of antibody to immobilized 791T/36, and
formation of complexes (assayed by gel filtration)
when 311-791T/36 was added to patients' plasma.
Antibody was detected within 7 days of 791T/36
administration and was present for at least 10
months. Formation of complexes in vivo was seen
in patients receiving antibody for a second or third
time. This resulted in reduction in image quality in
many patients, with uptake of radiolabel
predominantly in the spleen. Formation of anti-
idiotype antibodies was indicated by greater binding
of patients' antibodies to 791T/36 than to normal
mouse IgG2b and specific inhibition of binding
fluorescein 791T/36 to appropriate target cells.
These studies have shown that patients develop
antibodies to a monoclonal antibody used for
diagnostic immunoscintigraphy, and this may be a
serious limitation for repeated imaging. The
consequences of the production of anti-idiotypic
antibodies has yet to be assessed.
Increased oleic acid content in erythrocytes of cancer
patients
N. Habib', C. Wood', K. Apostolov2, A.
Thompson', W. Barker2 & M. Blount'
Departments of'Surgery and 2Virology, Royal
Postgraduate Medical School, Hammersmith
Hospital, Ducane Road, London W12 OHS, UK.
Lipids form 40% of the cell membrane mass. The
main properties of the lipids including their
viscosity depend mainly on the content of
unsaturated fatty acids. A larger proportion of
unsaturated fatty acids contributes to a higher
membrane fluidity and is associated with a higher
capacity for cell division. Peripheral erythrocytes
were taken from 100 cancer and 80 non-cancer
patients and were analysed for fatty acids contents
using gas liquid chromatography.
It was found that cancer patients have a decrease
in the saturation index (ratio of stearic to oleic
acids) of the erythrocytes cell membranes when
compared with non-cancer patients (P<0.001). This
ratio was found to be useful in monitoring therapy
in cancer patients as it is within normal range in
disease-free patients and revert to abnormal range
in patients with local or distant tumour recurrence.
Histogenesis of anaplastic thyroid tumours
A.D. Burt', D.J. Kerr2, I.L. Brown' & L.G.
Bobrow3
University Departments of'Pathology and 2Clinical
Oncology, Glasgow; and 3Department of
Histopathology, University College Hospital Medical
School, London, UK.
In an immunohistochemical study of 53 anaplastic448 AGM BACR ABSTRACTS
tumours of the thyroid we have identified a group
of 14 tumours that express neither the lymphoid
marker, common leucocyte antigen (CLA) nor the
epithelial marker, epithelial membrane antigen
(EMA). These tumours are characterised clinically
by rapid growth with a poor response to
radiotherapy and a poor prognosis (mean survival
4.5 months).
To further investigate the histogenesis of these
tumours we have used the avidin biotin technique
with antisera to intermediate filaments on formalin-
fixed, paraffin-embedded tumour tissue. Low
molecular weight intermediate filaments detected by
the monoclonal antibody CAM 5.2 were
demonstrated in 4/14 tumours indicating an
epithelial origin. Desmin, an intermediate filament
found almost exclusively in smooth muscle tissue
was detected in two tumours. No tumour was
found to contain vimentin. The use of antisera to
cytoskeletal proteins has thus provided information
regarding histogenesis in tumours that were
negative for CLA and EMA. These results
emphasise the need for the use of a panel of
antibodies in the investigation of anaplastic
tumours.
Cytogenetic analysis of cell populations from routine
diagnostic lymph node biopsies
M. Fitchett', M. Griffiths', D.B. Jones2, D.H.
Wright2 & J.L. Smith3
'Wessex Regional Cytogenetics Unit, Salisbury,
Wiltshire; and 2University Departments ofPathology
and 3Immunology, Southampton, UK.
Cytogenetic investigations have been carried out on
lymph node biopsies from 21 patients. Our findings
emphasise the need to use fresh specimens and the
value of stimulating cultured cells with PHA or
TPA in addition to analysing preparations from
unstimulated cultures. Stimulated cultures
frequently show an improved mitotic index and
superior quality of banded metaphase spreads
which allowed more detailed analysis. The use of
TPA revealed abnormal clones in 5 patients whose
unstimulated cells yielded either no mitoses or
unanalysable metaphases. Lymphoma biopsies of
all patients were fully characterised using a panel of
monoclonal antibodies. Clonal karyotypic
abnormalities were detected in all 16 patients.with
malignant B-cell disease (including one patient with
CLL). Detection of only karyotypically normal cells
in 4 patients confirmed an absence of lymphoid
malignancy. Both of our patients with deletion of
6q showed the presence of centroblasts. Two
patients with t(14; 18) had follicular lymphoma. A
single patient with duplication of Iq had diffuse
centroblastic lymphoma. Complex karyotypes were
found in association with the presence of
centroblasts in 6/7 cases, whereas 3/3 single
autosomal abnormalities were associated with
centrocytic lymphoma. We also report an unique
case of t(2; 8) in a non-Burkitt's lymphoma and the
finding of non-constitutional sex chromosome
abnormalities in 2 lymphoid malignancies.
Cytogenetic studies are being used to complement
routine histological and monoclonal antibody
investigations in the diagnosis of non-Hodgkin's
lymphoma.
Intravenous hydroxyurea and cis-platinum for non
small cell lung cancer (NSCLC)
B. Cantwell', D. Vealel, A.L. Harris', J. Bozzinol,
M. Earnshaw2 & A. Upfold2
'Clinical Oncology and 2Pharmaceutical Quality
Control Laboratory, Newcastle General Hospital,
Newcastle-upon-Tyne NE4 6BE, UK.
Hydroxyurea (HO) inhibits DNA synthesis by
inhibiting ribonucleotide reductase, and depletes
cells of nucleotide triphosphates. With higher doses,
HO inhibits DNA repair probably by preventing
the filling of gaps in DNA with nucleotides. Since
cis-platinum induces DNA interstrand cross links,
the 2 drugs were combined in a clinical study in an
attempt to maximise tumour cell kill by using high
dose intermittent infusions of HO to prevent repair
of DNA damage induced by cis-platinum. Patients
(pts) received 24 grams of HO by i.v. infusion over
24h and 8h after start of infusion, cis-platinum
50mgm2 i.v. Cycles were repeated 3 weekly to a
maximum of 6 cycles. Forty-seven patients with
inoperable assessable NSCLC have been treated, 3
of whom received only HO because of pretreatment
deafness. Mean age=59 yrs, SD+9.8, with 36
males, 11 females. Responses in 23 pts with
squamous cell lung cancer were complete response
(CR)= 1; partial response (PR)=3; stable disease
(SD) for 3 or more months=6 pts. Responses in 14
pts with adenocarcinoma of lung were PR= 1,
SD=6. No responses in 10 pts with large cell
,anaplastic lung cancer. Major symptomatic toxicity
was emesis (30 pts k3 vomits after cis-platinum), 1
pt developed urticaria after start of HO, only 2 pts
developed myelosuppression which led to changes
in management. Mean HO plasma levels in 6 pts
during the last 8h of i.v. infusion was 150jigml-'
(range 61-235) which is level required to inhibit
DNA synthesis by 80% in NSCLC cell lines in
vitro. HO with cis-platinum has activity in
squamous and adeno-NSCLC. We are now
assessing escalating doses of HO alone in NSCLC
since high dose intermittent infusional HO
appeared to lack significant toxicity in doses used
so far.AGM BACR ABSTRACTS 449
Randomised trial of oral out-patient chemotherapy
versus 4 drug intravenous chemotherapy for small cell
lung cancer (SCLC)
B. Cantwell, A.L. Harris, J. Bozzino, P. Corris, S.
Nariman, S. Pearce, J. Gibson, D. Hendrick, A.
Lishman & A. Hendrick
Department ofClinical Oncology, Newcastle General
Hospital, Newcastle-upon-Tyne NE4 6BE, UK.
We have found i.v. infusions of ifosfamide (ifos)
and mesna, both in doses of 5gm 2 to be active
2nd line treatment for SCLC in a crossover study
(Cantwell et al. (1984), Br. J. Cancer 50, 247).
Short courses of ifos and mesna were relatively
marrow sparing and lacked significant urinary tract
toxicity. We wished therefore to examine ifos earlier
in the course of SCLC, in a comparison of i.v. vs
an oral drug regimen both given for 4 courses.
Seventy-four patients (53 limited, 21 extensive
disease) have so far been treated. The i.v. arm
consists of course 1: VP16 lOOmgm-2 i.v. day 1
and 300mg orally on days 2 and 3, adriamycin
40mgm 2 and vincristine 2mg i.v. both on day 1.
Courses 2, 3 and 4: ifos 5gm-2 24h i.v. infusion
with mesna 5 gm-2 i.v. before, during and after
ifos infusion, VP16 JOOmgm-2 at Oh and at 24h,
adriamycin 30mgm 2, vincristine 2mg i.v. Oral
arm: chlorambucil 10mg daily, procarbazine 50mg
tds, prednisolone EC 10mg bd, all given days 1-10
and VP16 300mg days 1-3, oral and i.v. chemo-
therapies given 3-weekly to a total of 4 courses.
Patients with limited disease and good response
subsequently receive radiotherapy to primary site
and prophylactic cranial RT. Forty patients are
assessable for response to chemotherapy (20 in i.v.,
20 in oral arm). In i.v. arm there are 14 (70%)
objective responses (5CR, 9PR) and in oral arm 10
(50%) objective responses (3CR, 7PR). In the i.v.
arm 5 patients and 6 in the oral arm had at least 1
episode of leucopenia. Changes in therapy as a
result were more frequent in the oral arm, but the
only episode of certain septicaemia occurred after
course 1 in the i.v. arm. Early results suggest that
oral chemotherapy offers an easily administered
out-patient alternative for remission induction in
small cell lung cancer. Patient accrual continues.
A pharmacokinetic, endocrine and clinical study of
the LHRH analogue DSer(tBU) 6 AzaGlylO GnRH
(ICI 118630)
T.J. Perren', R.N. Clayton', G.R.P. Blackledgel,
D. Arkell2, J. Cottam2, D. Farrar3 & C. Young3
'Department ofMedicine, University ofBirmingham;
2Department of Urology, Dudley Road Hospital; and
3Department of Urology, Selly Oak Hospital,
Birmingham, UK.
Seventeen patients with advanced prostatic cancer
were treated with the gonadotrophin releasing
hormone (GnRH) analogue DSer(tBU)6 AzaGlylO
GnRH (ICI 118630) either as a constant s.c.
infusion (I) (n=4), or in the form of a slow release
depot formulation (D) (n= 13) in which case
patients were randomised to receive one of 3 doses.
Two out of four I patients later went onto D. Six
patients also received a single 250pg s.c. bolus of
ICI 118630 before starting I or D for pharmaco-
kinetic studies. Both I and D were effective in
reducing serum LH, and testosterone to castrate
levels by 1 month. Drug levels were measured using
a double antibody radioimmunoassay. In contrast
to I which gives a smooth drug level profile, drug
release from D was not constant, levels varied in a
predictable manner throughout each 28 day period
reaching a peak proportional to dose, on day 15-18
of each cycle. Treatment with ICI 118630 appears
effective, 7/9 patients evaluable for clinical response
showed a greater than 50% reduction in prostatic
dimensions. Toxicity was minimal 4/17 had an
initial flare in bone pain, 13/17 had flushing. D
preparations of GnRH analogues show great
promise for the treatment of advanced prostatic
cancer and may well become the treatment of
choice.
BCNU with autologous bone marrow grafting for
malignant melanoma and brain tumours
E. Mbidde, P. Selby, J. Maitland, H.J.G. Bloom &
T.J. McElwain
Royal Marsden Hospital, Down Road, Sutton,
Surrey, UK.
BCNU is active in the treatment of malignant
melanoma and brain tumours but its dose is limited
mainly by myelosuppression. Marrow autografting
avoids this toxicity. Although the plasma half life
of BCNU is short, cryopreservation of marrow cells
has previously been necessary to allow
administration of BCNU by a 24h infusion. We
have given BCNU 800mgm2 by a bolus injection
into a central venous line in 9ml of absolute
alcohol to 30 patients (pts) after a bone marrow
harvest and returned the marrow, without cryo-
preservation 12h later. Five pts were treated twice.
The procedure was well tolerated. Leucopenia
<1 x 109cellsI- occurred in 20 pts (median
duration 3 days, range 0-27 days) with no life
threatening infections. Thrombocytopenia
<25 x 109 platelets 1- I occurred in 18 pts (median
duration 1 day). Two pts had prolonged thrombo-
cytopenia >60 days. Partial alopecia in 3 pts.
Moderately severe pneumonitus in 3 pts.
Biochemical hepatitis occurred in 1 pt but no
treatment related deaths. The pts were managed as450 AGM BACR ABSTRACTS
out-patients with short admissions only. Among 11
previously untreated melanoma pts there were 4
partial remissions lasting 1.5, 2, 2 and 5 months
and one complete remission lasting 6 months.
Among 11 previously treated pts there are no
responses with one pt too early to assess. The
treatment appears to offer no advance in the
treatment of melanoma. The brain tumour pts (7
astrocytoma Grade IV) are being treated with
BCNU followed by radiotherapy. The treatment is
generally well tolerated and 6/7 glioma pts have
had substantial improvements in CT scans after
BCNU but it is too early to comment on the
overall efficacy of the combined treatment.
Effect of cholecystokinin on human pancreatic and
gastric cancer in nude mice
C. Huddl, M. LaRegina2, D. Palmer3, D.
Herbold3, J. Devine3 & F. Johnson'
Departments of'Surgery and 2Comparative
Medicine; and 3Pathology, St Louis University
Medical Center, St Louis, MO, USA.
Gastrointestinal (GI) hormones regulate growth of
normal GI tissues as well as certain GI cancers
(Hudd et al. (1984), Gastroenterology 86, 1118).
Since CCK promotes growth of nortnal pancreas
and also inhibits the trophic effect of gastrin on
stomach, we studied the impact of CCK on human
pancreatic and gastric cancer. In two separate
experiments, groups of nude mice bearing s.c.
nodules of human pancreatic or gastric cancer
received either saline or synthetic sulfated CCK-8
(Squibb), 50 mgkg-1 dose-1 BID i.p. for 14 days: a
dose, route, and schedule which produces maximum
pancreatic growth in the nude mouse. Tumour
volumes were calculated from vernier caliper
measurements taken every 3 days. On day 15,
pancreas and tumour were excised, weighed, and
submitted for histology (H & E) biochemistry
(DNA, RNA, and protein content), and CEA
staining. Results were analyzed by the Student t-
test and are expressed as mean + s.e.
We saw no histological differences between groups
in either series. We conclude that: (1) The dose of
CCK was biologically active. (2) CCK did not
affect growth of human pancreas cancer line P1420,
but retarded growth of human gastric cancer line
SLU 077.
Alternating platinum combination chemotherapy in
gynaecological malignancies
F.G. Lawton, G.R.P. Blackledge & J.J. Mould
West Midlands Ovarian Cancer Group, Queen
Elizabeth Medical Centre, Birmingham, UK.
Platinum (P) based combination chemotherapy
regimes produce high response rates in epithelial
ovarian cancer (EOC), but are associated with
sometimes unacceptable toxicity. Alternating the P
and non-P arms allows a large number of effective
drugs to be used as initial treatment and may also
reduce cumulative toxicity.
Twenty patients (18 EOC, 1 Ca endo-
metrium+ ovary, 1 Ca Fallopian tune) were given
P (60-100mgm-2) and cyclophosphamide
(600mgm2) i.v. alternating 3 weekly with cycles
of adriamycin (50 mgm-2), bleomycin 15mg i.v.
and chlorambucil (6mgm-2) od. 1-7 (CP-ABC). A
total of 3 courses of CP-ABC were planned.
Only 14/120 courses were delayed. (Nine by 1
week, 3 by 2 weeks, 2 by 3 weeks).. (Seven
neutropenia, 4 thrombocytopenia, 3 excess
vomiting). Alopecia was common (5 WHO Gd 1, 7
Gd 2, 4 Gd 3) but reversible in all cases.
Haematological toxicity (5 Gd 1, 4 Gd 2, 3 Gd 3)
was only severe in heavily pretreated patients. Only
5 patients experienced worse than Gd 1 nausea.
Three patients required blood transfusion. In 2
patients creatinine clearance fell below 50mlmin-1.
Five out of nine evaluable patients responded to
treatment (55%).
Such alternating regimes could allow the
incorporation of greater numbers of active drugs as
first-line treatment of EOC with little resulting
cumulative or cross toxicity.
Table
Pancreas cancer P1420 Gastric cancer SLU-077
Pancreas wt Tumor vol (cm3) Pancreas wt Thmor vol (cm3)
(9% body wt) Day 15 (9%body wt) Day 15
CCK 1.38+0.05 2.19+0.57 1.31+0.09 0.34+0.06
Saline 1.19+0.04 2.22+0.34 0.88+0.05 0.82+0.20
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Anti-emetic effect of dexamethasone (D) in
out-patient chemotherapy
D.L. Farquhar, S.G. Allan, D. Harrison & R.C.F.
Leonard
Departments ofClinical Oncology and Surgery,
University ofEdinburgh, Edinburgh, Scotland, UK.
A single blind trial was designed to assess the
efficacy of D as an anti-emetic agent for out-patient
cytotoxic chemotherapies including the potent
emetic drugs, cyclophosphXmite and adriamycin.
All patients had breast tarci*oma and received
either adjuvant CMF or advanced disease
combination chemotherapy including adriamycin.
Patients were randomised to receive either D 16mg
i.v. and oral Mrfotival 1 tablet tds (D/M) or N-saline
i.v. and Motival (S/M). They received the
alternative therapy on their subsequent course
allowing direct comparison. Patients could be
included in the trial for more than one
randomisation. The study includes 19 patients (30
paired courses of therapy). Patients assessed nausea
on a visual analogue scale, stated number of vomits
following chemotherapy and meals eaten on the
following day. Results show a significant reduction
in patients' assessment of nausea and numbers of
vomits in the D/M compared with the S/M group.
In only 4 of 30 paired assessments was S/M
associated with less nausea than D/M. This
confirms that D is an effective antiemetic agent in
out-patient chemotherapy.
A comparative study of nabilone and
prochlorperazine versus nabilone and placebo in the
control of emesis induced by cytotoxic drugs
D. Cunningham, G.J. Forrest, N.L. Gilchrist, I.
Calder & M. Soukop
Department ofMedical Oncology, Royal Infirmary,
Glasgow, UK.
Nabilone, a synthetic cannabinoid with structural
similarities to tetrahydrocannabinol (THC) is a
potent antiemetic, but dysphoric reactions have
limited its use. The addition of prochlorperazine to
THC has been shown to reduce the frequency of
CNS side effects, therefore the purpose of this
study was to investigate whether such an effect
would be observed with the addition of
prochlorperazine to nabilone. Thirty patients, mean
age 54 years (range 39-76) receiving a variety of
cytotoxic chemotherapy regimes without cis-platin
entered this double blind crossover study
comparing nabilone 2mg and prochlorperazine
5mg (N+P) with nabilone 2mg and placebo (N)
both given 12 hourly for 4 doses. Three patients
had previously received chemotherapy, but none
had been given nabilone or had taken cannabis in
the past. There was complete control of vomiting in
80% of patients given N+P and 80% of patients
given N. Toxicity was similar with both antiemetic
regimes with regard to sedation (85%) and dizziness
(60%) but more patients developed a dry mouth
with NS (90% vs 76%). However, only 5%
complained of dysphoria with N+P compared to
50% with N (P<0.01). Furthermore 45% of
patients preferred N+P as an antimetic because of
the reduction of dysphoria (P<0.01), 5% preferred
N and 50% had no preference. This study has
shown that nabilone and prochlorperazine is an
effective antiemetic and that the dysphoric effects of
nabilone are significantly reduced by the addition
ofprochlorperazine.
Protein synthesis rates in an animal model of cancer
cachexia
J.A. Plumb & K.C. Calman
Department ofClimical Oncology, University of
Glasgow, Horselethill Road, Glasgow G12 9LX, UK.
A chemically induced adenocarcinoma of the mouse
colon (MAC-16) can be grown subcutaneously in
NMRI mice. After 4 weeks the tumour grows to
6% of the mouse body wt. Although the mice
maintain their normal food intake for most of the
time, their body weight decreases by 20%.
Clearly the weight loss cannot be accounted for
either by the tumour growth rate or by a reduced
food intake; a situation similar to the severe weight
loss characteristic of cancer cachexia. After 4 weeks
the protein content of the gastrocnemious muscle452 AGM BACR ABSTRACTS
(total ninhydrin positive material after acid
hydrolysis) is decreased by 35% (P<0.01, n=8).
Protein synthesis rates were measured in vivo by the
method of Garlick et al. (1980), (J. Biochem. 192,
219). There was no difference between the rates in
muscle from control mice and from tumour bearing
mice. It is concluded that the loss of skeletal muscle
in tumour bearing mice is probably due to an
increased rate of protein degradation.
Body weight loss (cancer cachexia) following
transplantation of an adenocarcinoma of the mouse
colon (MAC 16)
S.A. Ali, M.C. Bibby & J.A. Double
Clinical Oncology Unit, University ofBradford
BD15 7AX, West Yorkshire, UK.
MAC 16 is one of the MAC series of colon
tumours originally induced in NMRI mice by
dimethylhydrazine (Double et al. (1975), J. Natl
Cancer Inst. 54, 271). It is a moderately well-
differentiated adenocarcinoma transplanted
subcutaneously in the flank. The tumour has a
volume doubling time of -6 days and produces a
reduction in body wt of -20% over a period of 3-
4 weeks. This weight loss is not accompanied by a
decrease in food intake and there is no evidence of
ketosis. Excision of the tumour results in cessation
of weight loss with subsequent weight gain on
recovery. Occasional local recurrence of tumour
growth is accompanied by further loss of body wt.
Twice weekly i.v. injection of serum from cachectic
tumour bearing mice into normal mice over a
period of 4 weeks did not affect body wt. A tumour
product is therefore unlikely to be responsible for
the cachexia.
The anti-tumour activity of a series of agents
against MAC 16 has been determined. Response
was measured by growth delay from semi-log plots
of relative tumour volumes calculated from serial
caliper measurements. Like other tumour lines
within this series responses are only seen close to
the maximum tolerated dose. The best anti-tumour
responses are seen with 5-fluorouracil and
cyclophosphamide. MAC 16 does not respond to
methyl CCNU or mitozolamide both of which have
been shown to be very effective against other lines
of the MAC series.
Inhibition of tumour growth in vivo by manipulation
of cellular energy metabolism
K.C.H. Fearon, J.A. Plumb, R. Sri-Pathmanathan
& K.C. Calman
Department ofClinical Oncology, University of
Glasgow, 1 Horselethill Road, Glasgow G129LX,
UK.
The mitochondria of many tumours are known to
be abnormal in number, morphology and enzyme
content. Moreover, many tumours are recognised to
have high rates of glycolysis and to be glucose
dependent. These abnormalities of the two major
sources of intracellular ATP have suggested that
the manipulation of tumour cell energy metabolism
might provide a method for selective inhibition of
tumour cell growth.
The fluorescent dye Rhodamine 1,2,3(R1,2,3)
inhibits the growth of Ehrlich ascites tumour in
mice and its activity is potentiated by the glycolytic
inhibitor 2-deoxyglucose (Bernal et al. (1983),
Science 222, 169). We have studied the effects of
i.p. administration of the antimitochondrial dyes
R1,2,3 and Rhodamine 6G (R6G) on the growth
rate of the Walker 256 carcinosarcoma in rats. The
inhibition of tumour growth when these drugs were
administered in combination with 2-deoxyglucose
or hydrazine sulphate (inhibitor of gluconeogenesis)
was also assessed.
The anti-tumour effects of R1,2,3 were
potentiated by 2-deoxyglucose but little inhibition
of tumour growth occurred if the administration of
either or both drugs commenced more than 24h
after tumour implantation. Alternatively, R6G was
a more potent drug and inhibited tumour growth
when administered more than 48 h after tumour
implanatation. The efficacy of R6G was increased
by hydrazine sulphate but not by 2-deoxyglucose.
Tumour cell energy metabolism, therefore, has the
potential as an important new target for
chemotherapeutic intervention.
The computerised storage and retrieval of chemical
and experimental antitumour data
J.A. Slack, M.D. Threadgill, D. Chubb, B. Kemp,
J.A. Hickman & K.J. Bowcock
CRC Experimental Chemotherapy Group, University
ofAston, Birmingham, UK.
A package of programs has been developed for the
storage and retrieval of chemical, structural and
biological data concerning compounds and their
activity against experimental murine tumours in
vivo. Access to the database is gained via Fortran
application programs using RAPPORT commands
on a Harris H500 minicomputer. The chemical data
stored consists of the molecular formula, solubility
and IUPAC systematic name of each compound
together with a concise code describing functional
groups and rings. This code was developed to be
much simpler to use than the Wiswesser system,
recognising some 200 major functional groups and
the Chemical Abstracts Ring Index. Compounds
are indexed through a unique Compound Code.
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dose, schedule, host toxicity and various
antitumour evaluation parameters. Three
application programs enable all users access to the
data without prior knowledge of database structure
and organisation. In the first, iterative searches are
available to retrieve data on all compounds in the
database having particular chosen groups and ring
systems. The second gives a summary of all
biological data for a given compound and the third
provides full screening and chemical data for a
given agent against the selected tumour. Data is
currently held on >200 compounds and >300
tests.
Development of drug resistance in a murine
mammary carcinoma
T.J. McMillan, T.C. Stephens & G.G. Steel
Radiotherapy Research Unit, Institute ofCancer
Research, Sutton, Surrey, UK.
The MT murine mammary carcinoma (caMT) was
examined before and after courses of treatment
with either melphalan, cyclophosphamide or cis-
platinum II in an attempt to understand the
mechanisms involved in the development of drug
resistance.
Single high-dose treatments were given in each
passage and the loss of therapeutic response was
assessed using a growth delay end point. Growth
delay at the given doses fell by a factor of 4.1 after
16 treatments with 12mgkg-1 melphalan, 10.6
after 20 treatments with 180mgkg-1 cyclo-
phosphamide and 3.8 after 20 treatments with
10mgkg-1 cis-platinum. The decrease in sensitivity
was confirmed by clonogenic cell survival following
either in vivo or in vitro drug treatment. The rate of
development of resistance to cyclophosphamide was
increased by prior treatment with the classical
mutagen EMS or with melphalan, but two widely
differing doses of cyclophosphamide brought about
resistance at equal rates.
The rates of drug-resistance development were
much slower than would be predicted by current
models involving the selection of a pre-existing
highly drug-resistant subpopulation. However,
studies with clonal lines from untreated tumours
indicated that clones with a wide spectrum of
sensitivity are present in caMT (range ofD1o values
of in vitro melphalan dose survival curve=0.35-
0.98pgml- 1). A model based on such a spectrum
of sensitivities suggests that drug-resistance may
emerge more slowly and this may therefore be a
better representation of the drug-resistance
development data obtained with caMT.
The effect of the rate of cell proliferation on the
synthesis of methotrexate poly-y-glutamates in two
human breast cancer cell lines
D.G. Kennedy', H.W. van den Berg,2, R. Clarke'
& R.F. Murphy'
Departments of 1Biochemistry and 2Therapeutics,
The Queen's University ofBelfast, NI, UK.
The therapeutic and toxic effects of methotrexate
(MTX), may in part be dependent on the rate and
extent of intracellular formation of poly-y-glutamyl
(PG) derivatives. These metabolites are extensively
retained within the cell and are at least as effective
as the parent drug in inhibiting dihydrofolate
reductase. As part of a study designed to investigate
factors controlling MTX-PG synthesis we have
examined the influence of initial cell plating density
on the rate of cell proliferation and MTX-PG
synthesis in the MCF-7 and MDA-MB-436 human
breast cancer cell lines.
Our results demonstrate that although slowly
proliferating cells accumulate MTX to the same
extent as rapidly proliferating cells, they convert a
lower percentage of the drug to PG forms. The
MDA-MB-436 line exhibited a biphasic response of
both doubling time and polyglutamation to
increasing initial cell number. Extremes of cell
density were associated with long doubling times
(>80h), and reduced PG synthesis (50-75% of
total intracellular drug). Optimum cell densities for
PG synthesis (>85% of total drug), was associated
with a more rapid growth rate (doubling time 30-
40h). MCF-7 cells showed increasing doubling time
(25-f >80 h), and decreasing PG synthesis
(80-+28% of total drug) with increasing initial cell
number.
We conclude that the decreased extent of MTX-
PG synthesis in slowly proliferating cells may
provide an additional mechanism by such cells
which are more resistant to the effects of MTX.
The growth of exfoliated colorectal carcinoma cells
in immune deprived mice
H.C. Umpleby, B. Fermor, J.V. Lever, M.O. Symes
& R.C.N. Williamson
Departments ofSurgery and Pathology, University of
Bristol, UK.
The viability of exfoliated colorectal cancer cells is
indicated by exclusion of trypan blue and
fluorescence following exposure to fluorescein
diacetate (Umpleby et al. (1984), Br. J. Surg. 71,
659). To determine whether such cancer cells can
undergo further proliferation they were trans-
planted into 4 month old mice, previously subjected
to thymectomy, 9Gy whole body irradiation and
isogenic bone marrow injection.454 AGM BACR ABSTRACTS
In 17 patients with carcinoma of the colorectum
the operative specimen was lavaged with TCM 199
and cancer cells in the fluid were concentrated on a
Nycodenz (Nyegaard, Oslo) column. Between 0.1
and 1.2 x 106 (median 0.75 x 106) viable cells from
each tumour were injected i.v. into separate groups
of 1-5 immune-deprived mice. The animals were
killed 2 weeks later, their lungs fixed in Bouins
fluid and macroscopic nodules were examined
histologically for foci of colorectal carcinoma. Cells
from 7 of the carcinomas formed pulmonary
metastases in one or more mice. No metastases
were seen in 12 immune-deprived mice receiving
TCM 199 alone. Thus exfoliated colorectal
carcinoma cells can undergo further division and
might account for the development of implantation
recurrence in man.
A companison of crypt-cell proliferation in rat colonic
mucosa in vivo and in vitro
K.J. Finney,1 P. Ince,1 D.R. Appleton,2 J.P.
Sunter1 & A.J. Watson'
1Department ofPathology, Royal Victoria Infirmary,
Newcastle-upon-Tyne NEJ 4LP; and 2Department of
Medical Statistics, University ofNewcastle-upon-
Tyne, UK.
The successful development of a long-term organ-
culture system has made it possible to perform
experiments on rat colonic mucosa in vitro. To
interpret these experiments it is necessary to
compare proliferative parameters in vitro with those
in vivo, since fundamental changes in these
parameters, due to trauma or the withdrawal of
trophic factors, may occur when the mucosa is
cultured.
Stathmokinetic experiments were performed in
vivo and in vitro to estimate cell birth-rate. Mitotic
and labelling indices were also calculated. The in-
vivo birth rate (7.8 +0.8 cells 1000 cells-1 h-1) and
the in-vitro birth-rate for the whole explant
(7.7+0.5 cells 1000 cells h') were found to be
similar.
However, when only perfect axially sectioned
crypts in the centre of the cultured tissue were
counted values for the mitotic and labelling indices
were found to be inconsistent with those of the
previous whole-explant study. To further investigate
this observation the explants were, for the purpose
of counting, divided into edge and middle regions.
Values obtained for birth-rate, mitotic and
labelling indices indicate that cultured explants
show enhanced proliferation at the edges compared
to the centre. Provided that this difference is
recognised the in-vitro model may still be regarded
as a valid system for study.
Morphometric studies with human malignant
melanoma xenografts
S. Sparrow
Toxicology Unit, Medical Research Council
Laboratories, Woodmansterne Road, Carshalton,
Surrey SM54EF, UK.
An interactive image analysis system was used to
measure the size and shape of nuclei and cells, the
distance between blood vessels and the amount of
necrosis in five different malignant melanoma
xenografts. A Cruz-Orive transformation was used
to convert the actual measured profiles of nuclei
and cells in 4pm histological sections of the
tumours into estimated values for nuclei and cell
diameters. Analysis of the results showed
reasonably consistent values for mean nuclear
diameter in four of the xenografts (- 9.2pm) and a
much lower value for the fifth (7.5pm). The
tumours show different distribution patterns for
nuclear diameters, suggesting some variation in the
degree of polyploidy. Cell size showed greater
variation between the different tumours and there
appeared to be a correlation between the mean cell
size and the rates of growth of the xenografts
obtained from previous studies. The most
interesting findings were the changes that occurred
in cell size following chemotherapy of the tumours.
Those tumours that showed some response in terms
of reduced growth rate also showed changes in cell
size. The relationships were even more striking
when the degree of melanogenesis (as a measure of
cell differentiation) and the mitotic count (cell
proliferation) were included in the analysis. It was
concluded that morphometric analysis, made much
simpler by modem computing methods, may prove
a valuable tool in studying tumour biology.
Protective role of MESNA on the gastrointestinal
toxicity of cis-platinum
S.G. Allan', F.G. Hay2, R.C.F. Leonard1, J.F.
Smyth1 & C.R. Wolf'
'Imperial Cancer Research Fund Medical Oncology
Unit, Western General Hospital; and 2University
Department ofClinical Oncology, Western General
Hospital, Edinburgh, UK.
The contribution of gut toxicity to the severe
vomiting (and diarrhoea) that attend cis-platinum
(P) therapy is uncertain but may be important.
Morphological and kinetic changes produced by P
in the mouse small intestine have been examined
using a microdissection technique. Partial villous
atrophy and loss of crypts were noted 3-7 days
after P (10 mgkg 1 i.p.) with subsequent recovery.
Marked inhibition of mitotic activity was seen 24 hAGM BACR ABSTRACTS 455
after P with a marked reduction in crypt cell
production rate per villus (CCPR/V). On day 5
after P, jejunal crypts were hyperactive with a
rebound in CCPR/V. CCPR/V showed a more
gradual recovery in the ileum suggesting more
intensive damage to this portion of the intestine.
Thiol containing compounds, e.g. metallothionines,
are intimately involved in the prevention of metal
toxicity. The synthetic thiol MESNA (M) was
administered to groups of 6 mice (400mgkg-'
oral) 2h before, at the time of and 2h after P
(10mgkg-' i.p.). Controls received P (10mgkg-'
i.p.), saline (0.2ml i.p.) and M (400mgkg-1 oral).
After colchicine induced metaphase arrest standard
portions of jejunum and ileum were taken on days
1, 2, 3, 5, 7 and 10 after P, and analysed in blinded
sequence for damage.
M protected the animals against a normally
lethal dose of P, was associated with a reduced
degree of weight loss and considerably reduced the
morphological insult to the gut with enhanced
kinetic recovery. The differences between P and
P+M are statistically significant by analysis of
variance. These data provide a potential method for
quantifying the gastrointestinal toxicity of cis-
platinum but whether the protective mechanism of
M against P lethality is due to protection in kidney
or the GI tract remains to be established.
Platinum drug toxicity
M. Laverickl, M. Gordon', P. Kind2, B. Slavin2 &
A.H.W. Nias'
'Research Center, Chinoin Works; and 2Department
and 2Department ofChemical Pathology, St
Thomas's Hospital Medical School, London
SE] 7EH, UK.
Neoplatin is the original platinum coordination
complex used in the successful chemotherapy of
ovarian, testicular and other human tumours. Apart
from causing haematological depression, the drug is
nephrotoxic and alternative platinum drugs have
been sought which are at least as effective
antitumour agents but with less toxicity. CHIP
(JM9) has been selected as one of the second
generation platinum drugs because it is more
soluble than Neoplatin and might be expected to be
less nephrotoxic. Previous biochemical data have
been based upon simple laboratory tests. In this
work, the assays are those used routinely in a
chemical pathology laboratory. The dose level used
was the maximum tolerated dose (MTD) for C3H
mice determined by lethality and intestinal crypt
survival assays to be 40mgkg'I for CHIP. This
was compared with the MTD of Neoplatin of
10mgkg-1. The time course of gastric distension
and the pattern of drug distribution was assayed
after a MTD of CHIP. A high level of drug uptake
was found in liver as well as kidney. For this
reason, tests for both kidney and liver damage were
undertaken up to 60 days post-treatment with
Neoplatin and CHIP. Reference ranges for all the
biochemical assays were first determined. (There is
a fall in alkaline phosphatase level with age.)
Despite the high level of platinum drug uptake in
liver, there was no evidence of hepatocellular or
cholestatic damage. There was the expected rise in
serum urea after Neoplatin but not after CHIP.
Other sensitive assays of renal function showed
minimal evidence ofdamage after both drugs. Some
enzyme levels and urinary protein were depressed
after drug treatment, to a greater extent after
Neoplatin than CHIP. However, the levels in
tumour bearing mice were found to be depressed
even before treatment.
Pharmacokinetic study of local dibromodulcitol
(DBD) treatment
J. Kaczmarek', L. Instit6ris', Gy. Pethes2 & P.
Rudas2
'Research Center, Chinoin Works and 2Department
ofPhysiology, University of Veterinary Medicine,
POB 110, Budapest, H-1325, Hungary
In earlier studies oral DBD treatment revealed
outstanding effects in the urinary bladder cancer
(RR= 51%) and in gynecological malignancies
(RR =44%).
We have investigated the absorption of DBD
from bladder and vagina of rats. After ligation of
the ureters 4.0mg of l-H3-DBD in 1:1 DMSO-
saline solution was introduced transurethrally into
the bladder. One and 3 h following administration
2% respectively 6-8% of the administered dose was
absorbed. Plasma concentration of the radiolabelled
substances at the same two periods was 4.4pgml-'
and 15.2 pgml'-, respectively, which included 6 and
3% unchanged DBD, 32 and 22% bifunctional
metabolites (l-Br-5,6-anhydrogalactitol and 1,2:5,6-
dianhydrogalactitol), 33 and 28% monofunctional
metabolites (l-Br-3,6-anhydrogalactitol and
1,2,:3,6-dianhydrogalactitol), as well as 29 and 47%
unidentified derivatives determined by TLC. Twelve
milligrams of 1-H3-DBD powder was deposited in
the vagina of the rats. Plasma concentration of the
radiolabelled substances 3 h after treatment was
1.0pgml-1. Distribution of DBD and its
metabolites was similar to that observed in the case
of intravesical treatment.
During the past year the local DBD treatment of
30 post-TUR bladder cancer patients have been
started. No relapses have so far occurred.456 AGM BACR ABSTRACTS
A detailed investigation of the activation mechanism
of diaziquone (AZQ) as a model compound of
aziridinylquinone antitumour agents
R. Driebergen', W. van Oort1, S. Postma2, D.
Reinhoudt2 & W. Verboom2
'Faculty ofPharmacy, Utrecht, 2Department Of
Organic Chemistry, Twente, The Netherlands
Among numerous aziridinylquinones synthesized,
several showed promising antitumour activity in
experimental tumour models, in particular
Carboquone, Trenimon and AZQ. Nevertheless,
clinical trials of these compounds, particularly of
AZQ, were disappointing, even when this
compound proved to be clinically useful for the
treatment of CNS cancer types. A detailed study of
the activation mechanism, which probably consists
of an electrochemical (reduction of quinone ring)
and/or a chemical step (opening of aziridine(s)),
using electrochemical techniques, might contribute
to more understanding about activity and toxicity
in vivo. To distinguish the role of individual sub-
stituents, more simple analogues of AZQ, 2,5-bis(l-
az)3, 6 - bis(ethoxycarbonylamino - 1, 4 -
benzoquinone (1), have been synthesized: 2,5-bis(1-
az) - 1, 4 - benzoquinone (2), 2-(l-az) - 1, 4 - and 2-
(1-az) - 3 - (ethoxycarbonylamino) - 1, 4, 4-
naphtoquinone (3, 4). Chemical and electrochemical
properties have been determined by direct current
and differential pulse polarography, cyclic voltam-
metry, etc. Polarographically obtained pk values
(see Table) of the (first) aziridinyl ring of the
quinones (pk,) and hydroquinones (pk2) of 1-4
show, that protonation of aziridines and subsequent
ring opening is highly favoured by reduction to the
hydroquinone derivatives (which might also
influence formation of toxic oxygen compounds in
aerobic media) and presence of the ethoxycarbonyl
substituent. When 1-4 are in oxidized, quinonoid
form, protonation proceeds faster in unsubstituted
quinones 2 and 3. Rate constants obtained from
kinetic studies of the acid catalyzed opening of the
aziridinyl ring(s) show this influence of quinone
ring substitution. Biological data indicate, that
parameters describing chemical stability of
aziridines can be useful to tune cytostatic activity.
Synthesis and binding properties of analogues of
(pA)3 an antagonist of 2-5A action
J.C. Jamoulle1, K. Lesiak2 and P.F. Torrence2
1Institute ofPharmacy, University ofLiege, 3, rue
Fusch, B-4000 Liege, Belgium; and 2Laboratory of
Chemistry, National Institutes ofHealth, Bethesda,
20205 MD, USA.
To explore the role played by the purine 6-amino
group of 5'-0-phosphoryl adenylyl(2', 5')adenylyl(2',
5')adenosine, (pA)3, an antagonist of 2-5A action
(2.5A:pp(pA)3), analogues were prepared via a
Pb+ + catalyzed coupling procedure. Their relative
ability to bind to the 2-5A dependent endonuclease
(RNase L) was determined in an assay based on the
displacement of 50% of the radiolabelled probe
pp(pA)3 [32p] pCp (C: cytosine) from an RNase-
nitrocellulose complex (IC50). The 6-methyl-
adenosine (m6A) analogue p5'A2'p5' (m6A)2'p5'
(m6A) showed approximatively the same binding
ability, (IC5O:6 x 10-7 M) as (p5' (m6A))3,
(IC50:8 x 10-8 M) which was bound to the RNase
L about 400 times less effectively than (pA)3,
(IC50:2,4 x 10-9M). This implies that methylation
of the amino group must disrupt binding at either
the second or the third residue of (pA)3. The
analogue containing guanosine (G) in the 5'
position, p5'G2'[p5'(c7A)]2 was bound to the
RNase L 104 times less effectively (IC50: lx 10 5)
than either (pc7A)3, (IC50:4 x 0-9 M) or (pA)3
itself, (c7A:7-deazaadenosine). This implies that
either the 2-oxo function of guanosine may interfere
with binding or that the N6 amino group of
adenosine is necessary but not sufficient for high
endonuclease activity. In any event the importance
of the 5' terminus nucleotide in enzyme binding is
suggested by this finding.
The effects ofmild hyperthermia on the metabolism
of three nitroimiidazole radiosensitizers in vivo and in
vitro
M.I. Walton, N.M. Bleehen & P. Workman
MRC Unit and University Department ofClinical
Oncology, Hills Road, Cambridge CB22QH, UK.
Hyperthermia is being evaluated clinically in com-
able
Compound E42{mV)a pkl pk2 KobSb ID7., ngml- " T/Cd
1 -300 2.1 8.1 0.4 1078 189
2 -145 3.9 7.5 15.5 4 156
3 -305 3.3 8.1 5.6 2360 nd
4 -300 1.5 8.4 0.2 3957 nd
apH=8.0; u=0.1; 20'C. bpH=4.0; g=0.1; 20'C. CL1210 clonogenic
assay. dL1210 in vivo.AGM BACR ABSTRACTS 457
bination with radiation and drugs. Hyperthermia
also causes enhanced tumour cytotoxicity with
nitroimidazole radiosensitizers in vitro, possibly
through toxic metabolite production. We have
investigated the effects of mild hyperthermia on the
metabolism of 3 nitroimidazoles. These reactions
were the oxidative demethylation of misonidazole
(MISO) to Ro 05-9963, the N-oxidation of Ro 03-
8799 to Ro 31-0313 and the nitroreduction of
benznidazole (BENZO) to its corresponding amine.
Drugs were given to C3H mice 10min before
whole-body hyperthermia (WBH) in an incubator
(41 +0.5°C, core temp, for 45 min). Drug con-
centrations were measured by HPLC. WBH
increased the plasma concentration of Ro 31-0313,
the N-oxide metabolite of Ro 03-8799, during the
heating period, e.g. by 63% at 40min. Plasma
levels of the MISO demethylation product, Ro 05-
9963, were also increased by WBH shortly after the
heating period, e.g. by 37% from 24.2 to
33.2pgml- at 90min. WBH reduced injected Ro
05-9963 plasma clearance by 15%, from 0.98 to
0.84mlg- h-1, but did not alter the plasma
clearance of injected Ro 03-0313. In vitro rates of
microsomal demethylation of MISO to Ro 05-9963
were increased by 20% at 41°C compared to 37°C.
at a substrate concentration of 5mM MISO. The
demethylase enzymes were not markedly more
labile at the higher temperature. In contrast, this
4°C rise decreased BENZO nitroreduction to its
amine by 22% at a substrate concentration of
1 mM, possibly through increased denaturation of
the nitroreductases. Thus mild hyperthermia clearly
can affect drug metabolism, which has important
implications for the pharmacokinetics and
therapeutic effects of drugs used in thermochemo-
therapy.
Novel drug metabolism and excretion studies using
high resolution proton NMR spectroscopy
J.K. Nicholson1, K. Tulip', J.A. Timbrell' J.R.
Bales2 & P.J. Sadler2
'Toxicology Unit, The School ofPharmacy,
University ofLondon, Brunswick Square, London
WCJNJAW; and 2Department ofChemistry,
Birkbeck College, University ofLondon, London
WCIE 7HX, UK.
High resolution 'H NMR spectroscopy can be
valuable in the study of normal excretory products
present in urine (Bales et al. (1984), Clin. Chem. 30,
426). We have investigated the use of this technique
to study the renal excretion of a well-known drug
paracetamol and that of the potential antitumour
agent N-methylformamide (NMF), the metabolism
of which is poorly understood. For paracetamol,
'H NMR of urine was found to be quantitatively
similar to conventional HPLC detection methods
and that free drug together with glucuronide,
sulphate, cysteinyl and N-acetylcysteinyl conjugates
could be rapidly and simultaneously detected in
untreated human urine samples after the ingestion
of a normal therapeutic dose (1 g). After treatment
of rats with 1 gNMF kg-1, urinary excretion of the
parent compound could be readily monitored by
'H NMR and several metabolites including methyl-
amine, formate, formamide, a cysteinyl derivative
and several N-acetylated compounds were detected.
Particular advantages of 'H NMR in this type of
study include its rapid multicomponent detection
capability, lack of sample preparation and its non-
destructive and non-equilibrium perturbing nature.
These studies indicate that 'H NMR has
considerable potential in the elucidation of the
metabolic modification and excretion of novel
therapeutic agents.
The use of 13C-labelled carboxylic acids in the study
of metabolic conjugation by NMR
J. Caldwell, B.P. Nutley, A.J. Hutt & M.V. Marsh
Department ofPharmacology, St Mary's Hospital
Medical School, London W2, UK.
Stable isotope labelled compounds are extensively
used in studies of xenobiotic metabolism, almost
exclusively for mass spectrometric analysis. In
comparisons, the opportunities for analysis by
NMR presented by paramagnetic isotopes such as
13C have been neglected. To maximize the value of
such an approach the isotope must be close to a
centre of interest whose chemical shift is altered by
metabolism. The carboxyl carbon of xenobiotic
acids is metabolically transformed to a range of
products (esters, amides, olefins, ketones, secondary
alcohols) in which its resonance varies over the
range 40-200ppm. We have examined the fates of
carboxyl-'3C-benzoic, phenylacetic and cinnamic
acids (all with '3C-isotope abundance >90%) and
have used 13C-NMR in addition to other
techniques to identify metabolites. The sensitivity of
13C-NMR at this level of enrichment is such that
spectra of urine and crude extracts were recorded
directly, without recourse to extensive purification
procedures. This technique has further charac-
terized minor metabolites of these acids, and is
suggested to have wider applicability.458 AGM BACR ABSTRACTS
Pharmacokinetic studies of thiotepa in patients and
mice and effect of co-administration of nandrolone
decanoate
B.J. McDermott, J.A. Double, M.C. Bibby, P.
Loadman & R.L. Turner
Clinical Oncology Unit, University ofBradford,
Bradford BD7 JDP, UK.
The synergism of the combination of nandrolone
decanoate (ND) and ThioTEPA observed in the
clinic (Turner et al. (1984), Br. J. Cancer 50, 259)
and in animal model systems (Double et al. (1981),
Br. J. Cancer 44, 305) could be explained in part by
a pharmacokinetic interaction. Plasma levels of
ThioTEPA and its primary metabolite, triethylene-
phosphoramide (TEPA), were estimated using
capillary gas chromatography with nitrogen
detection, in 11 patients who received 30 mg of
drug by i.m. dosage and in 17 studies in mice after
i.p. or s.c. administration of 20mgkg-1, with or
without ND (50mgkg-1) given by i.p. injection in
arachis oil (AO).
Values of the ratios under the plasma concentra-
tion versus time curves (AUC) of TEPA and
ThioTEPA in patients (mean, 1.41; range, 0.20-
2.46) and in mice (mean+s.e., 2.05+0.11) indicate
that the clearance of TEPA is slower than that of
ThioTEPA. When ND was administered con-
comitantly in mice, the clearance of the drug was
not affected. The AUC value of TEPA (mean + s.e.,
8.57 +0.40 ghml- 1, however, increased signifi-
cantly (P<0.01) by comparison with the value when
ThioTEPA was given alone (mean+s.e., 7.10
+0.46 Mghml-. When ThioTEPA was adminis-
tered with AO but without ND, the mean AUC
value of TEPA was 7.73+0.38 (s.e.) Mghml-,
which was significantly different from the values ob-
tained after dosage with ThioTEPA alone (P<0.05)
or in combination with ND (P<0.05). Dose-
dependence of AO on metabolite clearance was
established. The contribution of AO to the reduced
clearance of TEPA may be a consequence of
inhibition of cretion of the polar metabolite into
the peritoneum. The significant effect of ND on the
elimination of TEPA could have relevance to the
clinical studies.
Nitrogen mustard selectively inhibits the Na+K+Cl1
co-transporter and reduces cell volume in L1210
murine leukaenia cells
C. Wilcock, J.A. Hickman & S.B. Chahwala
CRC Experimental Chemotherapy Group,
Department ofPharmaceutical Sciences. University
ofAston, Birmingham B4 7ET, UK.
Studies on the interaction of antitumour drugs with
tumour cell membranes may reveal new, susceptible
targets for novel agents. We have shown previously
that nitrogen mustard (HN2) inhibited the uptake
of 86Rb+ (a K+ congener) into L1210 murine
leukaemia cells in a time-dependent manner (Br. J.
Cancer 50, 274 (1984)). After 3 h incubation of
5x 106ml-P L1210 cells in RPMI at 37°C with
10MM HN2, 86Rb uptake via the diuretic-sensitive
Na+K+Cl- cotransporter alone was inhibited. A
monofunctional analogue of HN2 had no effect at
10MM nor at concentrations of equivalent
cytotoxicity to HN2. In addition, other cytotoxic
agents e.g. adriamycin, mitozolomide and cis-platin,
had no effect on 86Rb+ transport at equivalent
cytotoxic concentrations. HN2 caused a decrease in
cellular K+, measured by atomic absorption, which
was completely offset by a 25% decrease in cell
volume, effectively maintaining K+ homeostasis
(118+ 19 mM). The cells retained the ability to
exclude trypan blue and maintain membrane
potential, estimated by accumulation of 13Hltri-
phenylmethylphosphonium bromide (-58+11 mv).
Under the same conditions HN2 inhibited, by 29%,
the uptake of an amino acid via the Na+-dependent
'A' system, but not via the Na+-independent 'L'
system. This was not a consequence of increased
cellular INa+| which was maintained at control
values (34+17mM), and was considered to be a
result of direct alkylation of the transport system.
HN2 had no effect upon the membrane enzyme
Na+K+ATPase. We consider that the reduction in
cell volume caused by HN2 may bring about events
which lead to cell death.
Effects of encapsulation of methotrexate in intact
erythrocytes on its efficacy in vivo
H.O. Alpar & D.A. Lewis
Department ofPharmaceutical Sciences, University
ofAston, Birmingham B4 7ET, UK.
By using a preswelling technique (Pitt et al. (1983),
Biochem. Pharmac. 22, 3359) methotrexate has been
encapsulated into intact erythrocytes at a loading of
0.56 mgml-1 packed cells and an encapsulation
efficiency of 28% w/v. When the encapsulated drug
was administered to mice and the urinary excretion
compared to that of free methotrexate the free drug
was excreted rapidly and completely in three days
whilst the encapsulated drug was excreted more
slowly and 9% was still excreted on the fourth day.
In vitro studies with both human and mouse cells
confirmed that the rate of leakage of drug from the
cells was slow. The encapsulated methotrexate was
administered i.v. (2.8 mgkg -1) to CBA/CA mice
inoculated (i.p.) 4 days previously with TL x 5 cells.
Other mice were treated with free methotrexate and
controls left untreated. Free methotrexate increasedAGM BACR ABSTRACTS 459
the survival time of the mice by 33% but the
encapsulted preparation increased the survival time
by 70% compared with untreated controls
(P<0.001) (Student t-test). In other work it was
found that encapsulted asparaginase produced
'cures' in C3H mice bearing the 6C3HED tumour
whilst the free enzyme did not. Therefore
encapsulated has improved the efficacy of both
antineoplastic agents.
Potentiation of the cytotoxicity of chemotherapeutic
drugs by Tween 80 in vitro
C.N. Parris, J.R.W. Masters, M.C. Walker & P.J.
English
Department ofHistopathology, Institute of Urology,
St Paul's Hospital, 24 Endell Street, London WC2,
UK.
There is evidence that the intravesical instillation of
a non-ionic detergent, Tween 80 (polyoxyethylene
sorbitan mono-oleate), together with adriamycin
can overcome resistance to this drug in patients
with superficial bladder cancer (Eksborg et al.
(1982), Eur. Urol. 8, 213). To extend this finding,
the effect of Tween 80 on the cytotoxicity of the
four drugs commonly used for intravesical chemo-
therapy: adriamycin, mitomycin-c, epodyl and
thiotepa, was examined in vitro using the
continuous cell line, RT112, derived from a
transitional cell carcinoma of the human bladder.
Inhibition of colony formation was determined
following a 1 h exposure to a range of concentra-
tions of these drugs alone and in combination with
a non-cytotoxic concentration of Tween 80, 0.1%.
Tween 80 enhanced the cytotoxicity of each drug at
all concentrations tested. Colony forming ability,
expressed as a percentage of control values, at one
concentration ofeach drug is shown in the table.
It is concluded that the addition of Tween 80
might enhance the therapeutic potential of
intravesical chemotherapy for superficial bladder
cancer.
Formulation of MZPES - The ethanesulphonic acid
salt of m-azidopyrimethamine
S:K. Wong', TJ. Schoemaker2, M.F.G. Stevens' &
J:A. Slack'
'Cancer Research Campaign Experimental
Chemotherapy Group, Department ofPharmaceutical
Sciences, University ofAston, Birmingham B4 7ET,
UK; and 2Slotervaartziekenhuis, Medisch Centrum
Slotervaart, Louwesweg 6, Amsterdam, The
Netherlands
m-Azidopyrimethamine ethanesulphonate (MZPES:
1) is a lipophilic (logP 2.94) inhibitor of L1210
DHFR (Ki 2.4+0.16nM). The drug (free base)
displays in vivo antitumour activity against mouse
P388, L1210, B16, TLX5 and M5076 tumours. The
pKa of MZPES is 7.19 close to physiological pH
ensuring adequate concentrations of free base (for










The water solubility of the free base of MZPES
is low (0.02mgml-') at 20°C. For clinical trial the
salt is sufficiently soluble (13.9mgml-') for
preparation of a parenteral formulation in water
(unbuffered at pH 4.14) at a concentration of
10mgml-' and sterilised by filtration. Aqueous
solutions of MZPES are photosensitive: in a
nitrogen environment the arylamine (MAP: 3) is the
major photoproduct whereas the nitroarene (MNP:
4) predominates in oxic conditions. The product
distribution points to the intermediacy of a triplet
nitrene reactive species (2) which either abstracts
hydrogen to form MAP or traps (triplet) oxygen to
afford MNP.
Table
Adriamycin Mitomycin-C Thiotepa Epodyl
350ngml-' 400ngml-' 15pgml-' 40pgml '
Drug alone 65 46 58 56
Drug+0.1% Tween 80 15 17 22 46
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Arm oedema and breast cosmesis related to surgery
in patients with breast cancer undergoing breast
conservation techniques
A. Rodger' and U. Chetty2
Departments of 'Clinical Oncology and 2Clinical
Surgery, University ofEdinburgh, UK.
From June 1982 until November 1983 60 patients
underwent breast conservation techniques by local
tumour excision and radiotherapy for breast cancer.
The first 37 consecutive patients also underwent
lower axillary (Level I and II) dissection (LAD)
while the next 23 underwent only axillary sampling
(LAS). The two groups were similar for local T
stage and node stage (clinical and histological). The
median follow-up period was 19 months for the
LAD group and 12 months for the LAS group.
Clinically detectable arm oedema was recorded at
any time after surgery in 59% of the LAD group
and 4% of the LAS patients (P=0.0388). The
median time of onset of arm oedema in the LAD
group was 10 months, while the arm oedema
appeared at 3 months in the one LAS patient.
Breast oedema was recorded in 78% of LAD
patients compared with 35% of LAS patients
(P<0.001); and was persistent in 38% and 23%
respectively (ns). The median onset of breast
oedema was the same in both groups at 7 months.
In the LAD group a central axillary radiation dose
of 45 Gy was associated with a higher risk of arm
oedema (67%) then a lower dose of less than 40 Gy
(25%). In both groups the incidence of breast
oedema was higher following the delivery of an
interstitial implant radiation boost of 25 Gy or
more when compared with 20 Gy but only reaches
significance in the LAD group (90% v. 38%
P=0.028). The incidence of arm oedema was not
related to node histology. The extent of axillary
surgery in patients undergoing this treatment
influences post therapy cosmetic sequelae as
measured by arm and breast oedema, and these
effects may be aggravated by higher radiation
doses.
Increased detection of metastases from primary
breast cancer to the axiliary nodes by
inmunohistochemical staining with monoclonal
antibodies
N. Berry', D.B. Jones', R. Marshall', J.
Smallwood2 & I. Taylor2
Department of 'Pathology and 2Surgery, University
ofSouthampton, UK.
The most accurate prognostic indicator for a
woman following surgical removal of a primary
breast cancer is the presence or absence of
metastases in the axillary lymph nodes. Detection
of metastases from sections stained with
haematoxylin and eosin (H & E) might be
improved by immunohistochemical staining. In this
study the breast and axillary tissue was studied
from 45 women who had mastectomy at
Southampton General Hospital in 1983-84. Four
gm sections of paraffin embedded lymph nodes were
stained in double-bridge immunoalkaline
phosphatase assay with the monoclonal antibodies
HMFG1, HMFG2 and E29/68. These antibodies
recognise antigens on breast carcinoma cells and
normal breast epithelium, but do not normally stain
cells of the lymphoreticular system. Conventional
diagnosis of the H&E stained sections detected
metastases in 55/345 nodes. This was increased to
61 positive nodes by sectioning through the tissue
at a deeper level, and to 66 positive nodes by using
immunostaining with monoclonal antibodies.
Immunohistochemical staining improved the
detection of metastases from 16/45 to 19/45 cases,
an increase of 19%. It will be interesting to see if
the increased detection of metastases has any
bearing on the patients' survival.
Abnormalities of cellular DNA content in human
solid tumours
D. Hedley, M. Friedlander & I. Taylor
Ludwig Institutefor Cancer Research, University of
Sydney, N.S. W. 2206, Australia
The majority of human cancers are aneuploid, i.e.
have an abnormal cellular DNA content, but the
significance of this finding remains obscure.
Recently we developed a flow cytometric method
for measuring DNA content of paraffin-embedded
tissues, and this has allowed us to study tumour
ploidy in large number of patients whose outcome
is already known. In 228 ovarian cancer patients
the incidence of aneuploidy in Stage I and II
disease was 57% and 69% for Stage III and IV. It
was a powerful adverse prognostic feature
(P<0.001) in all stages except Stage IV, where
patients with diploid tumours had an equally poor
survival. Out of 152 patients presenting with
metastatic adenocarcinoma of unknown primary
site 30% had diploid tumours, but their prognosis
was no better than that of the aneuploid group
(median survival 4.2 and 4.8 months, respectively).
Finally, we have so far looked at 415 breast
cancers, and again there is a correlation between
aneuploidy and stage. Aneuploid tumours tended to
be larger (59% of tumours<2cm, 81% of
tumours>2cm, P<0.02) with more extensive
axillary lymph node involvement (P<0.05). In
Stage II disease relapse-free survival was longer inAGM BACR ABSTRACTS 461
the diploid group (P<0.05), although this effect
was largely confined to pre-menopausal patients
where the projected 4 year disease free survival rate
was 83% and 43% for diploid and aneuploid
respectively. Following relapse, however, patients
with diploid tumours did not live longer than those
with aneuploid tumours. Taken together these
studies show that the incidence of aneuploidy in at
least some common solid tumours increases with
disease stage. This may account for the generally
more favourable prognosis for diploid tumours;
when they do metastasise they are apparently as
aggressive and refractory to treatment as aneuploid
tumours.
Effect of cholecystokinin on carcinoembryonic
antigen release in patients with cholangiocarcinoma
C. Huddl, J.E. Devine2 & F.E. Johnson1
Departments of'Surgery and 2Pathology, St Louis
University Medical Center, St Louis, MO, USA.
Biliary tract cancer accounts for -80 deaths weekly
in the USA. This tumour usually presents late with
little hope of cure. Earlier diagnosis might enhance
survival. Cholecystokinin (CCK) administered to
nude mice bearing human cholangiocarcinoma
(CCa) xenografts has been reported to retard
tumour growth and increase serum carcino-
embryonic antigen (CEA) levels (Hudd et al. (1984),
Gastroenterology 86, 1118). We chose to study
whether CCK challenge could be exploited as a
diagnostic test in humans with CCa by provoking a
rise in CEA. Patients with CCa were studied
irrespective of performance status, prior treatment,
or other factors. All such patients received
0.02mgkg-1 body wt of synthetic sulphated CCK-
8 (Squibb) as an i.v. bolus. This is the dose
recommended for CCK cholecystography in
humans. Serum CEA levels were measured (Abbott
CEA RIA) prior to CCK administration and
15min, 60min, and 24h later. No ill effects were
observed at this dose. The following day, CEA
levels were measured at similar time intervals after
saline control injection. Three consecutive patients
were evaluated; none showed a change in CEA level
in excess of 20%, which is the maximum expected
coefficient of variation of the test. These three
consecutive false-negatives are sufficient to
establish, with a 99% probability, that this test is
not 80% sensitive. We conclude that this
provocative test using low-dose CCK has no value
in the diagnosis of human CCa. Higher-dose CCK
might be effective, but the risk of side effects would
also be greater.
Acetylation phenotype as a risk factor in bladder
cancer
A.V. Kaisaryl, P.J.B. Smith1, R.A. Branch2, C.B.
McAllister2 & A. Ray3
1Department of Urology, Bristol Royal Infirmary,
Bristol, UK; and Departments of2Clinical
Pharmacology and 3Biostatistics, Vanderbilt
University, Nashville, Tennessee, USA.
Acetylation has been linked to carcinogenic
detoxification in aromatic amine induced bladder
cancer. Slow acetylation phenotype was reported to
be associated with bladder cancer more than rapid
acetylator phenotype. A prospective case control
study of acetylation phenotype was undertaken in
the Bristol area. Ninety-five patients with histo-
logically confirmed transitional cell carcinoma of
the bladder were compared with a control group of
111 patients who were sex and age matched and
had bladder cancer excluded. Sixty-two of the
bladder cancer patients had non-aggressive tumours
(GI and G2) and the remaining 33 had aggressive
ones (G3). The acetylation phenotype was
estimated from the ratio of monoacetyl dapsone
concentration to dapsone concentration in a plasma
sample obtained 8 h after monoacetyl dapsone oral
administration. Normit plots comparing this ratio
in the control population with non-aggressive (GI
and G2) and aggressive (G3) bladder cancer
population suggested a biphasic curve in each
group. The distribution in the aggressive tumour
group (G3) and the control group were similar. A
minor difference was present when the non-
aggressive tumour group (GI and G2) and controls
were compared. Slow acetylation phenotype was
49% of the control group and 65% of the non-
aggressive tumour population (GI and G2).
Univariate statistical analysis confers a relative risk
ratio of 1.93 on slow acetylators in comparison
with rapid acetylators in this population. Slow
acetylation phenotype association risk with bladder
cancer is comparable to previous reports but this is
the first time it is linked to non-aggressive rather
than aggressive tumours. It appears that non-
aggressive (Gl and G2) and aggressive (G3)
bladder cancer have different aetiological factors
and are possibly two different diseases.
The inflammatory response following intralesional
BCG immunotherapy: The relationship to Heaf
status and time course
R. Windlel, I.C. Talbot2 & E.H. Mackay2
Departments of 'Surgery and 2Pathology, Royal
Infirmary, Leicester, UK.
Immunotherapy using intralesional BCG has been462 AGM BACR ABSTRACTS
used in malignant melanoma (Morton et al. (1974),
Ann. Surg. 180, 635) and lung cancer (Holmes et al.
(1979), J. Thorax. Cardiovasc. Surg. 7, 362).
However there is no clear indication which patients
are most likely to develop a local inflammatory
response. To investigate this we have studied
patients undergoing excision of rectal carcinoma
having previously had an intralesional injection of
BCG.
Thirty-three patients were studied. BCG was
administered between 4 and 16 days prior to
surgery and the excised tumour and draining nodes
were examined histologically for evidence of
lymphocytic infiltration (LI) or reactive follicular
hyperplasia (RFH) respectively or for granuloma
formation and these were related to patient age,
tumour differentiation, Heaf status and immune
competence (PHA induced blastogenesis, LMIT
and NK activity).
Within the tumour, granulomata were seen in 10
patients and LI was found in a further 10.
Granulomata were significantly more frequent when
the interval following BCG administration exceeded
10 days (P<0.05 Fishers exact test). All but 3
patients with an inflammatory response in the
tumour were Heaf positive. Of the remaining 13
only 3 patients were Heaf positive (P<0.025
Fishers exact test). Tumour inflammatory response
was not related to patient age or immune
competence or tumour differentiation. Nodes from
21 patients demonstrated RFH and 5 had
granulomata. There was no significant relationship
with Heaf status but granulomata were only seen in
nodes from Heaf positive patients. These results
may have some bearing on the type of and timing
of immunotherapy in cancer.
Inter-regional epidemiological study of childhood
cancer (IRESCC). Case-control studies in children
with germ cell tumours
J.R. Mann, H.E. Johnston, J. Williams, J.A.H.
Waterhouse, J.M. Birch, R.A. Cartwright, G.J.
Draper, A.L. Hartley, P.A. McKinney, P. Hopton
& C.A. Stiller, for the IRESCC Group
Children's Hospital and West Midlands Cancer
Registry, Birmingham, Departments ofEpidemiology
and Social Research, Manchester Department of
Epidemiology, YRCO, Leeds, University ofOxford
Childhood Cancer Research Group, UK.
In 1980-83 members of IRESCC interviewed
parents of 555 children with newly diagnosed
cancer on a wide range of topics of possible
aetiological significance. Identical questions were
asked of the parents of 1100 control children
chosen from hospital admissions and general
practitioner lists. Medical information was
confirmed whenever possible by cross-checking with
NHS records. For the 41 children with germ cell
tumours and their 82 controls no differences were
shown for: birth weight and rank, maternal and
paternal age and chronic illnesses and smoking,
mothers' gynaecological histories and oral con-
traceptive usage. In index pregnancies there were no
case-control differences for maternal illness,
infections, alcohol intake, X-ray and ultra-sound
exposure, but case mothers took slightly more
analgesic and fewer hormones. More case than
control mothers and fathers reported occupational
exposure to chemicals. The cases had slightly more
congenital malformations than controls, including
one neural tube defect. More relatives of cases had
malformations and multiple tumours than did
control relatives. Interesting case pedigrees included
one each of multiple twinning probable neurofibro-
matosis and XY gonadal dysgenesis.
Pharmacokinetic study of high dose etoposide
infusion in patients with small cell lung cancer
A. Tarpey', J.A. Green2 & H.M. Warenius2
Departments of1Biochemistry and 2Radiation
Oncology, Clatterbridge Hospital, Merseyside, UK.
Etoposide is one of the most active agents in small
cell carcinoma of bronchus, although the optimum
dose and scheduling of the drug has not been
determined. Previous studies have suggested that
the peak plasma level is the most important and the
drug is conventionally given as a 30min infusion.
This study comprises 8 patients given 2 cycles of
single agent, high dose etoposide at 600mgm-2
daily for 3 days. All had received 2 prior cycles of
ifosfamide 8 gm-2 in the previous 8 weeks, but no
other radio- or chemotherapy. Etoposide was
assayed in plasma by HPLC using a Zorbax BP
ODS column with u.v. detection at 225 nm. An
internal standard of phenytoin was used and this
gave a typical run time of <4min. The method was
linear up to 100pgml-' with a sensitivity below
1 pgml-'. The method was found to be precise and
accurate. When etoposide was given for 6h out of
24h on each of 3 consecutive days peak plasma
levels of 55pgml- were detected (range 40-70).
There was little difference between successive days
within each cycle, or between 2 cycles given 4 weeks
apart. Data on comparison with the same total
dose given as a continuous 72h infusion will be
presented, as well as correlation with acute toxicity.AGM BACR ABSTRACTS 463
Chemical and biological oxidation of the
dimethoxyphenol ring of etoposide
J.M.S. van Maanen', C. de Ruiter2, R. van de
Straat2, J. Broersen2, J. de Vries2 & H.M. Pinedo
Departments of'Oncology and 2Medicinal
Chemistry, Free University, Van der Boechorststraat
7, 1081 BT Amsterdam, The Netherlands
Studies on the metabolism of etoposide (VP-16)
have yet failed to identify active metabolites of the
drug. Metabolic conversions in the dimethoxy-
phenol ring of VP-16 may be important for its
interaction with DNA and, as a consequence, for
its cytotoxicity. The purpose of our study was to
investigate the possible chemical and biological
oxidation of the dimethoxyphenol ring of VP-16.
The chemical one-electron oxidant persulphate-
ferrous and the enzymatic one-electron oxidants
myeloperoxidase (MPO)/H202 and horseradish
peroxidase (HRP)/H202 were found to catalyze the
formation of a VP-16 free radical, as observed by
electron spin resonance (ESR) spectroscopy. The
ESR spectra were identical to the spectrum
obtained on electrochemical oxidation of VP-16 at
+550mV. This indicates that the radical produced
by the chemical and the enzymatic one-electron
oxidants is formed at the phenolic position of VP-
16. The chemical half-life of the free radical in
1 mM Tris pH 7.4 0.1 M NaCl was found to be
253 +4 sec. A purification of rat liver cytochrome
P-450 and NADPH cytochrome P-450 reductase
was performed to study metabolism of the
dimethoxyphenol ring of VP-16 by reconstituted
mixed function oxydase. Incubations of VP-16 with
cytochrome P-450 and NADPH cytochrome P-450
reductase +NADPH (oxygenation) or with cyto-
chrome P-450 and cumene hydroperoxide (per-
oxygenation) resulted in 0-demethylation of VP-16.
The product of 0-demethylation could be the
ortho-dihydroxy derivative or ortho-quinone of VP-
16. In conclusion the formation of oxidative
products in the dimethoxyphenol ring of VP-16 was
observed, which could be important for its
mechanism of action.
Influence of Tween 80 on the pharmacokinetics,
metabolism and urinary excretion of adriamycin in
the cancer patient
G.J. Forrest', J. Cummings2, D. Cunningham', R.
Blackie2, N.L. Gilchrist' & M. Soukopl
1Department ofMedical Oncology, Royal Infirmary,
Glasgow G4OSF; and 2Department ofClinical
Oncology, University ofGlasgow G129LX, UK.
Tween 80 is a safe pharmaceutical vehicle used to
formulate poorly water soluble VP-16 for i.v.
administration to cancer patients. We have been
investigating what effects the Tween 80 itself can
have on the handling of other anti-cancer agents
given in combination with VP-16. In 6 patients
adriamycin (ADR, 30 or 40mgm 2 i.v.), was given
with cyclophosphamide (cyclo, 500 mgm-2 i.v.) and
Tween 80 (300mgm-2 i.v.). Then, 3 weeks later,
only ADR and cyclo were administered to the same
6 patients. Samples were collected for 24h; ADR
and metabolites concentrations were measured by
HPLC. Sera ADR profiles were best fitted to a bi-
exponential decay descriptive of a two compartment
open pharmacokinetic model (t,5 2 min; tp, 7
+4.9 h). The Tween 80 did not affect the apparent
kinetic rate constants for distribution of ADR from
the central compartment and for elimination of
ADR from the peripheral compartment, nor were
the area under the curve (AUC) of metabolite
serum profiles affected. Where the Tween 80 did
seem to exert an effect was on maximum serum
concentration (C0) and the apparent volume of the
central compartment (Va). C0 without Tween was
5240±2436ngml-1; C with Tween was 3065
+1775ngml-'. In all patients Co fell with Tween
(by 13% to 413%). Consequently, Vc increased (from
10.8+3.41 to 23.2+ 14.81) in all patients. Also 24h
urinary excretion of ADR was increased in all 6
patients by Tween 80 (by 15% to 500%). In
conclusion, administration of VP-16 plus Tween 80
is likely to affect the handling of ADR: peak serum
concentrations will fall, clearance will increase and
more drug will be excreted unchanged in the urine.
Pharmacokinetics of4'-epi-doxorubicin after
intravenous and intravesical administration
W.J.F. van der Vijghl, H. Weenen1, A. Osteropl,
S.E.J.M. van der Poort1, K.K. Kurth2, J.F.
Bogdanowicz1 & H.M. Pinedo1
'Department ofOncology, Free University Hospital,
1081 HV Amsterdam; and 2Department of Urology,
Erasmus University, 3000 DR Rotterdam, The
Netherlands.
4'-Epi-doxorubicin (E) is one of the 4'-modified
doxorubicin analogues. Phase I trials have indicated
that, compared to doxorubicin (D), E showed
comparable toxicities but less gastrointestinal
toxicity and less chronic cardiotoxicity. Possibly, it
also has a broader spectrum of antitumour activity.
The difference in biological activity between E and
D may be caused by differences in metabolic and
pharmacokinetic properties.
Seventeen patients with advanced soft tissue
sarcoma or advanced breast cancer received an i.v.
bolus injection of 75 or 90mgEm-2. Blood464 AGM BACR ABSTRACTS
samples and urine were collected at regular time
intervals. HPLC analysis revealed the presence of E
and 7 of its metabolites in plasma (mean AUC of
each metabolite as % of total AUC): E (24.0%),
Eol (21.9%), E-glu (12.5%), Eol-glu (23.3%), D-
one (0.5%), Dol-one (1.2%), 7d-D-one (5.4%) and
7d-Dol-one (11.2%). In urine E and 3 of its meta-
bolites were present (% of dose excreted in 48h): E
(5.9%), Eol (0.8%), E-glu (3.2%) and Eol-glu
(0.8%).
Five patients with carcinoma in situ of the
bladder were treated with E. Thirty or 50mg E
dissolved in 50ml saline was instilled in the bladder
for 1 h. Blood samples and urine were collected
during and after installation. At least 75% of the
dose was recovered in urine, while low and
undetectable concentrations of only E could be
detected in plasma.
It can be concluded that (a) E shows unique and
abundant glucuronidation, (b) only small amounts
of E reach the general circulation after intravesical
administration.
The relationship between plasma 5-FU clearance and
tissue levels of 5-FU metabolites
E.M. Chisholm, P.J. Finan, L.F. Woodhouse &
G.R. Giles
University Department ofSurgery, St James's
Hospital, Leeds, UK.
5-Fluorouracil (5-FU) is commonly administered by
i.v. bolus injection in doses of 10-15mgkg-1, but
is rapidly catabolised by the liver. An improvement
in therapeutic effect might be achieved either by
altering drug elimination or changing the uptake by
the tumour tissue. This study has examined the
relationship between 5-FU metabolites within tissue
and the measured clearance of 5-FU from the
plasma after an i.v. bolus.
Eight patients with colorectal cancer received
5-FU (15mgkg-1) 48h prior to surgery. Blood
samples were taken at 5min intervals for 1 h after
injection. 5-FU levels in the blood and fluorinated
metabolites within normal and neoplastic tissue
were estimated using HPLC. Elimination curves for
plasma FU revealed a half life (4') which ranged
from 8.6-25.1 min with all 8 patients having single
compartment curves over 60min. The plasma
clearances were also variable and ranged from
0.65-1.54dm3 min-1. By extrapolation of the
elimination curve to time zero, the theoretical
maximum concentration of 5-FU was calculated
and ranged from 30.4-66.3pgml-'. Total
fluorinated products were estimated from the levels
of FU, fluorodine and fluorodeoxyuridine in the
specimens and ranged from 4.37-31.05 nmolml-1
supernatant of normal mucosa and 13.9-
75.3 nmolml-1 supernatant of colorectal cancer. An
analysis of the total fluorinated products against t4,
plasma clearance and maximum plasma
concentration failed to demonstrate any significant
linear relationship (r=0.01, 0.004, 0.04
respectively). Similarly the ratios of FU metabolites
in tumour to normal mucosa ranged from 0.8-10.55
and could not be correlated to the pharmaco-
kinetics of 5-FU.
It is concluded that the cellular levels of active
5-FU metabolites reflect local cellular activity rather
than patient handling of the drug.
Modulation of5-fluorouracil (FU) metabolism in two
intestine cell lines: Relation to cytotoxicity
G.J. Peters, E. Laurensse, A. Leyva & H.J. Pinedo
Department ofOncology, Free University Hospital,
P.O. Box 7075, 1007 MB Amsterdam, The
Netherlands.
Initial metabolism of FU catalyzed by pyrimidine
nucleoside phosphorylase (PNP) requires ribose-l-P
(Rib-l-P) or deoxyRib-l-P (dRib-l-P) as
cosubstrates. Modulation of their availability can
elucidate the metabolic pathway and the mechanism
of action of FU in particular tumour types. We
used purine nucleosides to study the modulation of
FU metabolism in tWo human cell lines, WiDr a
colon carcinoma and Intestine 407 a transformed
intestine cell line. Both lines showed comparable
PNP activities with FU as substrate (about
2 nmolh-1 10-6 cells). With inosine as precursor
PNP activity was 30 and 86% in WiDr and
Intestine 407, respectively, and with deoxyinosine 7
and 19%. A 2h incubation with 1mM inosine
increased Rib-I-P concentration 2-4-fold, while
incubation with deoxyinosine gave dRib-I-P levels
comparable to those of Rib-i-P. In cell culture
inosine did not affect cell growth and showed no
synergism with FU. 1 mM deoxyinosine moderately
inhibited cell growth (20-30%). With 0.1-1 mM
deoxyinosine a synergism was found at non-toxic
concentrations of FU (0.1-0.5tM). This synergism
was greater with Intestine 407 than with WiDr
cells. Examination of the medium after 24h showed
that in both cell lines deoxyinosine was rapidly
broken down to hypoxanthine (at 0.1mM for 80
and 50% in Intestine 407 and WiDr, respectively).
dIMP (at 0.4 and 1 mM) also served as a source of
dRib-i-P and enhanced the cytotoxicity of FU. Cell
growth inhibition of this combination could be
reversed by 21M thymidine in Intestine 407 cells
but only partly in WiDr cells. The results show that
low non-toxic FU concentrations can be made
cytotoxic by supplementary dRib-I-P. The effect of
thymidine showed that inhibition of thymidylate
synthetase appears to be a limiting factor.AGM BACR ABSTRACTS 465
Measurement of BZQ (2,5-diaziridinyl-3,6-bis(2-
hydroxyethylamino)-1,4-benzoquinone; NSC 224070)
in human plasma by high-performance liquid
chromatography (HLPC)
A.G. Bosanquet, P. Hunt & E.D. Gilby
Department ofClinical Investigation, Royal United
Hospital, Combe Park, Bath BAJ 3NG, UK.
BZQ is about to go into Phase I clinical trials in
this hospital, and we have developed a method for
extracting the drug from human plasma and
measuring it by HPLC. Plasma (3ml) was injected
through a pre-wetted C-18 Seppak cartridge, and
the cartridge washed with water (pH 8.5; all
solutions used at 0°C). BZQ was eluted with
MeOH, and the eluate diluted 1 to 2 with 52.5mM
NH4Ac before 200 I of this solution was injected
into the HPLC. The mobile phase was 50mM
NH4Ac:MeOH 7:3 (v/v) pumped at 0.8mlmin-1
through a 5 um ODS-Spherisorb column and
detected at 254nm (u.v.) and +0.7V in oxidative
mode (electrochemical; EC). Minimum detection
was -20ngml-1 by u.v. and 3ngml-1 by EC.
Recovery from plasma averaged 79% with good
linearity over 0-100ngml-1 BZQ (r=0.988). The
half life (tq) of BZQ in plasma at 37°C was 209
+13min (mean + s.d.; n=3), slightly longer than
in 0.05M phosphate or bicarbonate buffers (pH 7)
at 96 and 126min respectively. Addition of albumin
(40mgml-') to BZQ in 150mM NaCl reduced the
t from 10 to 5.4h (22°C), thus it is possible that tIe degradation of BZQ is protected by plasma
lipoproteins. BZQ was stable for 5h in plasma at
0°C, whereas freezing at -35°C resulted in slight
decomposition. This is consistent with the fact that
we have found BZQ to be unstable (? polymerises)
when frozen in inorganic buffers.
Comparative tissue distribution of platinum and 14C
in mice receiving 14C carboplatin
S.E. Dible, Z.H. Siddik, F.E. Boxall & K.R. Harrap
Department ofBiochemistry and Pharmacology,
Institute ofCancer Research, Sutton, Surrey, UK.
Recent studies have identified carboplatin (JM8) as
a viable alternative to cis-platin. The reactivity of
carboplatin will depend upon the rate of removal of
the 1,1-cyclobutane decarboxylate ligand. Hence the
time course of this dissociation has been determined
in a number of tissues, using '4C-carboplatin
(cis-diammine-[1-14C]-CBCDA Pt II). Female
Balb C- mice received 14C-carboplatin (80mgkg';
1.1mCikg 1, i.v.) and were exsanguinated at times
ranging from 5min to 5 days. Tissues were
removed, solubilized in 0.5ml hyamine hydroxide
(44% w/v) overnight at 50-60°C, and diluted in
0.1 N HCI. Aliquots were analysed for Pt and 14C
using flameless atomic absorption and liquid
scintillation techniques respectively. Up to 2h after
drug administration the ratio of 14C:Pt in tissues
and plasma was comparable to that in the dose
solution (51 dpmng- Pt), indicating that carbo-
platin was structurally intact. Thereafter, the ratio
decreased progressively due to a greater rate of
removal of 14C than of Pt from the plasma and
tissues. At 5 days, the ratios in these tissues were 2
(kidney, ileum), 4 (muscle), 8 (heart), 12 (plasma)
and 26 (liver). Thus, at least 86-96% of the Pt
species was not associated with 14C, liver being the
exception ('50%). The half lives (h) for Pt during
the terminal phase varied with each tissue, being 40
(plasma), 54 (ileum heart), 71 (kidney), 98 (liver) and
116 (muscle). The corresponding half lives for 14C
were similar for each tissue (-27h). with liver being
an exception (216h). These results indicate that the
metabolic handling of carboplatin varies between
tissues.
Concentration of platinum in human brain tumors
after intravenous administration of cis-platin
J.G. McViel, M. Chatel2, J.A.G. Punt3, M.P.J.W.
Sokal3 & T. Dikhof4
IThe Netherlands Cancer Institute, Amsterdam, The
Netherlands, 2University ofRennes, France; 3Royal
Infirmary, Derby, UK; and 4Cyclotron Unit,
Eindhoven, The Netherlandsfor the EORTC Brain
Tumour Group.
In planning a protocol to test the activity of cis-
platin as a radiosensitizer in malignant gliomas a
pilot study was carried out with varying doses of
intravenous cis-platin (C) prior to craniotomy and
biopsies of normal brain and glioma were removed
for sampling. Seven patients (pts) were treated with
a bolus of C 4, 6 or 8mgm-2 i.v.; 6 pts with
60mgm-2 i.v. 30min prior to operation. Platinum
levels were measured by proton induced X-ray
emission using a cyclotron generated proton beam.
This technique is highly accurate and reproducable
down to 0.5ppm dry wt. There are no disturbances
in the measurements due to presence of tissue in
contrast to the conventional atomic absorption
technique. Patients' samples treated with low doses of
C showed no detectable platinum. The following
values were achieved after 60mgm-2
All biopsies were also examined histologically and
patient R* has no vital tissue in any of the 5
samples studied. The entire material was necrotic.
As animal and clinical experience has indicated that
-3 ppm platinum is required to achieve a radio-
sensitizing of platinum, it would appear that a dose
of 60mgm2 i.v. cis-platin would be appropriate
for a trial of the drug together with radiotherapy in
the treatment of malignant glioma.466 AGM BACR ABSTRACTS
Table Concentration of platinum (ppm dry wt)
Patient R* GUI TH GOU GUJ CHR
Normal brain 0, 0 0 1,1 1,1 0
Mixed histology 1, 6
Tumour 0, 0, 0 17 4, 5 13 3, 6, 7, 8
Pharmacokinetics of high dose melphalan in children
and adults
C. Ardiet, B. Tranchand, P. Biron, P. Rebattu & T.
Philip
Centre Leon B&ard 69373 LYON Cedex 08, France
The plasma kinetics of melphalan (L phenylalanine
mustard L-PAM) was investigated in 22 patients
(13 children, 9 adults). This Phase II trial was
conducted in bearers ofadvanced malignant tumours
with high dose L-PAM (140 mgm 2) as mono- or
polychemotherapy, followed by autologous bone
marrow graft. Parent L-PAM was assayed by
means of HPLC using methanolic extraction with
dansyl-proline as internal standard. Our results can
be summarized as follows: In all cases, L-PAM
pharmacokinetics closely followed a two
compartment open model. In spite of standardized
hydration and L-PAM rapid infusion, initial
concentrations of drug were found highly scattered
(range: 9.0 to 49.9 mg 1 1). The disposition (fi)
phases showed also a large dispersion; t1/21 ranging
from 18 to 71 min) and f-phase drug concentrations
at time 0 ranging from 1.2 to 8.0mgI1 of plasma
(mean: 4.6 mgI1). In all cases, the drug level was
<0.1 mg 1' at 8 h, allowing if necessary an early
bone marrow graft. CSF samples were drawn from
45 to 150min after L-PAM injection in 11 patients;
in only 4 out of these was the drug detectable. The
remaining 7 showed no drug in CSF. No kinetic
difference was found between children and adults.
In 5 additional patients, drug incubation with
plasma showed a variable hydrolysis rate; this para-
meter is presently to be related to the elimination
phase in connection with linearity studies.
Report on the Phase I trial of N2, N4, N6-
trihydroxymethyl-N2 N4, N6-trimethylmelamine
(trimelamol)
I.R. Judson, C.J. Rutty, G. Abel, L. Gumbrell,
K.R. Harrap & A.H. Calvert
Department ofBiochemical Pharmacology, Institute
Cancer Research, Sutton, Surrey, UK.
Trimelamol is an anti-tumour s-triazine which
unlike hexamethylmelamine and pentamethyl-
melamine (PMM) does not require metabolic
activation. Preclinical studies predict both enhanced
activity and reduced neurotoxicity compared with
PMM (Newell et al. (1981), Br. J. Cancer 44, 281).
Eighteen patients (pts) at the Royal Marsden
Hospital have so far been treated by rapid i.v.
infusion at 3 weekly intervals with doses escalating
from 25-2000 mgm-2. Tumours treated were:
ovary 9; mesothelioma 2; large bowel 3; lung 1;
uterus 1; sarcoma 1; Hodgkin's disease 1. Toxicity
has been far less than that reported for PMM and
consists of (1) dose-related nausea and vomiting of
<6 h duration, 76% of courses 280-1100 mgm-2,
all courses > 1500mgm-2; (2) lethargy and
anorexia of 1-2 weeks duration, most pts
>1100mgm-2; (3) minimal myelosuppression, i.e.
WBC nadir <2.0 x 1091-1 and platelets
<100x 1091-I in only 1 pt at 1500mgm2, fall in
Hb>2 gdl-1 in 2 pts after 3 courses 500-
1100mgm-2. No abnormality of liver or kidney
function attributable to the drug and no alopecia or
neuropathy have been observed. The maximum
tolerated dose is expected to be 1500-2500 ngm-2,
limited by sedation or myelosuppression. Anti-
tumour effects comprise significant alleviation of
pain in 3 pts, 2 differential responses (ovary), 1
static disease for 3 months (rectum) and 1 partial
response (Hodgkin's). Phase II evaluation will
follow.
Preclinical and clinical studies with N2, N4, N6-
trihydroxymethyl, N2, N4, N6-trimethylmelamine, an
alternative to pentamethylmelamine
C.J. Rutty, I.R. Judson, G. Abel, M.A. Graham,
A.H. Calvert & K.R. Harrap
Department ofBiochemical Pharmacology, Institute
ofCancer Research, Sutton, Surrey, UK.
The failure of pentamethylmelamine (PPM) in the
clinic has been attributed to its lack of metabolic
activation in man (Rutty et al. (1982), Cancer
Chemother. Pharmacol. 8, 105). For this reason, N2,
N4, N6-trihydroxymethyl, N2, N4, N6-trimethyl-
melamine (trimelamol, CB 10-375), which does not
require oxidative N-demethylation, has been
developed as an alternative. Trimelamol has aAGM BACR ABSTRACTS 467
number of advantages over PMM, in particular, its
relative lack of acute neurotoxicity. Following this
observation the penetration of PMM and
trimelamol into mouse brain has been examined.
Mice given 90mgkg-1 PMM i.p. showed high
levels of parent drug in the CNS compared to
plasma levels (brain:plasma=0.93), whereas
animals given an equivalent dose of Trimelamol
had much lower levels of the N-hydroxymethyl-
melamine in brain tissue (brain:plasma=0.063).
CNS penetration appears to be related to partition
coefficients (Poctanol/H20) for these two drugs
which are 67 and 2.5 for PMM and Trimelamol
respectively. However, it does not appear to
correlate with plasma protein binding which is
significantly greater for PMM (68.2%) than for
Trimelamol (17.5%). A Phase I clinical study of
Trimelamol (25-1800 mgm-2) has shown this drug
to be substantially less emetic than PMM. Since the
nausea and vomiting associated with this class of
compounds appears to be centrally mediated, these
differences in toxicity may also be explained in
terms of the different abilities of the two drugs to
penetrate the CNS.
A clinical pharmacokinetic study of LM985 and
LM975
D.J. Kerr', S.B. Kaye1, J. Cassidy', S. Duttal, A.
Setanoians', G. Forrest2, D. Cunningham2, M.
Soukop2 & W.R. Vezin3
Departments of1Clinical Oncology, University of
Glasgow and 2Glasgow Royal Infirmary; and 3CRC
Drug Formulation Unit, University ofStrathclyde,
Glasgow, UK.
LM985 is a new chromone derivative which was
selected for clinical trials because a high percentage
of cures were seen in the murine colon tumour 38
as part of the NCI preclinical screen. A Phase I
clinical and pharmacokinetic trial was initiated at
the starting dose of lOmgm-2 (10% of the LDI0
in mice) using a Q3W schedule. Treatment was
initially by i.v. bolus, however transient
hypotension was noted at 130mgm 2 and the drug
was administered thereafter by a 1-h infusion.
Blood samples were analysed by HPLC; p-
dimethylamino-benzaldehyde was utilised as the
internal standard, u.v. detection was at 303 nm and
a 25 cm bondapack 54m C18 column was used.
This system was found to be rapid (retention time
< 10min) and sensitive with good precision
maintained down to concentrations of 5ngml- . In
vitro studies indicated rapid degradation of LM985
(I) to LM975 (II) by OH- catalysed first-order
hydrolysis. In vivo, model independent pharma-
cokinetic data (dose range 40-800mgM2; 19
patients) show rapid degradation of I to II (the end
of infusion ratio of II/I varies from 10-40). I and II
decline biexponentially with respective 13t' of 0.85 h
and 2.2 h. It would appear that I acts as an
unstable prodrug in vivo and that rapid hydrolysis
converts it to II, which may be the active principle.
Clinical pharmacology of sodium butyrate in patients
with acute leukaemia
A.A. Miller
Innere Klinik und Poliklinik (Tumorforschung),
West German Tumor Center, University ofEssen,
D-4300 Essen 1, FRG
Butyric acid induces differentiation of leukaemic
cells in vitro (Novogrodsky et al. (1983), Cancer 51,
9-14). We undertook a study of the clinical
pharmacology of sodium butyrate (Na-B) in 6
patients with acute leukaemia. The dosage was
500mgkg-1 24h1- (isotonic solution) given as
continuous i.v. infusion for 10 days. Blood samples
were drawn daily during and hourly after infusion.
We developed a sensitive method employing high-
performance liquid chromatography (HPLC) after
derivatization of butyrate in order to monitor its
plasma concentrations. '4C labeled Na-B was used
as standard. Plasma was ultrafiltered for 45 min at
2000g (MPS-I; Amicon, Witten, FRG). To 300,u1
of the ultrafiltrate, 10jul of 1 M KHCO3 were
added. The sample was brought to dryness under a
stream of N2. The residue was dissolved in 100,ul
reaction mixture and 500 1 CH3CN. The reaction
mixture consisted of 0.2 M 2,4'-dibromoaceto-
phenone and 0.2M dicyclohexyl-18-crown-6 (20:1,
v:v; Merck, Darmstadt, FRG). The sample was
heated at 80°C for 30min in a shaking water bath.
After centrifugation, the clear solution could be
directly injected into the HPLC. The separation
was achieved on a pBondapak C18 column
(Waters) with H20:CH3CN 550:450 (v:v) as
solvent under isocratic conditions (2ml/min). The
UV-detector was set at 354nm. The retention time
of Na-B was 12min. Mean plasma concentrations
of Na-B ranged from 59 to 79pM during infusion.
After infusion, the plasma curve showed an
exponential decay with a half-life of 6.1 min.
Although high doses of Na-B were given, the
concentrations known to induce differentiation in
vitro were not reached in vivo; no response and no
toxicity were seen.
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